MXPA06010357A - Indol-1-yl-acetic acid derivatives - Google Patents

Abstract

The invention relates to indol-1-yl-acetic acid derivatives and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more of those compounds and methods of treatment comprising administration of said compounds.

Description

ACID DERIVATIVES INDOL 1-IL-ACETIC FIELD OF THE INVENTION The present invention relates to the indole-1-yl-acetic acid derivatives and their use as potent antagonists of the "chemoattractant receptor homologous molecule, expressed on Th2 cells" (hereinafter referred to as CRTH2) in the treatment of prostaglandin-mediated diseases, pharmaceutical compositions containing these derivatives and processes for their preparation. In particular, at least one such derivative of the general formula I can be used in pharmaceutical compositions for the treatment of chronic and acute allergic / immune disorders comprising allergic asthma, rhinitis, chronic obstructive pulmonary disease (COPD), dermatitis, inflammatory bowel disease, rheumatoid arthritis, allergic nephritis, conjunctivitis, atopic dermatitis, bronchial asthma, food allergy, systemic disorders of mast cells, anaphylactic shock, urticaria, eczema, itching, inflammation, ischemia- damage reperfusion, cerebrovascular disorders, pleuritis, ulcerative colitis, related diseases, eosinophils, such as Churg-Strauss syndrome and sinusitis, basophil-related diseases, such as basophilic leukemia and basophilic leukocytosis in humans Ref.:175606 and other mammals . The invention also relates to novel compounds of formula II which can also be used in pharmaceutical compositions as described above.

BACKGROUND OF THE INVENTION Prostaglandin D2 is a known agonist of the thromboxane A2 receptor (TxA2), the PGD2 receptor (DP) and the "homologous chemoattractant receptor molecule expressed on Th2 cells" coupled to the newly identified G protein (CRTH2). The response to exposure to allergens in a previously sensitized host results in a cascading effect involving numerous cell types and the release of a number of cytokines, chemokines, and multiple mediators. Among these critical initiators are the cytokines, interleukins, (IL) -4, IL-13 and IL-15, which play critical roles in the differentiation of Th2 cells, immunoglobulin synthesis, (Ig) E, growth and differentiation of mast cells, upregulation of CD23 expression and the differentiation, recruitment and activation of eosinophils. The stimulated release of the mediator arrangement causes damage to final organs, including constriction and hyper-response, vascular permeability, edema, mucus secretion and subsequent inflammation. Due to the number of targeted responses, corticosteroids have proven to be the most effective therapy.

Instead of antagonizing these specific responses in a targeted manner, another procedure is to alter the immune response, that is, change the nature of the immune response to the allergen. CRTH2 is preferably expressed on Th2 cells and is a chemoattractant receptor for PGD2 that mediates the PGD2-dependent migration of Th2 blood cells. The chemoattractants are responsible for the recruitment of Th2 cells and other effector cells of allergic inflammation and can provide the conceptual basis for the development of new therapeutic strategies, especially in allergic conditions. So far, few compounds that have CRTH2 antagonist activity have been reported in the patent literature. Bayer AG claims in the Patent Specification British No. 2 388 540 to the use of Ramatroban ((3R) -3- (4-fluorobenzenesulfonamido) -1,2,3,4-tetrahydrocarbazole-9-propionic acid) for the prophylaxis and treatment of allergic diseases, such as asthma , allergic rhinitis or allergic conjunctivitis (see also Journal of Pharmacology and Experimental Therapeutics (2003), 305 (1), 347-352, where a certain oral bioavailability of Ramatroban and its ability to inhibit the eosinophil migration induced by protaglandin D2 in vitro, Has been reported) . In addition, the acid (2-tert-butoxycarbonyl-1,2,3,4-tetrahydropyrido [4, 3-b] indol-5-yl) -acetic acid and the acid (2-ethoxycarbonyl- 1,2,3) , 4-tetrahydro-pyrido [4, 3-b] indol-5-yl) -acetic are described by Kyle F. et al in two patent specifications, for example in U.S. Patent No. 5,817,756 and in U.S. Pat. World Document WO 95/07294, respectively. More recently, certain 1-carboxymethyl-indole derivatives of the formula: - - ' (Al) wherein R may be primarily hydrogen, halogen or alkyl of 1 to 6 carbon atoms, R 2 may be primarily hydrogen and R 3 is optionally substituted aryl or heteroaryl, have been described. These compounds are presented as active on the CRTH2 receptor and therefore are potentially useful for the treatment of various respiratory diseases.

BRIEF DESCRIPTION OF THE INVENTION The present invention relates firstly to the compounds of the general formula I: i wherein A represents hydrogen; I rent; halogen or cyano; B represents hydrogen, alkyl or halogen; R1, R2, R3 and -R4 independently represent hydrogen, alkyl; halogen; nitro; cyano or formyl (and preferably independently represent hydrogen, alkyl, halogen or nitro); R5 and R6 independently represent hydrogen; I rent; cycloalkyl; cycloalkyl-alkyl; heteroaryl; heteroaryl-alkyl; alkenyl; carboxyalkyl; cyanoalkyl; diphenylalkyl; arylaryl-alkoxy-aryl, arylalkyl, aryl-alkyl-aryl, arylcarbonyl-aryl or aryloxy-aryl, or R5 and R6, together with the nitrogen atom to which they are attached, form a heterocyclic ring system; for use as medicines.

Any reference to a compound of the general formula I for use as a medicament should be understood as referring also to optically pure enantiomers, mixtures of enantiomers, racemates, optically pure diastereoisomers, mixtures of diastereoisomers, diastereoisomeric racemates, mixtures of diastereoisomeric racemates, meso, geometric isomers, as well as solvates and morphological forms and pharmaceutically acceptable salts thereof. The same applies for mutatis mutandis to the compounds of the formulas I, Icl, Ic2, IP, IIP, III ?, or IVP (in which case the reference to the compounds should also be understood as referring also to the different salts of the pharmaceutically salts acceptable), to them as medicaments, to the pharmaceutical compositions containing them and to their uses according to the invention. The present invention also relates to prodrugs of a compound of formula I which are converted in vivo to the compounds of formula I as such. Any reference to a compound of formula I should therefore be understood as also referring to the corresponding prodrugs of the compound of formula I, as appropriate and expedient. The same applies mutatis mutandis to the compounds of the formulas I, Ic ?, Ic2 / Ip / II ?, IIIP, or IVp, to them as medicaments, to the pharmaceutical compositions containing them and to their uses according to the invention. The compounds of the general formula I are antagonists of the CRTH2 receptor and can be used for the prevention and treatment of chronic and acute allergic immune disorders, comprising allergic asthma, rhinitis, chronic obstructive pulmonary disease (COPD), dermatitis, inflammatory disease of the intestine, rheumatoid arthritis, allergic nephritis, conjunctivitis, atopic, bronchial dermatitis, food allergy, systemic disorders of mast cells, anaphylactic shock, urticaria, eczema, itching, inflammation, ischemia or reperfusion injury, cerebrovascular disorders,. pleuritis, ulcerative colitis, diseases related to eosinophils that include Churg-Strauss syndrome and sinusitis, diseases related to basophils, which includes basophilic leukemia and basophilic leukocytosis in humans and other mammals. Preferred compounds of the general formula I for use as medicaments are those in which at least one of the following characteristics is present: A is cyano; OR B is hydrogen or methyl; Or R1, R2, R3 and R4 are all hydrogen atoms, or one of R1, R, R3 and R4 is halogen (preferably fluorine), while the others are all hydrogen; Or at least one of R 5 and R ° is chosen from the group consisting of heteroaryl, heteroaryl-alkyl, diphenylalkyl, aryl, arylalkoxy-aryl, arylalkyl, aryl-alkyl-aryl, arylcarbonyl-aryl and aryloxy-aryl; or R3 and R6, together with the nitrogen atom to which they are bound, form a heterocyclic ring system. The even more preferred compounds of the general formula I for use as medicaments are those in which at least one of the following characteristics is present: A is cyano; OR B is hydrogen; < L > R1, R2, R3 and R4 are all hydrogen atoms, or one of Ra, R2, R3 and R4 is halogen (preferably fluorine), while the others are all hydrogen; R5 is selected from the group consisting of heteroarylalkyl, diphenylalkyl, aryl, aryl-alkoxy-aryl, arylalkyl, aryl-alkyl-aryl, arylcarbonyl-aryl and aryloxyaryl (aryl, arylalkoxy-aryl, arylalkyl, aryl-alkyl- aryl, arylcarbonyl-aryl and aryloxy-aryl, which are preferably such that their aryl groups are unsubstituted or substituted once or twice with substituents independently selected from the group consisting of halogen, alkoxy, haloalkoxy and alkylcarbonyl) and R6 is selected from the group which consists of alkyl, alkenyl, cycloalkyl, aryl, arylalkyl and cyanoalkyl (aryl and aryl-alkyl which is preferably such that its aryl groups are unsubstituted or substituted one or two times with substituents independently selected from the group consisting of halogen, alkoxy, haloalkoxy and alkylcarbonyl); or Rs and R6, together with the nitrogen atom to which they are bound, form a dihydrophenanthyridine, dihydroacridine, dihydrodibenzoazocin, dihydrodibenzoazepine, dihydroindol, dihydroquinoline, dibenzoazepine, phenothiazine, oxa-aza-dibenzocycloheptene, dihydroisoquinoline, which may be substituted or unsubstituted with a substituent selected from halogen, methyl, methoxy and trifluoromethyl (and preferably a ring of 5,6-dihydro-phenanthridine, 9,10-dihydro-acridine, 5, β-dihydro-dibenzo [b, f] azozine, 10,11 -dihydro-dibenzo [b, f] azepine, 11,12-dihydro-6H-dibenzo [b, f] azocine, 2,3-dihydro-indole, 3,4-dihydro-2H-quinoline, 6,11-dihydro -dibenzo [b, e] azepine, dibenzo [b, f] azepine, 2-chlorophenothiazine, HH-10-oxa-5-aza-dibenzo [a, d] cycloheptene, 3,4-dihydro-lH-isoquinoline, -trifluoromethyl-3,4-dihydro-2H-quinoline, dibenzo [b, f] azepine, 6,11-dihydro-dibenzo [b, e] azepine). According to a particularly preferred embodiment, the compounds of the general formula I for use as medicaments will be such that A is cyano, B is hydrogen and R1, R2, R3 and R4 are all hydrogen atoms. According to another particularly preferred embodiment, the compounds of the general formula I for use as medicaments will be such that A is cyano, B is hydrogen and one of Ra, R2, R3 and R4 is halogen (preferably fluorine, while the others they are all hydrogen According to a particularly particularly preferred embodiment, the compounds of the general formula I for use as medicaments will be such that A is cyano, B is hydrogen and one of R2 and R3 is halogen (preferably fluorine), while that the other R1 and R4 are hydrogen atoms, a representative example thereof will be the case where R2 is halogen (preferably fluorine), while the other R1, R3 and R4 are hydrogen atoms. compounds of the general formula I for use as medicaments, is one in which the R? and Rs groups do not form a heterocyclic ring system together with the nitrogen atom to which they are linked. In such a case, each of the following combinations will constitute a more particularly preferred embodiment. < > R5 which is aryl and Rs which is selected from the group consisting of alkyl, cycloalkyl, alkenyl, cyanoalkyl, diphenylalkyl, heteroaryl-alkyl, aryl-alkyl and aryl (and preferably R5 which is phenyl and R6 which is selected from the group consisting of alkyl, cycloalkyl, alkenyl, cyanoalkyl, diphenylalkyl, heteroaryl-alkyl, phenylalkyl and phenyl); or O R5 which is aryl or alkyl and R6 which is selected from the group consisting of alkyl, aryl and aryl-alkyl (and preferably R 5 which is phenylalkyl and R 6 which is selected from the group consisting of alkyl, phenyl and phenyl-alkyl). An alternative preferred embodiment with respect to the compounds of the general formula I for use as medicaments is that wherein the groups R5 and R6 form a heterocyclic ring system together with the nitrogen atom to which they are linked. In such a case, each of the following NR5R6 groups will constitute a more particularly preferred embodiment: O NR5R6 which is an unsubstituted dihydroquinoline ring (e.g., -? R5R6 representing 3,4-dihydro-2H-quinolin-l- ilo); Or NR5R6 which is an unsubstituted dihydroisoquinoline ring (for example, -? R5RS representing 3,4-dihydro-lH-isoquinolin-2-yl); O? R5RS which is an unsubstituted dibenzoazepine ring (for example, -? R5R6 representing dibenzo [f, f] zepin-5-yl); O? R5R6 which is an unsubstituted dihydrodibenzoazepine ring (for example, -? R5Re representing 6,11-dihydrodibenzo [b, e] azepin-5-yl or a 10,11-dihydrodibenzo [b, f] azepin-5 -ilo); O? RSRS which is an unsubstituted phenothiazine ring or a phenothiazine ring substituted once with halogen (for example, -NR5R6 representing 2-chloro-phenothiazin-10-yl); Or NR5Rd which is an unsubstituted oxa-aza-dibenzocycloheptene ring (for example, -? R5R6 representing HH-10-oxa-5-aza-dibenzo [a, dj cyclohepten-5-yl). Another aspect of the present invention is the use of the compounds of the general formula I as medicaments, in particular for treating the aforementioned diseases. In this regard, the use of the following compounds is particularly preferred: [3- ((E) -2-cyano-2-phenylcarbamoyl-vinyl) -indol-1-yl] -acetic acid; [3- ((E) -2-cyano-2-m-tolylcarbamoyl-vinyl) -indol-1-yl] -acetic acid; Acid { 3- [(E) -2-cyano-2- (4-methoxy-phenylcarbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- t (E) -2- (3-bromo-phenylcarbamoyl) -2-cyanovinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (cyclohexyl ethylcarbamoyl) -vinyl] -indol-1-yl} -acetic; [3- ((E) -2-cyano-2-phenethylcarbamoyl-vinyl) -indol-1-yl] -acetic acid; [3- ((E) -2-cyano-2-isopropylcarbamoyl-vinyl) -indol-1-yl] -acetic acid; [3- ((E) -2-cyano-2-propylcarbamoyl-vinyl) -indol-1-yl] -acetic acid; [3- ((E) -2-cyano-2-cyclohexylcarbamoyl-vinyl) -indol-1-yl] -acetic acid; Acid { 3- [(E) -2-cyano-2- (3-methyl-butylcarbamoyl) -vinyl] -indol-1-yl} -acetic; [3- ((E) -2-benzylcarbamoyl-2-cyanovinyl) -indol-1-yl] -acetic acid; Acid { 3- [(E) -2- (benzyl-phenyl-carbamoyl) -2-cyano-vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (4-cyano-phenylcarbamoyl) -vinyl] -indol-1-yl} -acetic; [3- ((E) -2-cyano-2-o-tolylcarbamoyl-vinyl) -indol-1-yl] -acetic acid; Acid { 3- [(E) -2-cyano-2- (4-ethyl-phenylcarbamoyl) -vinyl] -indol-1-yl} -acetic, - Acid. { 3- [(E) -2-cyano-2- (4-fluoro-phenylcarbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (4-phenoxy-phenylcarbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (naphthalen-2-ylcarbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (2-isopropyl-phenylcarbamoyl) -vinyl] -indol-1-yl} -acetic; [3- ((E) -2-cyano-2-p-tolylcarbamoyl-vinyl) -indol-1-yl] -acetic acid; Acid { 3- [(E) -2-cyano-2- (4-isopropyl-phenylcarbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (3-methoxy-phenylcarbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (3-fluoro-phenylcarbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (9H-fluoren-2-ylcarbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (4-propyl-phenylcarbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2- (biphenyl-4-ylcarbamoyl) -2-cyano-vinyl] -indol-l-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (3,2'-dimethyl-biphenyl-4-ylcarbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2- (4-tert-Butyl-phenylcarbamoyl) -2-cyanovinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2- (2-benzyl-phenylcarbamoyl) -2-cyanovinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2- (4-Butyl-phenylcarbamoyl) -2-cyanovinyl] -indol-1-yl} -acetic; Acid (3- [(E) -2- (2-acetyl-phenylcarbamoyl) -2-cyano-vinyl] -indol-1-yl.} -acetic acid: {.3- [(E) -2- cyano-2- (indan-5-ylcarbamoyl) -vinyl] -indol-1-yl.} -acetic acid; {.3- [(E) -2- (4-sec-butyl-phenylcarbamoyl) -2 -cyanovinyl] -indol-1-yl.} -acetic; (3- [(E) -2-cyano-2- (4-ethoxy-phenylcarbamoyl) -vinyl] -indol-1-yl}. -acetic acid: {.3- [(E) -2-cyano-2- (3-ethoxy-phenylcarbamoyl) -vinyl] -indol-1-yl} -acetic acid: {.3-3 [( E) -2-cyano-2- (2-propyl-phenylcarbamoyl) -vinyl] -indol-1-yl.} -acetic acid: {.3- [(E) -2-cyano-2- (3 -phenoxy-phenylcarbamoyl) -vinyl] -indol-1-yl.} -acetic acid; {.3- [(E) -2-cyano-2- (3-ethyl-phenylcarbamoyl) -vinyl] -indol- 1-acetic acid; {.3- [(E) -2-cyano-2- (2-ethoxy-phenylcarbamoyl) -vinyl] -indol-1-yl} -acetic acid; {.3- [(E) -2- (3-benzyloxy-phenylcarbamoyl) -2-cyano-vinyl] -indol-1-yl} -acetic acid; {.3- [(E) -2- (4-bromo-phenylcarbamoyl) -2-ci ano-vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (4-iodo-phenylcarbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (3-iodo-phenylcarbamoyl) -vinyl] -indol-1-yl} -acetic; (3- { (E) -2-cyano-2- [(4-fluoro-phenyl) -methyl-carbamoyl] -vinyl] -indol-1-yl) -acetic; (3- ({(E) -2-cyano-2- [(4-methoxy-phenyl) -methyl-carbamoyl] -vinyl} -indol-1-yl) -acetic acid; Acid { 3- [(E) -2-cyano-2- (methyl-phenyl-carbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-3- (3,4-dihydro-2H-quinolin-1-yl) -3-oxo-propenyl] -indol-1-yl} -acetic; Acid (3- [(E) -2-cyano-2- (methyl-p-tolyl-carbamoyl) -vinyl] -indol-1-yl.} -acetic; (3- {(E) -2 -cyano-2- [2- (2,4-dichloro-phenoxy) -phenylcarbamoyl] -vinyl] -indol-1-yl) -acetic acid: {.3- [(E) -2-cyano- 2- (2,5-dimethyl-phenylcarbamoyl) -vinyl] -indol-1-yl.} -acetic acid; {.3- [(E) -2-cyano-2- (9-ethyl-9H- carbazol-3-ylcarbamoyl) -vinyl] -indol-1-yl.} -acetic acid; {.3- [(E) -2- (3,5-bis-trifluoromethyl-phenylcarbamoyl) -2- cyano- vinyl] -indol-1-yl.} -acetic acid: {.3- [(E) -2-cyano-2- (5-methoxy-2-methyl-phenylcarbamoyl) -vinyl] -indol-1- Figure imgf000014_0001 acetic acid, {.3- [(E) -2- (4-tert-butyl-phenylcarbamoyl) -2-cyanovinyl] -indol-1-yl} -acetic acid; {.3- [(E) -2- (2-benzyl-phenylcarbamoyl) -2-cyano-vinyl] -indol-1-yl}. -acetic acid-3. [3- (E) -2 - (4-Butyl-phenylcarbamoyl) -2-cyano-vinyl] -indol-1-yl.} -acetic acid: {.3- [(E) -2- (2-acetyl-phenylcarbamoyl) -2- cyanovinyl] -indol-1-yl.}. acetic acid. 3- [(E) -2-cyano-2- (indan-5-ylcarbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2- (4-sec-Butyl-phenylcarbamoyl) -2-cyano-vinyl] -indol-1-yl} -acetic; Acid (3- [(E) -2-cyano-2- (4-ethoxy-phenylcarbamoyl) -vinyl] -indol-1-yl.} -acetic acid; {.3- [(E) -2- cyano-2- (3-ethoxy-phenylcarbamoyl) -vinyl] -indol-1-yl.} -acetic acid; {.3- [(E) -2-cyano-2- (2-propyl-phenylcarbamoyl)) -vinyl] -indol-1-yl.} -acetic acid: {.3- [(E) -2-cyano-2- (3-phenoxy-phenylcarbamoyl) -vinyl] -indol-1-yl}. .-acetic; Acid { 3- [(E) -2-cyano-2- (3-ethyl-phenylcarbamoyl) -vinyl] -indol-1-yl.} -acetic acid; (E) -2-cyano-2- (2-ethoxy-phenylcarbamoyl) -vinyl] -indol-1-yl.} -acetic acid: {.3- [(E) -2- (3-benzyloxy-) phenylcarbamoyl) -2-cyano-vinyl] -indol-1-yl.} -acetic acid; {.3- [(E) -2- (4-bromo-phenylcarbamoyl) -2-cyano-vinyl] -indole -1-yl.) -acetic acid: {.3- [(E) -2-cyano-2- (4-iodo-phenylcarbamoyl) -vinyl] -indol-1-yl.} -acetic acid; {.3- [(E) -2-cyano-2- (3-iodo-phenylcarbamoyl) -vinyl] -indol-1-yl} -acetic acid (3 { (E) -2 -ciano-2- [(4-fl uoro-phenyl) -methyl-carbamoyl] -vinyl} -indol-1-yl) -acetic; (3- ({(E) -2-cyano-2- [(4-methoxy-phenyl) -methyl-carbamoyl] -vinyl} -indol-1-yl) -acetic acid; Acid { 3- [(E) -2-cyano-2- (methyl-phenyl-carbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-3- (3,4-dihydro-2H-quinolin-1-yl) -3-oxo-propenyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (methyl-p-tolyl-carbamoyl) -vinyl] -indol-1-yl} -acetic; (3- ({(E) -2-cyano-2- [2- (2,4-dichloro-phenoxy) -phenylcarbamoyl] -vinyl} -indol-1-yl) -acetic acid; Acid { 3- [(E) -2-cyano-2- (2,5-dimethyl-phenylcarbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (9-ethyl-9H-carbazol-3-ylcarbamoyl) - "vinyl] -indol-1-yl} -acetic acid; E) -2- (3, 5-bis-trifluoromethyl-phenylcarbamoyl) -2-cyano-vinyl] -indol-1-yl.} -acetic acid: {.3- [(E) -2-cyano- 2- (5-methoxy-2-methyl-phenylcarbamoyl) -vinyl] -indol-1-yl.} -acetic acid: {.3- [(E) -2- (3-benzoyl-phenylcarbamoyl) -2 -cyanovinyl] -indol-1-yl. -acetic acid; {.3- [(E) -2- (4-benzyloxy-phenylcarbamoyl) -2-cyano-vinyl] -indol-1-yl. .-.acetic acid, {.3- [(E) -2-cyano-2- (3-nitro-phenylcarbamoyl) -vinyl] -indol-1-yl} -acetic acid; - [(E) -2-cyano-2- (9-oxo-9H-fluoren-2-ylcarbamoyl) -vinyl] -indol-1-yl.} -acetic acid: {.3- [(E)} -2-cyano-2- (4-methoxy-biphenyl-3-ylcarbamoyl) -vinyl] -indol-l-yl} -acetic acid; {.3- [(E) -2-cyano-2- (2-methoxy-dibenzofuran-3-ylcarbamoyl) -vinyl] -indol-1-yl.} -acetic acid: {.3- [(E) -2-cyano-2- (9-oxo-9H- fluoren-4-ylcarbamoyl) -vinyl] -in dol-l-il.}. -acetic; Acid { 3- [(E) -2-cyano-2- (9-oxo-9H-fluoren-1-ylcarbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2- (2-benzoyl-phenylcarbamoyl) -2-cyanovinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2- (3-chloro-4-methoxy-phenylcarbamoyl) -2-cyano-vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2- (5-chloro-2-methoxy-phenylcarbamoyl) -2-cyanovinyl] -indol-1-yl} -acetic; 3- [(E) -3- (l-carboxymethyl-lH-indol-3-yl) -2-cyano-acryloylamino] -4-methyl-benzoic acid methyl ester; Acid (3- [(E) -2- (4-chloro-2-methyl-phenylcarbamoyl) -2-cyano-vinyl] -indol-1-yl.} -acetic acid methyl ester 2- [(E ) -3- (1-carboxymethyl-lH-indol-3-yl) -2-cyano-acryloylamino] -benzoic acid; {.3- [(E) -2-cyano-2- (4-trifluoromethoxy-phenylcarbamoyl) ) -vinyl] -indol-1-yl.} -acetic acid: {.3- [(E) -2-cyano-2- (3, 5-dimethyl-phenylcarbamoyl) -vinyl] -indol-1- il.}. -acetic; Acid { 3- [(E) -2- (3-bromo-4-methyl-phenylcarbamoyl) -2-cyanovinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2- (4-bromo-3-methyl-phenylcarbamoyl) -2-cyanovinyl] -indol-1-yl} -acetic; 4- [(E) -3- (1-carboxymethyl-1H-indol-3-yl) -2-cyano-acryloylamino] -benzoic acid ethyl ester; 3- [(E) -3- (l-Carboxymethyl-7H-indol-3-yl) -2-cyano-acryloylamino] -benzoic acid methyl ester; Acid { 3- [(E) -2-cyano-2- (4-trifluoromethyl-phenylcarbamoyl) -vinyl] -indole-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (3,5-dimethoxy-phenylcarbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2- (4-bromo-3-chloro-phenylcarbamoyl) -2-cyanovinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2- (4-bromo-2-methyl-phenylcarbamoyl) -2-cyanovinyl] -indol-1-yl} -acetic; - Acid { 3- [(E) -2- (4-acetyl-phenylcarbamoyl) -2-cyanovinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2- (2-bromo-4-methyl-phenylcarbamoyl) -2-cyanovinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2- (benzo [1,3] dioxol-5-ylcarbamoyl) -2-cyanovinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (2,3-dihydro-benzo [1,4] dioxin-6-ylcarbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (2-methoxy-phenylcarbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (2-phenoxy-phenylcarbamoyl) -vinyl] -indol-1-yl} -acetic; Acid (3- [(E) -2-cyano-2- (phenethyl-phenyl-carbamoyl) -vinyl] -indol-1-yl.} -acetic acid; {.3- [(E) -2- cyano-3- (11,12-dihydro-6H-dibenzo [b, f] azocin-5-yl) -3-oxo-propenyl] -indol-1-yl.} -acetic acid [3- (( E) -2-cyano-2-diphenylcarbamyl-vinyl) -indol-1-yl] -acetic; [3- ((E) -2-cyano-3-dibenzo [b, f] azepin-5-yl- Sodium 3-oxo-propenyl) -indol-1-yl] -acetate; (3- ({(E) -2- [(4-chloro-phenyl) -methyl-carbamoyl] -2-cyano-vinyl} -indol-1-yl) -acetic acid; Acid { 3- [(E) -2-cyano-3- (6,11-dihydro-dibenzo [b, e] azepin-5-yl) -3-oxo-propenyl] -indol-1-yl} -acetic; [3- ((E) -2-cyano-2-diphenethylcarbamoyl-vinyl) -indol-1-yl] -acetic acid; Acid { 3- [(E) -2-cyano-3- (10,11-dihydro-dibenzo [b, f] azepin-5-yl) -3-oxo-propenyl] -indol-1-yl} -acetic; (3- ({(E) -2-cyano-2- [methyl- ((R) -1-phenyl-ethyl) -carbamoyl] -vinyl} -indol-1-yl) -acetic acid; Acid { 3- [(E) -2- (benzyl-methyl-carbamoyl) -2-cyano-vinyl] -indol-1-yl} -acetic; (3- ({(E) -2- [(4-acetyl-phenyl) -methyl-carbamoyl] -2-cyano-vinyl} -indol-1-yl) -acetic acid; (3- ({(E) -2- [(4-acetyl-phenyl) -furan-2-ylmethyl-carbamoyl] -2-cyano-vinyl} -indol-1-yl) -acetic acid; Acid { 3- [(E) -2- (benzyl-carboxymethyl-carbamoyl) -2-cyanovinyl] -indol-1-yl} -acetic; Acid 3-. { benzyl- [(E) -3- (1-carboxymethyl-1H-indol-3-yl) -2- cyano-acryloyl] -amino} -propionic; Acid { 3- [(E) -2-cyano-3- (2,3-dihydro-indol-1-yl) -3-oxo-propenyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2 - (carboxymethyl-phenyl-carbamoyl) -2-cyanovinyl] -indol-l-yl} -acetic; (3 - { (E) -2-cyano-2- [(2-cyanp-ethyl) -f-enyl-carbamoyl] -vinyl} -indol-1-yl) -acetic acid; (3- ({(E) -2- [(3-chloro-phenyl) -methyl-carbamoyl] -2-cyano-vinyl} -indol-1-yl) -acetic acid; Acid { 3- [(E) -2- (allyl-phenyl-carbamoyl) -2-cyano-vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (cyclohexyl-phenyl-carbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (methyl-o-tolyl-carbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (ethyl-phenyl-carbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2- (butyl-phenyl-carbamoyl) -2-cyano-vinyl] -indol-1-yl} -acetic; [5-Bromo-3- ((E) -2-cyano-2-phenylcarbamoyl-vinyl) -indol-1-yl] -acetic acid; [3- ((E) -2-cyano-2-phenylcarbamoyl-vinyl) -7-methyl-indol-1-yl] -acetic acid; [3- ((E) -2-cyano-2-phenylcarbamoyl-vinyl) -5-fluoro-indol-1-yl] -acetic acid; [3- ((E) -2-cyano-2-phenylcarbamoyl-vinyl) -6-fluoro-indol-1-yl] -acetic acid; - ~ [3- ((E) -2-cyano-2-phenylcarbamoyl-vinyl) -6-nitro-indol-1-yl] -acetic acid; [3- ((E) -2-cyano-2-phenylcarbamoyl-vinyl) -5-methyl-indol-1-yl] -acetic acid; Acid { 3- [(E) -3- (2-chloro-phenothiazin-10-yl) -2-cyano-3-oxo-propenyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (phenyl-thiophen-3-ylmethyl-carbamoyl) -vinyl] -indol-1-yl} -acetic; (3- ({(E) -2-cyano-2- [(2, 2-diphenyl-ethyl) -phenyl-carbamoyl] -vinyl} -indol-1-yl) -acetic acid; (3- ({(E) -2-cyano-2- [phenyl- (3-phenyl-propyl) -carbamoyl] -vinyl} -indol-1-yl) -acetic acid; . [3- ((E) -2-cyano-2-. {[2- (4-fluoro-phenyl) -ethyl] -phenylcarbamoyl} -vinyl) -indol-1-yl] -acetic acid; Acid { 3- [(E) -2-cyano-3- (HH-10-oxa-5-aza-dibenzo [a, d] cyclohepten-5-yl) -3-oxo-propenyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2 - (isopropyl-phenyl-carbamoyl) -vinyl] -indol-1-yl} -acetic; (3- {(E) -2-cyano-2- [(3,4-dichloro-phenyl) -methylcarbamoyl] -vinyl} -indol-1-yl) -acetic acid; (3- ({(E) -2-cyano-2- [ethyl- (4-trifluoromethoxy-phenyl) -carbamoyl] -vinyl} -indol-1-yl) -acetic acid; Acid { 3- [(E) ~ 2- (Benzhydryl-carbamoyl) -2-cyanovinyl] -indol-1-yl} -acetic; (3- ({(E) -2-cyano-2- [methyl- (2-trifluoromethoxy-phenyl) -carbamoyl] -vinyl} -inddl-1-yl) -acetic acid; Acid { 3- [(E) -2-cyano-2- (2,4-di-fluoro-phenylcarbamoyl) -vinyl] indole-1-yl} -acetic; (3- ({(E) -2-cyano-2- [methyl- (4-trifluoromethoxy-phenyl) -carbamoyl] -vinyl} -indol-1-yl) -acetic acid; Acid { 3- [(E) -2-cyano-2- (ethyl-naphthalen-1-yl-carbamoyl) -vinyl] -indol-1-yl} -acetic; (3- {(E) -2-cyano-2- [(2,4-difluoro-phenyl) -methyl-carbamoyl] -vinyl} -indol-1-yl) -acetic acid; Acid { 3- [(E) -2-cyano-2- (2,4,6-trifluoro-phenylcarbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (2,3-, 4-trifluoro-phenylcarbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-3- (3,4-dihydro-lH-isoquinolin-2-yl) -3-oxo-propenyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-3-oxo-3- (7-trifluoromethyl-3,4-dihydro-2H-quinolin-1-yl) -propenyl] -indol-1-yl} -acetic; 2H-quinolin-1-yl) -propenyl] -5-fluoro-indol-1-yl} -acetic; (3- ({(E) -2-cyano-2- [ethyl- (4-trifluoromethoxy-phenyl) -carbamoyl] -vinyl} -5-fluoro-indol-1-yl) -acetic acid; Acid { 3- [(E) -2-cyano-3- (3,4-dihydro-lH-isoquinolin-2-yl) -3-oxo-propenyl] -5-fluoro-indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (phenethyl-phenyl-carbamoyl) -vinyl] -5-fluoro-indol-1-yl} -acetic; [3- ((E) -2-cyano-3-dibenzo [b, f] azepin-5-yl-3-oxo-propenyl) -6-methyl-indol-l-yl] -acetic acid; Acid { 3- [(E) -2-cyano-3- (6,11-dihydro-dibenzo [b, e] azepin-5-yl) -3-oxo-propenyl] -6-methyl-indol-1-yl} -acetic-; Acid { 3- [(E) -2-cyano-3- (10,11-dihydro-dibenzo [b, f] azepin-5-yl) -3-oxo-propenyl] -6-methyl-indol-1-yl} -acetic; Acid { 3- [(E) -2- (benzyl-phenyl-carbamoyl) -2-cyano-vinyl] -6-methyl-indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (cyclohexyl-phenyl-carbamoyl) -vinyl] -6-methyl-indol-1-yl} -acetic; (3- {(E) -2-cyano-2- [(4-fluoro-phenyl) -methyl-carbamoyl] -vinyl} - 6-methyl-indol-1-yl) -acetic acid; Acid { 3- [(E) -2- (Butyl-phenyl-carbamoyl) -2-cyano-vinyl] -6-methyl-indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (cyclohexyl-phenyl-carbamoyl) -vinyl] -7-methyl-indole-1-yl} -acetic; (3- {(E) -2-cyano-2- [(4-fluoro-phenyl) -methyl-carbamoyl] -vinyl} - 7-methyl-indol-1-yl) -acetic acid. (3- {(E) -2-cyano-2- [(3-fluoro-phenyl) -methyl-carbamoyl] -vinyl} -indol-1-yl) -acetic acid; [3- ((E) -2-cyano-3-dibenzo [b, f] azepin-5-yl-3-oxo-propenyl) -5-fluoro-indol-1-yl] -acetic acid; Acid { 3- [(E) -2-cyano-3- (6,11-dihydro-dibenzo [b, e] azepin-5-yl) -3-oxo-propenyl] -5-fluoro-indol-1-yl} -acetic; Acid { 3- [(E) -2- (benzyl-phenyl-carbamoyl) -2-cyano-vinyl] -5-fluoro-indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (cyclohexyl-phenyl-carbamoyl) -vinyl] -5-fluoro-indol-1-yl} -acetic; Acid { 3- [(E) -2- (Butyl-phenyl-carbamoyl) -2-cyano-vinyl] -5-fluoro-indol-1-yl} -acetic; (3- {(E) -2-cyano-2- [(4-fluoro-phenyl) -methyl-carbamoyl] -vinyl} -5-fluoro-indol-1-yl) -acetic acid; (3- ({(E) -2-cyano-2- [(3-fluoro-phenyl) -methyl-carbamoyl] -vinyl} -5-fluoro-indol-1-yl) -acetic acid; Acid (3- {(E) -2-cyano-2- [(3,4-dichloro-phenyl) -methyl-carbamoyl] -vinyl} -5-fluoro-indol-1-yl) -acetic acid; (3- ({(E) -2-cyano-2- [methyl- (2-trifluoromethyl-phenyl) -carbamoyl] -vinyl} -5-fluoro-indol-1-yl) -acetic acid; Acid (3- {(E) -2-cyano-2- [(2,4-difluoro-phenyl) -methyl-carbamoyl] -vinyl} -5-fluoro-indol-1-yl) -acetic acid; Acid { 3- [(E) -2-cyano-2- (phenyl-thiophen-3-ylmethyl-carbamoyl) -vinyl] -5-fluoro-indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-3-oxo-3- (7-trifluoromethyl-3,4-dihydro- In addition, the use of the first 112 compounds of the above list as medicines, in particular to treat diseases mentioned above, is more particularly preferred The invention relates more generally to the compounds of the general formula I, and especially to the 156 compounds listed above (and in particular the first 112 compounds). The compounds of the above general formula I are novel, with the exception of the following compounds which, however, are also potent CRTH2 receptor antagonists and in this respect are not described in the literature: Acid. { 3- [(E) -2-cyano-2- (4-fluoro-phenylcarbamoyl) -vinyl] -indol-1-yl} -acetic; [3- ((E) -2-cyano-2-m-tolylcarbamoyl-vinyl) -indol-1-yl] -acetic acid; Acid { 3- [(E) -2- (3-bromo-phenylcarbamoyl) -2-cyanovinyl] -indol-1-yl} -acetic; [3- ((E) -2-cyano-2-phenylcarbamoyl-vinyl) -indol-1-yl] -acetic acid; [3- ((E) -2-Benzylcarbamoyl-2-cyanovinyl) -indol-1-yl] -acetic acid; [3- ((E) -2-cyano-2-o-tolylcarbamoyl-vinyl) -indol-1-yl] -acetic acid; [3- ((E) -2-cyano-2-p-tolylcarbamoyl-vinyl) -indol-1-yl] -acetic acid; Acid { 3- [(E) -2- (4-bromo-phenylcarbamoyl) -2-cyano-vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (4-ethyl-phenylcarbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (4-methoxy-phenylcarbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (4-ethoxy-phenylcarbamoyl) -vinyl] -indol-1-yl} -acetic; [3- ((E) -2 -'-cyano-2-isopropylcarbamoyl-vinyl) -ipdol-1-yl] -acetic acid; Acid { 3- [(E) -2-cyano-2- (3-ethoxy-phenylcarbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-3- [[2- (lH-indol-3-yl) ethyl] amino] -3-oxo-1-propenyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (4-chloro-phenylcarbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-3- (4-methyl-piperidin-1-yl) -3-oxo-propenyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2- (3-chloro-4-methyl-phenylcarbamoyl) -2-cyanovinyl] -indol-1-yl} acetic; . Acid { 3- [(E) -2-cyano-2- (3-phenyl-propylcarbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (2,3-dichloro-phenylcarbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2- (5-chloro-2-methyl-phenylcarbamoyl) -2-cyanovinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (4-methoxy-benzylcarbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (2-fluoro-phenylcarbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-3-oxo-3- (4-phenyl-piperazin-1-yl) -propenyl] -indol-1-yl} -acetic; A further objective of the invention therefore relates to the compounds of the general formula I selected from the group consisting of: Acid. { 3- [(E) -2-cyano-2- (cyclohexylmethyl-carbamoyl) -vinyl] -indol-1-yl} -acetic; [3- ((E) -2-cyano-2-phenethylcarbamoyl-vinyl) -indol-1-yl] -acetic acid; [3- ((E) -2-cyano-2-isopropylcarbamoyl-vinyl) -indol-1-yl] -acetic acid; [3- ((E) -2-cyano-2-propylcarbamoyl-vinyl) -indol-1-yl] -acetic acid; [3- ((E) -2-cyano-2-cyclohexylcarbamoyl-vinyl) -indol-1-yl] -acetic acid; Acid { 3- [(E) -2-cyano-2- (3-methyl-butylcarbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2- (benzyl-phenyl-carbamoyl) -2-cyano-vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (4-cyano-phenylcarbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (4-fluoro-phenylcarbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (4-phenoxy-phenylcarbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (naphthalen-2-ylcarbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (2-isopropyl-phenylcarbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano- "2- (4-isopropyl-phenylcarbamoyl) -vinyl] -indol-1-yl.} -acetic acid; {.3- [(E) -2-cyano] -2- (3-methoxy-phenylcarbamoyl) -vinyl] -indol-1-yl.} -acetic acid: {.3- [(E) -2-cyano-2- (3-fluoro-phenylcarbamoyl) - vinyl] -indol-1-yl.} -acetic acid: {.3- [(E) -2-cyano-2- (9H-fluoren-2-ylcarbamoyl) -vinyl] -indol-1-yl} -Acetic; Acid {3- [(E) -2-cyano-2- (4-propyl-phenylcarbamoyl) -vinyl] -indol-1-yl} -acetic, - Acid. - [(E) -2- (biphenyl-4-ylcarbamoyl) -2-cyano-vinyl] -indol-1-yl.} -acetic acid: {.3- [(E) -2-cyano-2 - (3,2'-dimethyl-biphenyl-4-ylcarbamoyl) -vinyl] -indol-1-yl.} -acetic acid; Acid { 3- [(E) -2- (4-tert-butyl-phenylcarbamoyl) -2-cyanovinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2- (2-benzyl-phenylcarbamoyl) -2-cyanovinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2- (4-Butyl-phenylcarbamoyl) -2-cyanovinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2- (2-acetyl-phenylcarbamoyl) -2-cyanovinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (indan-5-ylcarbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2- (4-sec-Butyl-phenylcarbamoyl) -2-cyano-vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2 ~ (2-propyl-phenylcarbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (3-phenoxy-phenylcarbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (3-ethyl-phenylcarbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (2-ethoxy-phenylcarbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2- (3-benzyloxy-phenylcarbamoyl) -2-cyanovinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (4-iodo-phenylcarbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (3-iodo-phenylcarbamoyl) -vinyl] -indol-1-yl} -acetic; (3- ({(E) -2-cyano-2- [(4-fluoro-phenyl) -methylcarbamoyl] -vinyl} -indol-1-yl) -acetic acid; (3- {(E) -2-cyano-2- [(4-methoxy-phenyl) -methyl-carbamoyl] -vinyl} -indol-1-yl) -acetic acid; Acid { 3- [(E) -2-cyano-2- (methyl-phenyl-carbamoyl) -vinyl] -indol-1-yl} -acetic, - Acid. "{. 3- [(E) -2-cyano-3- (3,4-dihydro-2H-quinolin-l-yl) -3-oxo-propenyl] -indol-1-yl .) -Acetic; Acid {3- [(E) -2-cyano-2- (methyl-p-tolyl-carbamoyl) -vinyl] -indol-1-yl.} -acetic; {. (E) -2-cyano-2- [2- (2,4-dichloro-phenoxy) -phenylcarbamoyl] -vinyl} -indol-1-yl) -acetic acid; (E) -2-cyano-2- (2,5-dimethyl-phenylcarbamoyl) -vinyl] -indol-1-yl.} -acetic acid: {.3- [(E) -2-cyano-2 - (9-ethyl-9H-carbazol-3-ylcarbamoyl) -vinyl] -indol-l-yl.} -acetic acid: {.3- [(E) -2- (3,5-bis-trifluoromethyl) phenylcarbamoyl) -2-cyano-vinyl] -indol-1-yl.} -acetic acid; {.3- [(E) -2-cyano-2- (5-methoxy-2-methyl-phenylcarbamoyl) -vinyl] -indol-1-yl.} -acetic; • acid. {3 - [(E) -2- (3-benzoyl-phenylcarbamoyl) -2-cyano-vinyl] -indol-1-yl} -acetic, - Acid. {3- [(E) -2- (4-benzyloxy-phenylcarbamoyl) -2-cyano-vinyl] -indol-1-yl} -acetic acid; Acid { 3- [(E) -2-cyano-2- (3-nitro-phenylcarbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (9-oxo-9H-fluoren-2-ylcarbamoyl) -vinyl] -indol-1-yl} -acetic; (3- [(E) -2-Cyano-2- (4-methoxy-biphenyl-3-ylcarbamoyl) -vinyl] -indol-1-yl.} -acetic acid; Acid. {3- ([E]) ) -2-cyano-2- (2-methoxy-dibenzofuran-3-ylcarbamoyl) -vinyl] -indol-1-yl.} -acetic acid: {.3- [(E) -2-cyano-2 - (9-Oxo-9H-fluoren-4-ylcarbamoyl) -vinyl] -indole-1-yl.} -acetic acid: {.3- [(E) -2-cyano-2- (9-oxo -9H-fluoren-1-ylcarbamoyl) -vinyl] -indol-1-yl.} -acetic acid; {.3- [(E) -2- (2-benzoyl-phenylcarbamoyl) -2-cyano-vinyl; ] - indol-1-yl.} -acetic acid: {.3- [(E) -2- (3-chloro-4-methoxy-phenylcarbamoyl) -2-cyano-vinyl] -indol-1-yl .). -acetic; Acid { 3- [(E) -2- (5-chloro-2-methoxy-phenylcarbamoyl) -2-cyano-vinyl] -indol-1-yl.} -acetic; 3- [(E) -3- (l-carboxymethyl-lH-indol-3-yl) -2-cyano-acryloylamino] -4-methyl-benzoic acid methyl; 2- [(E) - methyl ester] 3- (l-carboxymethyl-lH-indol-3-yl) -2-cyano-acryloylamino] -benzoic acid; {.3- [(E) -2-cyano-2- (4-trifluoromethoxy-f enylcarbamoyl) -vinyl] -indol-l-il} -acetic; Acid { 3- [(E) -2-cyano-2- (3, 5-dimethyl-phenylcarbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2- (3-bromo-4-methyl-phenylcarbamoyl) -2-cyanovinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2- (4-bromo-3-methyl-phenylcarbamoyl) -2-cyanovinyl] -indol-1-yl} -acetic; Methyl ester of 4- [(E) -3- (l-carboxymethyl-lH-indol-3-yl) -2-cyano-acryloylamino] -benzoic acid methyl ester; 3- [(E) -3- (l-carboxymethyl-lH-indol-3-yl) -2-cyano-acryloylamino] -benzoic acid; Acid { 3- [(E) -2-cyano-2- (4-trifluoromethyl-phenylcarbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (3, 5-dimethoxy-phenylcarbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2- (4-bromo-3-chloro-phenylcarbamoyl) -2-cyanovinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2- (4-bromo-2-methyl-phenylcarbamoyl) -2-cyanovinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2- (4-acetyl-phenylcarbamoyl) -2-cyanovinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2- (2-bromo-4-methyl-phenylcarbamoyl) -2-cyanovinyl] -indol-1-yl} -acetic; Acid (3- [(E) -2- (benzo [1,3] dioxol-5-ylcarbamoyl) -2-cyano-vinyl] -indol-1-yl.} -acetic acid; (E) -2-cyano-2- (phenethyl-phenyl-carbamoyl) -vinyl] -indol-1-yl.} -acetic; Acid { 3- [(E) -2-cyano-3- (11,12-dihydro-6 H -dibenzo [b, f] azocin-5-yl) -3 -oxo-propenyl] -indol-1-yl} -acetic; [3- ((E) -2-cyano-2-diphenylcarbamoyl-vinyl) -indol-1-yl] -acetic acid; [3- ((E) -2-cyano-3-dibenzo [b, f] azepin-5-yl-3-oxo-propenyl) -indol-1-yl] -acetic acid; (3- { (E) -2- [(4-chloro-phenyl) -methyl-carbamoyl] -2-cyano-vinyl} - indol-1-yl) -acetic; To Acid. { 3- [(E) -2-cyano-3- (6,11-dihydro-dibenzo [b, e] azepin-5-yl) -3-oxo-propenyl] -indol-1-yl} -acetic; [3- ((E) -2-cyano-2-diphenethylcarbamoyl-vinyl) -indol-1-yl] -acetic acid; Acid { 3- [(E) -2- (5-chloro-2-methoxy-phenylcarbamoyl) -2-cyano-vinyl] -indol-1-yl} -acetic; 3- [(E) -3- (l-carboxymethyl-lH-indol-3-yl) -2-cyano-acryloylamino] -4-methyl-benzoic acid methyl ester; 2 - [(E) -3- (1-carboxymethyl-1H-indol-3-yl) -2-cyano-acryloylamino] -benzoic acid methyl ester; Acid { 3- [(E) -2-cyano-2- (4-trifluoromethoxy-phenylcarbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (3, 5-dimethyl-phenylcarbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2- (3-bromo-4 ~ methyl-phenylcarbamoyl) -2-cyanovinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2- (4-bromo-3 ~ methyl-phenylcarbamoyl) -2-cyanovinyl] -indol-1-yl} -acetic; Methyl ester of 4- [(E) -3- (l-carboxymethyl-lH-indol-3-yl) -2-cyano-acryloylamino] -benzoic acid methyl ester; 3- [(E) -3- (1-Carboxymethyl-1H-indol-3-yl) -2-cyano-acryloylamino] -benzoic acid methyl ester; Acid { 3- [(E) -2-cyano-2- (4-trifluoromethyl-phenylcarbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (3, 5-dimethoxy-phenylcarbamoyl) -vinyl] -indol'-1-yl} -acetic; ~ Á.oido. { 3- [(E) -2- (4-bromo-3-chloro-phenylcarbamoyl) -2-cyanovinyl] -indol-1-yl} -acetic; - Acid { 3- [(E) -2- (4-bromo-2-methyl-phenylcarbamoyl) -2-cyanovinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2- (4-acetyl-phenylcarbamoyl) -2-cyanovinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2- (2-bromo-4-methyl-phenylcarbamoyl) -2-cyanovinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2- (benzo [1,3] dioxol-5-ylcarbamoyl) -2-cyanovinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (phenethyl-phenyl-carbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-3- (11,12-dihydro-6 H -dibenzo [b, f] azocin-5-yl) -3 -oxo-propenyl] -indol-1-yl} -acetic; [3- ((E) -2-cyano-2-diphenylcarbamoyl-vinyl) -indol-1-yl] -acetic acid; [3- ((E) -2-cyano-3-dibenzo [b, f] azepin-5-yl-3-oxo-propenyl) -indol-1-yl] -acetic acid; (3- { (E) -2- [(4-chloro-phenyl) -methyl-carbamoyl] -2-cyano-vinyl} - indol-1-yl) -acetic; Acid { 3- [(E) -2-cyano-3- (6,11-dihydro-dibenzo [b, e] azepin-5-yl) -3-oxo-propenyl] -indol-1-yl} -acetic; [3- ((E) -2-cyano-2-diphenethylcarbamoyl-vinyl) -indol-1-yl] -acetic acid; Acid { 3- [(E) -2-cyano-3- (10,11-dihydro-dibenzo [b, f] azepin-5-yl) -3-oxo-propenyl] -indol-1-yl} -acetic; (3- ({(E) -2-cyano-2 ~ [methyl- ((R) -1-phenyl-ethyl) -carbamoyl] vinyl} -indol-1-yl) -acetic acid; Acid { 3- [(E) -2- (benzyl-methyl-carbamoyl) -2-cyano-vinyl] -indol-1-yl} -acetic; (3- ({(E) -2- [(4-acetyl-phenyl) -methyl-carbamoyl] -2-cyano-vinyl} -indol-1-yl) -acetic acid; Acid (3- { (E) -2- [(4-acetyl-phenyl) -furan-2-ylmethyl-carbamoyl] 2-cyanovinyl} -indol-1-yl) -acetic, - Acid. { 3- [(E) -2- (benzyl-carboxymethyl-carbamoyl) -2-cyanovinyl] -indol-1-yl} -acetic; Acid 3-. { benzyl- [(E) -3- (l-carboxymethyl-lH-indol-3-yl) -2-cyano-acryloyl] -amino} -propionic; Acid { 3- [(E) -2-cyano-3- (2,3-dihydro-indol-1-yl) -3-oxo-propenyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2- (carboxymethyl-phenyl-carbamoyl) -2-cyanovinyl] -indol-1-yl} -acetic; (3- {(E) -2-cyano-2- [(2-cyano-ethyl) -phenyl-carbamoyl] -vinyl} -indol-1-yl) -acetic acid; (3- ({(E) -2- [(3-chloro-phenyl) -methyl-carbamoyl] -2-cyanovinyl} -indol-1-yl) -acetic acid; Acid { 3- [(E) -2- (allyl-phenyl-carbamoyl) -2-cyano-vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (cyclohexyl-phenyl-carbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (methyl-o-tolyl-carbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (ethyl-phenyl-carbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2- (butyl-phenyl-carbamoyl) -2-cyano-vinyl] -indol-l-yl} -acetic; [5-Bromo-3- ((E) -2-cyano-2-phenylcarbamoyl-vinyl) -indol-1-yl] -acetic acid; [3- ((E) -2-cyano-2-phenylcarbamoyl-vinyl) -5-fluoro-indol-1-yl] -acetic acid; [3- ((E) -2-cyano-2-phenylcarbamoyl-vinyl) -5-methyl-indol-1-yl] -acetic acid; [3- ((E) -2-cyano-2-phenylcarbamoyl-vinyl) -6-fluoro-indol-1-yl] -acetic acid; [3- ((E) -2-cyano-2-phenylcarbamoyl-vinyl) -6-nitro-indol-1-yl] -acetic acid; [3- ((E) -2-cyano-2-phenylcarbamoyl-vinyl) -7-methyl-indol-1-yl] -acetic acid; Acid { 3- [(E) -3- (2-Chloro-phenothiazin-10-yl) -2-cyano-3-oxo-propenyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (phenyl-thiophen-3-ylmethyl-carbamoyl) -vinyl] -indol-1-yl} -acetic; (3- {(E) -2-cyano-2- [(2, 2-diphenyl-ethyl) -phenyl-carbamoyl] -vinyl} -indol-1-yl) -acetic acid; (3- ({(E) -2-cyano-2- [phenyl- (3-phenyl-propyl) -carbamoyl] -vinyl} -indol-1-yl) -acetic acid; [3- ((E) -2-cyano-2- {[2- (4-fluoro-phenyl) -ethyl] -phenylcarbamoyl} -vinyl) -indol-1-yl] -acetic acid; Acid { 3- [(E) -2-cyano-3- (HH-10-oxa-5-aza-dibenzo [a, d] cyclohepten-5-yl) -3-oxo-propenyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (isopropyl-phenyl-carbamoyl) -vinyl] -indol-1-yl} -acetic; (3- {(E) -2-cyano-2- [(3,4-dichloro-phenyl) -methyl-carbamoyl] -vinyl} -indol-1-yl) -acetic acid; (3- ({(E) -2-cyano-2- [ethyl- (4-trifluoromethoxy-phenyl) -carbamoyl] -vinyl} -indol-1-yl) -acetic acid; Acid { 3- [(E) -2- (benzhydryl-carbamoyl) -2-cyanovinyl] -indol-1-yl} -acetic; (3- ({(E) -2-cyano-2- [methyl- (2-trifluoromethoxy-phenyl) -carbamoyl] -vinyl} -indol-1-yl) -acetic acid; Acid { 3- [(E) -2-cyano-2- (2,4-difluoro-phenylcarbamoyl) -vinyl] indole-1-yl} -acetic; (3- ({(E) -2-cyano-2- [methyl- (4-trifluoromethoxy-phenyl) -carbamoyl] -vinyl} -indol-1-yl) -acetic acid; Acid { 3- [(E) -2-cyano-2- (ethyl-naphthalen-1-yl-carbamoyl) -vinyl] -indol-1-yl} -acetic; (3- ({(E) -2-cyano-2- [(2,4-difluoro-phenyl) -methylcarbamoyl] -vinyl} -indol-1-yl) -acetic acid; Acid { 3- [(E) -2-cyano-2- (2,4,6-trifluoro-phenylcarbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (2,3-, 4-trifluoro-phenylcarbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-3- (3,4-dihydro-lH-isoquinolin-2-yl) -3-oxo-propenyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-3-oxo-3- (7-trifluoromethyl-3,4-dihydro-2H-quinolin-1-yl) -propenyl] -indol-1-yl} -acetic; (3- ({(E) -2-cyano-2- [(3-fluoro-phenyl) -methyl-carbamoyl] -vinyl} -indol-1-yl) -acetic acid; . [3- ((E) -2-cyano-3-dibenzo [b, f] azepin-5-yl-3 -oxo-propenyl) -5-f-luoro-indol-1-yl] -acetic acid; Acid { 3- [(E) -2-cyano-3 - (6,11-dihydro-dibenzo [b, e] azepin-5-yl) -3 -oxo-propenyl] -5-fluoro-indol-1-yl} -acetic; Acid { 3 - [(E) -2 - (benzyl-phenyl-carbamoyl) -2-cyanovinyl] -5-f luoro-indol-1-yl} -acetic; Acid { 3 - [(E) -2-cyano-2- (cyclohexyl-f-enyl-carbamoyl) -vinyl] -5-fluoro-indol-1-yl} -acetic; Acid { 3- [(E) -2- (Butyl-phenyl-carbamoyl) -2-cyano-vinyl] -5-fluoro-indol-1-yl} -acetic; (3- {(E) -2-cyano-2- [(4-fluoro-phenyl) -methyl-carbamoyl] -vinyl} -5-fluoro-indol-1-yl) -acetic acid; (3- ({(E) -2-cyano-2- [(3-fluoro-phenyl) -methyl-carbamoyl] -vinyl} -5-fluoro-indol-1-yl) -acetic acid; Acid (3- {(E) -2-cyano-2- [(3,4-dichloro-phenyl) -methyl-carbamoyl] -vinyl} -5-fluoro-indol-1-yl) - acetic; (3- ({(E) -2-cyano-2- [methyl- (2-trifluoromethyl-phenyl) -carbamoyl] -vinyl} -5-fluoro-indol-1-yl) -acetic acid; (3- ({(E) -2-cyano-2- [(2,4-difluoro-phenyl) -methylcarbamoyl] -vinyl} -5-fluoro-indol-1-yl) -acetic acid; Acid { 3- [(E) -2-cyano-2- (phenyl-thiophen-3-ylmethyl-carbamoyl) -vinyl] -5-fluoro-indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-3-oxo-3- (7-trifluoromethyl-3,4-dihydro-2H-quinolin-1-yl) -propenyl] -5-fluoro-indol-1-yl} -acetic; (3- ({(E) -2-cyano-2- [ethyl- (4-trifluoromethoxy-phenyl) -carbamoyl] -vinyl} -5-fluoro-indol-1-yl) -acetic acid; Acid { 3- [(E) -2-cyano-3- (3,4-dihydro-lH-isoquinolin-2-yl) -3-oxo-propenyl] -5-fluoro-indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (phenethyl-phenyl-carbamoyl) -vinyl] -5-fluoro-indol-1-yl} -acetic; [3- ((E) -2-cyano-3-dibenzo [b, f] azepin-5-yl-3-oxo-propenyl) -6-methyl-indol-1-yl] -acetic acid; Acid { 3- [(E) -2-cyano-3- (6,11-dihydro-dibenzo [b, e] azepin-5-yl) -3-oxo-propenyl] -6-methyl-indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-3- (10,11-dihydro-dibenzo [b, f] azepin-5-yl) -3 -oxo-propenyl] -6-methyl-indole-1-yl} -acetic; Acid { 3- [(E) -2- (benzyl-phenyl-carbamoyl) -2-cyano-vinyl] -6-methyl-indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (cyclohexyl-phenyl-carbamoyl) -vinyl] -6-methyl-indole-1-yl} -acetic; (3- {(E) -2-cyano-2- [(4-fluoro-phenyl) -methyl-carbamoyl] -vinyl} -6-methyl-indol-1-yl) -acetic acid; Acid { 3- [(E) -2- (Butyl-phenyl-carbamoyl) -2-cyano-vinyl] -6-methyl-indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (cyclohexyl-phenyl-carbamoyl) -vinyl] -7-methyl-indole-1-yl} -acetic; and Acid '(3- {(E) -2-cyano-2- [(4-fluoro-phenyl) -methyl-carbamoyl] -vinyl} -7-methyl-indol-1-yl) -acetic acid . The present invention also relates therefore to the compounds of the general formula IC? Ici where A represents hydrogen; I rent; halogen or cyano; B represents hydrogen; alkyl or halogen; R1, R2, R3 - and R4 independently represent hydrogen; I rent; halogen; nitro; cyano or formyl (and preferably independently represent hydrogen, alkyl, halogen or nitro); R5 and R6 independently represent hydrogen; I rent; cycloalkyl; cycloalkyl-alkyl; heteroaryl; heteroarylalkyl; alkenyl; carboxyalkyl; cyanoalkyl; diphenylalkyl; aryl, aryl-alkoxy-aryl, aryl-alkyl, aryl-alkyl-aryl, arylcarbonyl-aryl or aryloxyaryl, or R5 and R6, together with the nitrogen atom, to which they are bonded, form a heterocyclic ring system; with the exception, however, of the following compounds: Acid. { 3- [(E) -2-cyano-2- (4-fluoro-phenylcarbamoyl) -vinyl] -indol-1-yl} -acetic; [3- ((E) -2-cyano-2-m-tolylcarbamoyl-vinyl) -indol-1-yl] -acetic acid; Acid { 3 - [(E) -2- (3-bromo-phenylcarbamoyl) -2-cyano-vinyl] -indol-1-yl} -acetic; [3- ((E) -2-cyano-2-phenylcarbamoyl-vinyl) -indol-1-yl] -acetic acid; [3- ((E) -2-benzylcarbamoyl-2-cyanovinyl) -indol-1-yl] -acetic acid; [3- ((E) -2-cyano-2-o-tolylcarbamoyl-vinyl) -indol-1-yl] -acetic acid; [3- ((E) -2-cyano-2-p-tolylcarbamoyl-vinyl) -indol-1-yl] -acetic acid; Acid { 3- [(E) -2- (4-bromo-phenylcarbamoyl) -2-cyano-vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (4-ethyl-phenylcarbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (4-methoxy-phenylcarbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (4-ethoxy-phenylcarbamoyl) -vinyl] -indol-1-yl} -acetic; [3- ((E) -2-cyano-2-isopropylcarbamoyl-vinyl) -indol-1-yl] -acetic acid; Acid { 3- [(E) -2-cyano-2- (3-ethoxy-phenylcarbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-3 - [[2- (lH-indol-3-yl) ethyl] amino] -3 -oxo-1-propenyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (4-chloro-phenylcarbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-3- (4-methyl-piperidin-1-yl) -3-oxo-propenyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2- (3-chloro-4-methyl-phenylcarbamoyl) -2-cyanovinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (3-phenyl-propylcarbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (2,3-dichloro-phenylcarbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2- (5-chloro-2-methyl-phenylcarbamoyl) -2-cyanovinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (4-methoxy-benzylcarbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (2-fluoro-phenylcarbamoyl) -vinyl] -indol-1-yl} -acetic; and Acid. { 3- [(E) -2-cyano-3-oxo-3- (4-phenyl-piperazin-1-yl) -propenyl] -indol-1-yl} -acetic. The invention also relates to the compounds of the general formula IC2. where: XC2 wherein A represents hydrogen; I rent; halogen or cyano; B represents hydrogen; alkyl or halogen; R1, R2, R3 and R4 independently represent -hydrogen; I rent; halogen; nitro; cia.no or formyl (and preferably independently represent hydrogen, alkyl, halogen or nitro); R5 and R6 independently represent hydrogen; I rent; cycloalkyl; cycloalkyl-a.lkyl; heteroaryl; heteroarylalkyl; alkenyl; carboxyalkyl; cyanoalkyl; diphenylalkyl; aryl, aryl-alkoxy-aryl, aryl-alkyl, aryl-alkyl-aryl, arylcarbonyl-aryl or aryloxyaryl, or R5 and R6, together with the nitrogen atom, to which they are bonded, form a heterocyclic ring system; it being understood however that at least one of the following conditions must be met: Or one of R1, R2, R3 and R4 is different from a hydrogen atom; or O when R5 and R6 are such that they do not form a heterocyclic ring system with the nitrogen atom to which they are linked, then R? and R6 are different from hydrogen and one of R5 and R6 is different from alkyl; or O when R5 and R6 are such that they form a heterocyclic ring system, together with the nitrogen atom to which they are linked, then said heterocyclic ring system is neither an unsubstituted or substituted pyridine nor an unsubstituted or "substituted" piperazine. The invention also relates to the compounds of the general formula IC1 for use as medicaments, as well as the compounds of the general formula IC2 as medicaments A further aspect of the invention relates to pharmaceutical compositions containing, as active ingredient, at least one compound of the general formula I, and a pharmaceutically acceptable carrier The invention also encompasses the pharmaceutical compositions containing, as active ingredient, at least one compound of the general formula IC ?, and a pharmaceutically acceptable carrier, as well as pharmaceutical compositions containing, as an active ingredient, at least one compound of the general formula IC2 and a pharmaceutically acceptable carrier The invention also relates to the use of a compound of the formula I for the preparation of a medicament intended for the prevention and treatment of chronic and acute allergic immune disorders comprising allergic asthma, rhinitis, chronic obstructive pulmonary disease (COPD), dermatitis, inflammatory bowel disease, rheumatoid arthritis, allergic nephritis, conjunctivitis , atopic dermatitis, bronchial asthma, food allergy, systemic disorders of mast cells, anaphylactic shock, urticaria, eczema, itching, inflammation, ischemia-reperfusion injury, cerebrovascular disorders, pleuritis, ulcerative colitis, diseases related to eosinophils, such as Churg-Strauss syndrome and sinusitis, diseases related to basophils, such as basophilic leukemia and basophilic leukocytosis. The invention also relates to the use of a compound of the general formula IC1 or a compound of the general formula IC2 for the preparation of a medicament for the prevention and treatment of the aforementioned diseases. Medications prepared in this way can be used for humans or other mammals. The invention also relates to methods for preventing and treating in humans selected diseases of chronic and acute allergic immune disorders comprising allergic asthma, rhinitis, chronic obstructive pulmonary disease (COPD), dermatitis, inflammatory bowel disease, rheumatoid arthritis, Allergic nephritis, conjunctivitis, atopic dermatitis, bronchial asthma, food allergy, systemic disorders of mast cells, anaphylactic shock, urticaria, eczema, itching, inflammation, ischemia-reperfusion injury, cerebrovascular disorders, pleuritis, ulcerative colitis, diseases related to eosinophils, such as Churg-Strauss syndrome and sinusitis, diseases related to basophils, such as basophilic leukemia and basophilic leukocytosis, said methods comprise administration to humans in need thereof, of an effective amount of a compound of the formula general I The invention also relates to methods for preventing or treating the same diseases in humans, the methods comprising the administration to humans in need thereof, of an effective amount of a compound of the general formula IC? or of a compound of the general formula I2 • The preferences indicated for the compounds of the general formula I are applicable mutatis mutandis to the compounds of the general formula IC? and to the compounds of the general formula IC2 - In addition, a particular variant of the invention relates, in its first aspect, to pharmaceutical compositions containing at least one compound of the general formula IP wherein ~ '- * A represents alkyl; halogen or cyano; B represents hydrogen; alkyl or halogen; R1, R2, R3 and R4 independently represent hydrogen; I rent; halogen; nitro; cyano or formyl; R5 and R5 independently represent hydrogen; I rent; alkenyl; cycloalkyl; heteroaryl; or a member selected from the group consisting of aryl, alkoxy-aryl, alkoxycarbonyl-aryl, alkylcarbonyl-aryl, aryl-alkoxy-aryl, aryl-alkyl, aryl-alkyl-aryl, arylcarbonyl-aryl and aryloxy-aryl, wherein the aryl group is unsubstituted or mono- or di-substituted with one or more substituents independently selected from the group consisting of alkyl, alkoxy, halogen, cyano, alkoxycarbonyl, alkylcarbonyl, phenyl, benzyl, benzoyl, benzyloxy, benzyloxycarbonyl, trifluoromethyl and trifluoromethoxy; or R5 and R6, together with the nitrogen atom to which they are linked, form a heterocyclic ring system; and optically pure enantiomers, mixtures of enantiomers, racemates, optically pure diastereomers, mixtures of diastereomers, racemates, diastereoisomers, mixtures of diastereomeric racemates, meso forms, geometric isomers, prodrugs of compounds in which a prodrug-forming group is present, as well such as the solvates and the morphological forms, the pharmaceutically acceptable salts thereof and the usual inert carrier materials or adjuvants, - it being understood however that in the formula: general IP: i) the term "alkyl" or "lower alkyl", used alone or in any combination, it refers to a separate aliphatic group that includes a straight or branched hydrocarbon chain containing 1 to 8 carbon atoms (and preferably 1 to 4 carbon atoms), whose saturated aliphatic group can be optionally substituted with one or more substituents, each independently selected from alkenyl , alkoxy, alkoxycarbonyl, alkylcarbonyl, alkylcarbonyloxy, alkylenedioxy, alkylsulfinyl, alkylsulfonyl, alkylthio, alkynyl, amino, aminocarbonyl, aryl, arylalkenyl, arylalkyloxy, aryloxy, aryloxycarbonyl, arylsulfinyl, arylsulfonyl, arylthio, carboxyl, cyano, formyl, halogen, haloalkoxy, heterocyclyl , hydroxyl, mercapto, nitro, and the like, linked to any carbon atom of the alkyl portion; ii) the term "alkenyl" or "lower alkenyl", used alone or in any combination, refers to a straight or branched hydrocarbon chain containing 2 to 8 carbon atoms, with at least one carbon-carbon double bond (RaRbC = CRcRd wherein Ra-Rrj refers to substituents, each individually and independently selected from hydrogen and alkyl, alkoxy, alkoxyalkyl and the like); iii) the term "alkoxy" used alone or in any combination, refers to an alkyl group linked to the parent molecular moiety through an oxygen bridge; iv) the term "aryl" used alone or in any combination, refers to a carbocyclic group having at least one aromatic ring, for example, phenyl or biphenyl, or multiple fused ring systems, in which at least one ring is aromatic (eg, 1,2,3,4-tetrahydronaphthyl, naphthyl, anthryl, phenanthryl, fluorenyl, and the like), which aryl group may be optionally substituted with one or more functional groups individually and independently selected from alkenyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, alkyl, alkylcarbonyl, alkylcarbonylalkyl, alkylcarbonyloxy, alkylenedioxy, alkylsulfinyl, alkylsulfinylalkyl, alkylsulfonyl, alkylsulfonylalkyl, alkylthio, alkylthioalkyl, alkynyl, amino, aminoalkyl, aminocarbonyl, aminocarbonyalkyl, aryl, arylalkenyl, arylalkyloxy, arylalkyl, aryloxy aryloxycarbonyl, aryloxycarbonylalkyl, arylsulfinyl, arylsulfinylalkyl, arylsulfonyl, arylsulfonylalkyl, arylthio, arylthioalkyl, carboxyl, carboxyalkyl, cyano, cyanoalkyl, formyl, formylalkyl, halogen, haloalkoxy, haloalkyl, heteroaryl, heterocyclyl, hydroxyl, hydroxyalkyl, mercapto, nitro, and the like; v) the term "arylakoxy", used alone or in any combination, refers to an aryl group which can be unsubstituted or substituted as previously defined and which is linked to the parent molecular moiety through an alkoxy group; vi) the term "arylalkyl", used alone or in any combination, refers to an aryl group which may be unsubstituted or substituted as previously defined and which is linked to the parent molecular moiety through an alkyl group; vii) the term "aryloxy" used alone or in any combination, refers to an aryl group which may be unsubstituted or substituted as previously defined and which is linked to the parent molecular moiety through an oxygen bridge; viii) the term "arylcarbonyl" or "aroyl" used alone or in any combination, refers to an aryl group linked to the parent molecular moiety through a carbonyl group; ix) the term "cycloalkyl" used alone or in any combination, refers to a saturated cyclic hydrocarbon portion containing 3 to 15 carbon atoms, optionally substituted with one or more groups, each individually and independently selected from alkenyl, alkoxy , alkoxyalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, alkyl, alkylcarbonyl, alkylcarrylalkyl, alkylcarbonyloxy, alkylenedioxy, alkylsulfinyl, alkylsulfinylalkyl, - "alkylsulfonyl, alkylsulfonylalkyl, .alkylthio, alkylthioalkyl, alkynyl, amino, aminoalkyl, aminocarbonyl, aminocarbonylalkyl, aryl, arylalkenyl, arylalkyloxy, arylalkyl , aryloxy, aryloxycarbonyl, aryloxycarbonylalkyl, arylsulfinyl, arylsulfinylalkyl, arylsulfonyl, arylsulfonylalkyl, arylthio, arythioalkyl, carboxyl, carboxyalkyl, cyano, cyanoalkyl, formyl, formylalkyl, halogen, haloalkoxy, haloalkyl, heteroaryl, heterocyclyl, hydroxyl, hydroxyalkyl, mercapto, nitro, and Similar; it being understood that the polycyclic cycloalkyl groups of the distal rings may be aromatic (e.g., 1-indanyl, 2-indanyl, tetrahydronaphthalene, and the like (e.g., 1-indanyl, 2-indanyl, tetrahydronaphthalene, and the like); "heterocyclyl" alone or in any combination, refers to a monocyclic, bicyclic or polycyclic ring system containing up to 15 ring atoms, at least one of which is a heteroatom independently selected from nitrogen, oxygen or sulfur, whose system The ring may be saturated, partially unsaturated, unsaturated or aromatic, or may be optionally substituted with one or more groups, each individually and independently selected from alkenyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, alkyl, alkylcarbonyl, alkylcarbonylalkyl, alkylcarbonyloxy, alkylenedioxy , alkylsulfinyl, alkylsulfinylalkyl, alkylsulfonyl, alkylsulfonylalkyl, alkyl io, alkylthioalkyl, alkynyl, amino, aminoalkyl, aminocarbonyl, aminocarbonylalkyl, aryl, arylalkenyl, arylalkyloxy, arylalkyl, aryloxy, aryloxycarbonyl, aryloxycarbonylalkyl, arylsulfinyl, arylsulfinylalkyl, arylsulfonyl, arylsulfonylalkyl, arylthio, arythioalkyl, carboxyl, carboxyalkyl, cyano, cyanoalkyl, formyl , formylalkyl, halogen, haloalkoxy, haloalkyl, heteroaryl, heterocyclyl, hydroxyl, hydroxyalkyl, mercapto, nitro, and the like; xi) the term "heteroaryl" used alone or in any combination, is a special case of heterocyclyl and refers to a mono- or bicyclic or polycyclic ring system, in which at least one heterocyclic ring is aromatic. The compounds of the above general formula IP are novel with the exception of the following compounds, which, however, are also potent antagonists of the CRTH2 receptor and were not previously described in this regard in the literature: Acid. { 3- [(E) -2-cyano-2- (4-fluoro-phenylcarbamoyl) -vinyl] -indol-1-yl} -acetic; [3- ((E) -2-cyano-2-m-tolylcarbamoyl-vinyl) -indol-1-yl] -acetic acid; Acid { 3- [(E) -2- (3-bromo-phenylcarbamoyl) -2-cyanovinyl] -indol-1-yl} -acetic; [3- (()) -2-cyano-2-phenylcarbamoyl-vinyl) -indol-1-yl] -acetic acid; [3- ((E) -2-Benzylcarbamoyl-2-cyanovinyl) -indol-1-yl] -acetic acid; [3- ((E) -2-cyano-2-o-tolylcarbamoyl-vinyl) -indol-1-yl] -acetic acid; [3- ((E) -2-cyano-2-p-tolylcarbamoyl-vinyl) -indol-1-yl] -acetic acid; Acid { 3- [(E) -2- (4-bromo-phenylcarbamoyl) -2-cyanovinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (4-ethyl-phenylcarbamoyl) -vinyl] -indol-1-yl} acetic; Acid { 3- [(E) -2-cyano-2- (4-methoxy-phenylcarbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (4-ethoxy-phenylcarbamoyl) -vinyl] -indol-1-yl} -acetic; [3- ((E) -2-cyano-2-isopropylcarbamoyl-vinyl) -indol-1-yl] -acetic acid; Acid { 3- [(E) -2-cyano-2- (3-ethoxy-phenylcarbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-3- [[2- (l-rindol-3-yl) ethyl] amino] -3-oxo-1-propenyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (4-chloro-phenylcarbamoyl) -vinyl] -indol-1-yl} -acetic A second aspect of the aforementioned particular variant of the invention is the use of the compounds of the general formula IP as medicaments for treating the aforementioned diseases. A third aspect of the aforementioned particular variant of the invention relates to the novel compounds of the general formula IIP wherein A 'represents hydrogen; lower alkyl; halogen or cyano; B 'represents hydrogen; lower alkyl or halogen; R11, R12, R13 and R14 independently represent hydrogen; lower alkyl; halogen; nitro; cyano or formyl; R15 and R16 independently represent hydrogen; lower alkyl; lower alkenyl; lower aryl; lower alkoxy-aryl; lower alkoxycarbonyl-aryl; lower alkylcarbonyl; aryl- (lower alkoxy-aryl); aryl- (lower alkyl); aryl- (lower alkyl) -aryl; arylcarbonyl-aryl; aryloxy-aryl; whereby the aryl group is unsubstituted or mono- or di-substituted with lower alkyl, lower alkoxy, halogen, cyano, lower alkoxycarbonyl, lower alkylcarbonyl, phenyl, benzyl, benzoyl, benzyloxycarbonyl, trifluoromethyl or trifluoromethoxy; cycloalkyl or heteroaryl; R15 and R16 together with the nitrogen atom to which they are bound form a heterocyclyl ring system; and optically pure enantiomers, mixtures of racemate enantiomers, optically pure diastereomers, mixtures of diastereomers, diastereomeric racemates, mixtures of diastereomeric racemates, meso forms, geometric isomers, prodrugs of the compounds, in which a prodrug-forming group is present, as well as as solvates and morphological forms and the pharmaceutically acceptable salts thereof; _. with the proviso that the substituents R11, R12, R13, R14, R15 and R16 all at the same time do not represent hydrogen or in addition and in any case any of the substituents R15 or R16 represent hydrogen, and the other aryl, then the group aryl is not an unsubstituted indole-3-yl-ethyl, benzyl or phenyl group, and also an alkyl of 1 to 3 carbon atoms, alkoxy of 1 to 2 carbon atoms or phenyl group mono-substituted with halogen, or R15 and R1S together with the nitrogen atom to which they are attached do not form a piperazine ring substituted with phenyl; it being understood, however, that in general formula IIP, they apply the same definitions i) to xi) as those given for general formula Ip. A fourth aspect of the aforementioned particular variant of the invention relates to these new compounds per se, as well as to their use as pharmaceutically active ingredients. A fifth aspect of the aforementioned particular variant of the invention relates to pharmaceutical compositions containing one or more of these novel compounds. A sixth aspect of the aforementioned particular variant of the invention relates to the use of these novel compounds as CRTH2 antagonists for the prevention and / or treatment of chronic and acute allergic immune disorders comprising allergic asthma, rhinitis, chronic obstructive pulmonary disease ( COPD), dermatitis, inflammatory bowel disease, rheumatoid arthritis, allergic nephritis, conjunctivitis, atopic dermatitis, bronchial asthma, food allergy, systemic disorders of mast cells, anaphylactic shock, urticaria, eczema, itching, inflammation, ischemia-reperfusion injury, cerebrovascular disorders, pleuritis, ulcerative colitis, eosinophil-related diseases, such as Churg-Strauss syndrome and sinusitis, diseases related to basophils, such such as basophilic leukemia and basophilic leukocytosis in humans and other mammals. A seventh aspect of the aforementioned particular variant of the invention relates to the novel compounds of the general formula IIIP wherein A "represents hydrogen; methyl; trifluoromethyl; chlorine; or cyano; B" represents hydrogen; methyl; trifluoromethyl; or chlorine; R21, R22, R23 and R24 independently represent hydrogen; lower alkyl; halo- (lower alkyl); lower alkoxy; halogen; nitro; cyano or formyl; R25 and R26 independently represent hydrogen, lower alkenyl, alkoxy-aryl, alkoxycarbonyl-aryl, lower alkyl, alkylcarbonyl-aryl, arylalkoxy-aryl, arylalkyl, arylalkyl-aryl, aryl, arylcarbonyl-aryl, aryloxy-aryl, cycloalkyl, heteroaryl; R25 and R26, together with the nitrogen atom to which they are bound, form a heterocyclic ring system with 3 to atoms in the ring; R25 represents hydrogen; lower alkyl; or arylalkyl; and R2 ° represents lower alkyl; alkoxy-aryl; alkoxycarbonyl aryl; alkylcarbonyl-aryl; arylalkoxy-aryl; Arylalkyl; arylalkyl-aryl; arylcarbonyl-aryl; aryloxy-aryl or cyclylalkyl; and optically pure enantiomers, mixtures of racemate enantiomers, optically pure diastereomers, mixtures of diastereomers, diastereomeric racemates, mixtures of diastereomeric racemates, meso forms, isomers -geometric, prodrugs of the compounds, in which-a prodrug-forming group is present, as well as solvates and morphological forms and pharmaceutically acceptable salts thereof; with the proviso that the substituents R21, R22, R23, R24, R25 and R26 all at the same time do not represent hydrogen or in addition and in any case any of the substituents R25 or R26 represent hydrogen, and the other aryl, then the group aryl is not an unsubstituted indole-3-yl-ethyl, benzyl or phenyl group, and also an alkyl of 1 to 3 carbon atoms, alkoxy of 1 to 2 carbon atoms or phenyl group mono-substituted with halogen, or R25 and R26 together with the nitrogen atom to which they are attached do not form a piperazine ring substituted with phenyl, - however, it is understood that in general formula IIIP, they apply the same definitions i) to xi) as those given for general formula Ip . In an eighth aspect, the particularly mentioned variant of the invention, R25 and R26, together with the nitrogen atom to which they are linked, can form a heterocyclic ring system with 3 to 15 ring atoms and this preferred aspect encompasses the new ones compounds of the formula IVP - wherein R, 3J1 ±, R, 3J2 /, R and R independently represent methyl; trifluoromethyl; methoxy; fluoro, chlorine; R35 and R36, together with the nitrogen atom to which they are linked, form an acridine, azepine, azocine, carbazole, indole, phenanthyridine or quinoline ring; or R 35 represents hydrogen, R 36 represents 2-ethoxy-phenyl, 2-methoxycarbonyl-phenyl, 2-methyl-5-methoxycarbonyl-phenyl, 3-methoxycarbonyl-phenyl, 4-ethoxycarbonyl-phenyl; 3-methyl-butyl, propyl, 2-acetyl-phenyl, 4-acetyl-phenyl, 3-benzyloxy-phenyl, 4-benzyloxy-phenyl, benzyl, phenethyl; 2-benzyl-phenyl, 2-benzoyl-phenyl, 3-benzoyl-phenyl, 2,3-dihydro-benzo [1,4] dioxin-6-yl, 2,5-dimethyl-phenyl, 2-bromo-4- methyl-phenyl, 2-isopropyl-phenyl, 2-methoxy-dibenzofuran-3-yl, 2-methoxy-phenyl, 2-propyl-phenyl, 3,2 '-dimethyl-biphenyl-4-yl, 3,5-bis-trifluoromethyl-phenyl, 3,5-dimethoxy -phenyl, 3, 5-dimethyl-phenyl, 3-bromo-4-methyl-phenyl, 3-bromophenyl, 3-chloro-4-methoxy-phenyl, 3-ethyl-phenyl, 3-fluoro-phenyl, 3-iodo phenyl, 3-methoxy-phenyl, 3-nitro-phenyl, 4-bromo-2-methyl-phenyl, 4-bromo-3-chloro-phenyl, 4-bromo-3-methyl-phenyl, 4-butyl-phenyl, -4-chloro-2-methyl-phenyl, 4-cyano-phenyl, 4-iodo-phenyl, 4-isopropyl-phenyl, 4-methoxy-biphenyl 3-yl, 4-propyl-phenyl, 4-sec-butyl-phenyl, 4-tert-butyl-phenyl, 4-trifluoromethoxy-phenyl, 4-trifluoromethyl-phenyl, 5-chloro-2-methoxy-phenyl, 5-methoxy-2-methyl-phenyl, 9-ethyl-9H-carbazol-3-yl, 9H-fluoren-2-yl, 9-oxo-9H-fluoren-1-yl, 9-oxo-9H-fluoren- 2-yl, 9-oxo-9H-fluoren-4-yl, benzo [1,3] dioxol-5-yl, biphenyl-4-yl, indan-5-yl, naphthalene-2-yl; 2,4-dichloro-phenoxy) -phenyl, 2-phenoxy-phenyl, 3-phenoxy-phenyl, 4-phenoxy-phenyl, cyclohexylmethyl, or R 35 represents methyl; and R36 represents 4-acetyl-phenyl, (R) -1-phenyl-ethyl, benzyl, 3-chloro-phenyl, 4-chloro-phenyl, 4-fluoro-phenyl, 4-methoxy-phenyl, o-tolyl, -tolyl or p-tolyl; and optically pure enantiomers, mixtures of racemate enantiomers, optically pure diastereomers, mixtures of diastereomers, diastereomeric racemates, mixtures of diastereomeric racemates, meso forms, geometric isomers, prodrugs of the compounds, in which a prodrug-forming group is present, as well as as solvates and morphological forms and the pharmaceutically acceptable salts thereof; In a ninth aspect of the particularly mentioned variant of the invention, the compounds of the formula IVP wherein the substituent R35 represents phenyl; and R36 represents allyl, 2-cyano-ethyl, -butyl, carboxymethyl, ethyl benzyl, phenethyl phenyl or cyclohexyl. In a tenth aspect of the particularly mentioned variant of the invention, the substituents R3? and R36, together with the nitrogen atom to which they are linked, form an acridine ring; azepine; azocine; carbazole; indole; Phenanthyridine; or quinoline; preferably 5,6-dihydro-phenanthridine; 9, 10-dihydro-acridine; 5,6-dihydro-dibenzo [b, f] azocine; 10, 11-dihydro-dibenzo [b, f] azepine; 11, 12-dihydro-ßH-dibenzo [b, f] azocine; 2, 3-dihydro-indole; 3,4-dihydro-2H-quinoline; 6, 11-dihydro-dibenzo [b, e] azepine; dibenzo [b, f] azepine. The most preferred novel compounds of the particularly mentioned variant of the invention include, but are not limited to: [3- ((E) -2-cyano-3-dibenzo [b, f] azepin-5-yl-3-oxo -propenyl) -indol-1-yl] -acetate sodium; 6 Acid { 3- [(E) -2- (allyl-phenyl-carbamoyl) -2-cyano-vinyl] indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (phenethyl-phenyl-carbamoyl) vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2- (Butyl-phenyl-carbamoyl) -2-cyano-vinyl] indol-1-yl} -acetic acid (3-. {(E) -2-cyano-2- [(2-cyano-ethyl) -phenylcarbamoyl] -vinyl} -indol-1-ryl) -acetic; Acid { 3- [(E) -2-cyano-3- (10,11-dihydro-dibenzo [b, f] azepin-5-yl) -3-oxo-propenyl] -indol-1-yl} - acetic; (3- {(E) -2-cyano-2- [(4-fluoro-phenyl) -methylcarbamoyl] -vinyl} -indol-1-yl) -acetic acid; Acid { 3- [(E) -2-cyano-2- (ethyl-phenyl-carbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-3- (6,11-dihydro-dibenzo [b, e] azepin-5-yl) -3 -oxo-propenyl] -indol-1-yl} -acetic; Acid { 3- [(?) -2-cyano-2- (cyclo-phenyl-carbamoyl) -vinyl] -indol-1-yl} -acetic; Acid (3- {(2)} -2- [(4-chloro-phenyl) -methyl-carbamoyl] -2-cyano-vinyl} -indol-1-yl) -acetic acid; (3- ({(E) -2-cyano-2- [(4-methoxy-phenyl) -methylcarbamoyl] -vinyl} -indol-1-yl) -acetic acid; Acid { 3- [()) -2-cyano-2- (methyl-o-tolyl-carbamoyl) -vinyl] -indol-1-yl} -acetic; [3- ((E) -2-cyano-2-diphenethylcarbamoyl-vinyl) -indol-1-yl] -acetic acid; (3- ({(E) -2- [(4-acetyl-phenyl) -furan-2-ylmethyl- and carbamoyl] -2-cyano-vinyl} -indol-1-yl) -acetic acid; Acid (3- { "E) -2- [(4-acetyl-phenyl) -methyl-carbamoyl] -2-cyano-vinyl} -indol-1-yl) -acetic acid. [(?) -2-cyano-3- (3, 4-dihydro-2H-quinolin-1-yl) - ' 3 - . 3-oxo-propenyl] -indol-1-yl} -acetic. Other preferred novel compounds of the above-mentioned "particular variant of the invention, include: Acid. {3- [3- (cyano-2- (methyl-phenyl-carbamoyl) -vinyl] -indol-1-yl} .) -Acetic; Acid (3- {(E) -2- [(3-chloro-phenyl) -methyl-carbamoyl] -2-cyano-vinyl} -indol-1-yl) -acetic acid; Acid { 3- [(E) -2- (carboxymethyl-phenyl-carbamoyl) -2-cyano-vinyl] -indol-1-yl.} -acetic acid; {.3. 3- [(E)} -2- (benzyl-phenyl-carbamoyl) -2-cyano-vinyl] -indol-1-yl}. -acetic acid; {.3- [(E) -2- (3-benzoyl-phenylcarbamoyl) -2-cyanovinyl] -indol-1-yl.} -acetic acid: {.3- [(?) -2-cyano-2- (2-ethoxy-phenylcarbamoyl) -vinyl] indole-1- il.) -Acetic; Acid { 3- [(E) -2-cyano-2- (4-methoxy-biphenyl-3-ylcarbamoyl-) -vinyl] -indol-1-yl.} -acetic; [3- ((E) -2-cyano-2-diphenylcarbamoyl-vinyl) -indol-1-yl] -acetic acid; (3- ({E) -2-cyano-2- (2- (2,4-dichloro-phenoxy) -phenylcarbamoyl] -vinyl.}. -indol-1-yl) -acetic acid; gone { 3- [(E) -2-cyano-2- (2-methoxy-dibenzofuran-3-ylcarbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (methyl-p-tolyl-carbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2- (5-chloro-2-methoxy-phenylcarbamoyl) -2-cyano-vinyl] -indol-1-yl} -acetic; Acid { 3- [()) -2- (2-benzyl-phenylcarbamoyl) -2-cyanovinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-3- (11,12-dihydro-6 H -dibenzo [b, f] azocin-5-yl) -3 -oxo-propenyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2- (2-benzoyl-phenylcarbamoyl) -2-cyanovinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-3- (2,3-dihydro-indol-1-yl) -3-oxo-propenyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (2-phenoxy-phenylcarbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (3, 5-dimethyl-phenylcarbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2- (3-bromo-4-methyl-phenylcarbamoyl) -2- cyanovinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (2-methoxy-phenylcarbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2- (2-acetyl-phenylcarbamoyl) -2-cyanovinyl] -indol-1-yl} -acetic; [3- ((E) -2-cyano-2-phenylcarbamoyl-vinyl) -7-methyl-indol-1-yl] -acetic acid. Preferred novel compounds of the aforementioned particular variant of the invention include: Acid. { 3- [(E) -2-cyano-2- (4-trifluoromethoxy-phenylcarbamoyl) -vinyl] -indol-1-yl} -acetic; (3- ({(E) -2-cyano-2- [methyl- ((R) -1-phenyl-ethyl) -carbamoyl] -vinyl} -indol-1-yl) -acetic acid; 3- [(E) -3- (1-carboxymethyl-1H-indol-3-yl) -2-cyano-acryloylamino] -benzoic acid methyl ester; Acid { 3- [(E) -2-cyano-2- (9-oxo-9H-fluoren-4-ylcarbamoyl) -vinyl] -indol-1-yl} -acetic, - Acid. { 3- [(E) -2-cyano-2- (4-iodo-phenylcarbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2- (3-benzyloxy-phenylcarbamoyl) -2-cyanovinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2- (benzyl-methyl-carbamoyl) -2-cyano-vinyl] indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (2-propyl-phenylcarbamoyl) -vinyl] -indol-1-yl} -acetic; [5-Bromo-3- ((E) -2-cyano-2-phenylcarbamoyl-vinyl) -indol-1-yl] -acetic acid; Acid { 3- [(E) -2-cyano-2- (3-methoxy-phenylcarbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (3-nitro-phenylcarbamoyl) -vinyl] indole-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (3, 5-dimethoxy-phenylcarbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (9-ethyl-9H-carbazol-3-ylcarbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (2,3-dihydro-benzo [1,4] dioxin-6-ylcarbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2- (3-chloro-4-methoxy-phenylcarbamoyl) -2-cyanovinyl] -indol-1-yl} -acetic; 4- [()) -3- (1-carboxymethyl-1H-indol-3-yl) -2-cyano-acryloylamino] -benzoic acid methyl ester; Acid { 3- [(E) -2- (4-acetyl-phenylcarbamoyl) -2-cyanovinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (2-isopropyl-phenylcarbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2- (4-tert-butyl-phenylcarbamoyl) -2-cyanovinyl] -indol-1-yl} -acetic; Acid { 3 -; - [":( E) -2-cyano-2- (naphthalen-2-ylcarbamoyl) -vinyl] indole-1-yltr-} -acetic acid; Acid { 3- [(?) - 2- (Benzo [1,3] dioxol-5-ylcarbamoyl) -2- cyanovinyl] -indol-1-yl.} -acetic acid: {.3- [(E) -2- (2- bromo-4-methyl-phenylcarbamoyl) -2- cyano-vinyl] -indol-1-yl.} -acetic acid; {.3- [(?) -2-cyano-2- (4-cyano-phenylcarbamoyl) ) -vinyl] indole-1-yl} -acetic acid; {.3- [(E) -2- (4-bromo-3-methyl-phenylcarbamoyl) -2-cyano-vinyl] -indol-1 -yl.} -acetic; [3- ((E) -2-cyano-2-phenylcarbamoyl-vinyl) -5-fluoro-indol-1-yl] -acetic; Acid { 3- [(?) -2- (biphenyl-4-ylcarbamoyl) -2-cyano-vinyl-indol-1-yl.} -acetic acid: {.3- [(E) -2-cyano-2- (4-isopropyl- phenylcarbamoyl) -vinyl] -indol-1-yl.} -acetic acid: {.3- [(?) -2- (4-chloro-2-methyl-phenylcarbamoyl) -2- cyanovinyl] -indole -1-yl.) -acetic acid [3- ((E) -2-cyano-2-phenylcarbamoyl-vinyl) -5-methyl-indol-1-yl] -acetic acid; (E) -2-cyano-2- (4-propyl-feni) lcarbamoyl) -vinyl] -indol-l-il} -acetic; Acid { 3- [(Ex-2-cyano-2- (2,5-dimethyl-phenylcarbamoyl) -vinyl] -indol-1-yl} -acetic acid 3 - [(E) -3- methyl ester (l -carboxymethyl-1H-_indol-3-yl) -2-cyano-acryloylamino] -4-methyl-benzoic acid; 2- [(E) -3- (1-carboxymethyl-1H-indol-3-yl) -2-cyano-acryloylamino] -benzoic acid methyl ester; Acid { 3- [(E) -2- (4-sec-butyl-phenylcarbamoyl) -2-cyanovinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (3-iodo-phenylcarbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2- (4-bromo-3-chloro-phenylcarbamoyl) -2-cyanovinyl] -indol-1-yl} -acetic; [3- ((E) -2-cyano-2-cyclohexylcarbamoyl-vinyl) -indol-1-yl] -acetic acid; Acid { 3- [(E) -2-cyano-2- (3-fluoro-phenylcarbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2- (4-benzyloxy-phenylcarbamoyl) -2-cyanovinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (3,2'-dimethyl-biphenyl-4-ylcarbamoyl) -vinyl] -indol-1-yl} -acetic; acid. { 3- [(E) -2-cyano-2- (5-methoxy-2-methyl-phenylcarbamoyl) -vinyl] -indol-1-yl} -acetic; Acid 3-. { benzyl- [(E) -3- (l-carboxymethyl-lH-indol-3-yl) -2- cyanb-acryloyl] -amino} -propionic; Acid { 3- [()) -2-cyano-2- (9-oxo-9H-fluoren-2-ylcarbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (3-ethyl-phenylcarbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2- (3, 5-bis ~ trifluoromethyl-phenylcarbamoyl) -2-cyanovinyl] -indol-1-yl} -acetic; [3- ((E) -2-cyano-2-phenethylcarbamoyl-vinyl) -indol-1-yl] -acetic acid; [3- (()) -2-Cyano-2-phenylcarbamoyl-vinyl) -6-fluoro-indol-1-yl] -acetic acid; Acid { 3- [()) -2- (4-bromo-2-methyl-phenylcarbamoyl) -2-cyanovinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (4-trifluoromethyl-phenylcarbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (4-phenoxy-phenylcarbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [()) -2-cyano-2- (indan-5-ylcarbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [()) -2-cyano-2- (9H-fluoren-2-ylcarbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (cyclohexylmethyl-carbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2- (4-Butyl-phenylcarbamoyl) -2-cyanovinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2- (benzyl-carboxymethyl-carbamoyl) -2-cyano-vinyl] -indol-1-yl} -acetic; - Acid-. { 3- [(E) -2-cyano-2- (3-phenoxy-phenylcarbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (9-oxo-9H-fluoren-1-ylcarbamoyl) -vinyl] -indol-1-yl} -acetic. Other preferred novel compounds of the above-mentioned particular variant of the invention include: [3- ((E) -2-cyano-2-propylcarbamoyl-vinyl) -indol-1-yl] -acetic acid; Acid { 3- [(E) -2-cyano-2- (3-methyl-butylcarbamoyl) -vinyl] -indol-1-yl} -acetic; [3- ((E) -2-cyano-2-phenylcarbamoyl-vinyl) -6-nitro-indol-1-yl] -acetic acid. The following paragraphs provide definitions for example of the various chemical moieties constituting the compounds according to the invention, and are intended to apply uniformly throughout the specification and claims, unless a definition "is expressly detailed otherwise. , provide a broader or narrower definition. ~ Therefore, unless explicitly stated otherwise, the general terms and names used above and hereinafter preferably have, within the context of this description, the following meanings: First, any reference to a compound of the general formula I should be understood as referring to the configurational isomers, mixtures of enantiomers such as racemates, or diastereomers, mixtures of diastereomers, diastereomeric racemates, and mixtures of diastereoisomeric racemates, as well as salts , solvent complexes and forms morphological characteristics of such compounds, as appropriate and expeditious. The term "alkyl" or "lower alkyl", as used herein, alone or in any combination, refers to a saturated aliphatic group that includes a straight or branched hydrocarbon chain containing 1 to 8 carbon atoms, preferably 1 to 4 carbon atoms. Representative examples of alkyl include, but are not limited to, methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, tert-butyl, iso-butyl (or 2-methylpropyl), n-pentyl (or n-amyl), iso-pentyl (or iso-amyl), n-hexyl, n-heptyl, n-octyl and the like. The term "alkenyl" or "lower alkenyl", as used herein, alone or in any combination, refers to a straight or branched hydrocarbon chain containing 2 to 8 carbon atoms with at least one carbon-double bond. carbon Representative examples of alkenyl include, but are not limited to, £. ethenyl, 2-propenyl, 2-methyl-2-propenyl, 3-butenyl, 4-pentenyl, 5-hexenyl and the like. The term "alkoxy" or "lower alkoxy," as used herein, alone or in any combination, refers to an alkyl group linked to the parent molecular moiety through an oxygen bridge. Representative examples of alkoxy include, but are not limited to, methoxy, ethoxy, propoxy, 2-propoxy, butoxy, tert-butoxy, pentyloxy, hexyloxy, and the like. The term "aryl", as used herein, alone or in any combination (except for the arylalkoxy, arylalkyl, aryloxy and arylcarbonyl that are defined below), refers to either a carbocyclic group having at least one ring aromatic, for example phenyl biphenyl, or multiple fused ring systems, in which at least one ring is aromatic (for example 1,2,3,4-tetrahydronaphthyl, naphthyl, anthryl, phenanthryl, fluorenyl, indanyl and the like) or a a phenyl group having two neighboring substituents forming together a methylenedioxy chain or an ethylenedioxy chain (ie a 2,3-dihydrobenzo [1,4] dioxinyl group or a benzo [1,3] dioxolyl group). The aryl group may be optionally substituted with one to three functional groups individually and independently selected from alkoxy, alkoxycarbonyl, alkyl, alkylcarbonyl, arylalkoxy, arylcarbonyl, arylalkyl, aryloxy, cyano, halogen, haloalkoxy, haloalkyl, nitro, and the like. Further, in particular cases where the aryl group consists of multiple fused ring systems, in which not all rings are aromatic, one of the carbon atoms that is not the member of an aromatic ring may be in an oxidized form and the corresponding -CH2-ring member will then be replaced by -C (O) -; Representative examples of such groups include, but are not limited to, 9-oxo-9H-fluorenyl. A particular example of the "aryl" group is "phenyl". The term "phenyl", as used herein, alone or in any combination (except for phenylalkyl and diphenylalkyl which are defined below), refers to an unsubstituted phenyl group or a phenyl group substituted with one to three functional groups individually and independently selected from alkoxy, alkoxycarbonyl, alkyl, alkylcarbonyl, arylalkoxy, arylcarbonyl, arylalkyl, aryloxy, cyano, halogen, haloalkoxy, haloalkyl, nitro and the like. The term "phenylalkyl", as used herein, alone or in combination, refers to a phenyl group linked to the parent molecular moiety through an alkyl group, wherein the phenyl group may be unsubstituted or substituted. with 1 to 3 substituents independently selected from the group consisting of halogen, alkyl, alkoxy, trifluoromethyl and trifluoromethoxy. Representative examples of the phenylalkyl include, but are not limited to, benzyl, 2-phenylethyl, 3-phenylpropyl and the like. The term "diphenylalkyl", as used herein, alone or in any combination, refers to an alkyl group wherein two hydrogen atoms each have been replaced by an unsubstituted phenyl group. The term "arylalkoxy", as used herein, alone or in combination, refers to an aryl group linked to the parent molecular moiety through an alkoxy group, wherein the aryl group may be unsubstituted or substituted. with 1 to 3 substituents independently selected from the group consisting of halogen, alkyl, alkoxy, trifluoromethyl and trifluoromethoxy. Representative examples of arylalkoxy include, but are not limited to, 2-phenylethoxy, 5-phenylpentyloxy, 3-naphth-2-ylpropoxy, and the like. The term "arylalkyl", as used herein, alone or in any combination, refers to an aryl group linked to the parent molecular moiety through an alkyl group, wherein the aryl group may be unsubstituted or substituted with 1 to 3 substituents independently selected from the group selected from halogen, alkyl, alkoxy, trifluoromethyl and trifluoromethoxy. Representative examples of arylalkyl include, but are not limited to, benzyl, 2-phenylethyl, 3-phenylpropyl, 2-naphth-2-ylethyl and the like. The term "aryloxy", as used herein, alone or in any combination, refers to an aryl group linked to the parent molecular moiety through an oxygen bridge, wherein the aryl group may be unsubstituted or substituted with 1 to 3 substituents independently selected from the group consisting of halogen, alkyl, alkoxy, trifluoromethyl and trifluoromethoxy. Representative examples of aryloxy include, but are not limited to, phenoxy, naphthyloxy, 3-bromophenoxy, 4-chlorophenoxy, 4-methylfenoxy, 3,4-dimethoxyfenoxy and the like. The term "arylcarbonyl" or "aroyl", as used herein, alone or in any combination, refers to an aryl group linked to the parent molecular moiety through a carbonyl group, wherein the aryl group may nevertheless being unsubstituted or substituted with 1 to 3 substituents independently selected from the group consisting of halogen, alkyl, alkoxy, trifluoromethyl and trifluoromethoxy. Representative examples of alkylcarbonyl include, but are not limited to, phenylcarbonyl - '(or benzoyl), naphthylcarbonyl and the like The term "carbonyl", as used herein, alone or in any combination, refers to a -C (O) - group The term "carboxyl", as used herein, alone or in any combination, refers to a group -C02H.The term "carboxyalkyl" as used herein, alone or in any combination, it refers to a carboxyl group bonded to the progenitor molecular moiety through an alkyl group, Representative examples of carboxyalkyl include, but are not limited to, carboxymethyl, 2-carboxyethyl, 3-carboxypropyl and the like.

The term "cyano", as used herein, alone or in any combination, refers to a group -C = N. The term "cycloalkyl", as used herein, alone or in any combination, refers to a saturated cyclic hydrocarbon portion containing from 3 to 15 carbon atoms. Representative examples of cycloalkyl include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, and the like. The term "cyclylalkyl" or "cycloalkyl-alkyl", as used herein, alone or in any combination, refers to a cycloalkyl group linked to the parent molecular moiety through an alkyl group. Representative examples of cyclylalkyl or cycloalkyl-alkyl include, but are not limited to, cyclopropylmethyl, cyclohexylethyl, and the like. The term "formyl", as used in the present, alone or in any combination, refers to a group -C (0) H. The term "halo" or "halogen", as used herein, alone or in any combination, refers to fluorine, bromine, chlorine and iodine. The term "heterocyclyl" or "heterocyclic ring system", as used herein, alone or in any combination, refers to a monocyclic, bicyclic or polycyclic ring system containing up to 15 ring atoms, at least one of these is a heteroatom independently selected from the group consisting of nitrogen, oxygen and sulfur. The ring system may be saturated, partially unsaturated, unsaturated or aromatic. Representative examples of the heterocyclyl or heterocyclic ring system include, but are not limited to, furyl, imidazolyl, imidazolidinyl, isothiazolyl, isoxazolyl, morpholinyl, oxadiazolyl, oxazolyl, oxazolinyl, oxazolidinyl, piperazinyl, piperidinyl, pyranyl, pyrazinyl, pyrazolyl, pyridyl, pyrimidinyl, pyridazinyl, pyrrolyl, pyrrolinyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydrothienyl, thiadiazolyl, thiazolyl, thiazolinyl, thiazolidinyl, thienyl, thiomorpholinyl, benzimidazolyl, benzothiazolyl, benzothienyl, benzoxazolyl, benzofuranyl, indolyl, indolinyl, isobenzofuranyl, isobenzothienyl, isoindolyl, isoindolinyl, isoquinolinyl, dihydroisoquinolinyl, quinolinyl, dihydroquinolinyl, carbazolyl, phenothiazinyl, phenoxazinyl, dihydrodibenzoazocinyl, dibenzoazepinyl, dihydrodibenzoazepinyl, oxa-aza-dibenzocycloheptenyl and the like. The defined heterocyclic moieties may be optionally substituted with one or more groups, each individually and independently selected from the group consisting of alkoxy, alkyl, alkylcarbonyl, halogen, haloalkoxy and haloalkyl. The term "heteroaryl", as used herein, alone or in any combination, refers to an aromatic, mono-, bi- or tricyclic ring system containing up to 14 ring atoms, wherein at least one of the rings contain at least one heteroatom independently selected from the group consisting of nitrogen, oxygen and sulfur. The heteroaryl group may be unsubstituted or substituted with 1 to 3 substituents independently selected from the group consisting of halogen, alkyl, alkoxy, trifluoromethyl and trifluoromethoxy. Representative examples of heteroaryl include, but are not limited to, thienyl, furanyl, pyrrolyl, thiazolyl, imidazolyl, oxazolyl, pyridyl, quinolinyl, benzimidazolyl, benzothiazolyl, benzothienyl, benzoxazolyl, benzofuranyl, indolyl, carbazolyl, phenothiazine, phenoxazine, and the like. The term "nitro", as used herein, alone or in any combination, refers to a group -N02. The term "oxo", as used herein, alone or in any combination, refers to a group = 0. The term "oxy", as used herein, alone or in any combination, refers to a group -O-. Within the scope of the present invention, a. unless otherwise indicated, the compounds of the formulas I IC ?, Ic2 or IP or the new compounds of the formulas IIP, IIIP or IVP and the pharmaceutically acceptable salts thereof are included, which may exist in, and be isolated in, isomeric forms, including the cis or trans isomers or mixtures thereof, and tautomers. Other compounds of this invention may contain one or more stereogenic or asymmetric centers, such as one or more asymmetric carbon atoms, and thus may give rise to the optically pure enantiomers, mixtures of enantiomers, racemates, pure dimer-isomers of enantiomers , mixtures of diastereoisomers, epimers and other stereoisomeric forms which can be defined, in terms of absolute stereochemistry, as (R) -, (S) - or (R, S) - configuration, preferably in the (R) - configuration or (S) -. Such isomers can be obtained by methods within the knowledge of a person skilled in the art, for example, by stereochemically controlled synthesis using chiral synthons or chiral reagents, or by means of classical separation techniques, such as chromatographic or crystallization methods, or by other methods known in the art, such as through the formation of diastereomeric salts, for example by salt formation with an enantiomerically pure chiral acid, or by means of chromatography, for example by the use of chromatographic materials modified with chiral ligands. In addition, the present invention relates to compounds that contain centers of any geometric asymmetry, such as, for example, the non-symmetrically substituted olefinic double bond, including geometric isomers E or Z and mixtures thereof. In general, the pure isomers of the compounds of the formulas I, IC ?, Ic2, IP or II are preferred over the isomeric mixtures. In the present invention, the compounds of the formulas I, IC ?, Ic2 Ip, Hp, IIIP or IVP can be used "in the form of the pharmaceutically acceptable salts." The term "pharmaceutically acceptable salts" refers to the salts by addition of inorganic or organic acids and bases, relatively non-toxic, which preserve the biological effectiveness and properties of the parent compound, and which are not biologically or otherwise undesirable (see for example Berge et al., J. Pharm. Sci. 1977), 66, 1-19 or "Salt selection for basic drugs", Int. J. Pharm. (1986), 33, 201-217) Certain compounds of the present invention may contain one or more basic functional groups such as amino, alkylamino or arylamino, and, thus, be able to form the pharmaceutically acceptable acid addition salts.These salts by addition of acid can be prepared by standard procedures in a suitable solvent from the progen compound. Formula I or II, with an appropriate amount of inorganic acid, including, but not limited to, for example, hydrochloric acid, hydrobromic acid, sulfuric acid, or phosphoric acid; or of an organic acid, including, but not limited to, acetic acid, propionic acid; or of an organic acid, including but not limited to, acetic acid, propionic acid, octanoic acid, decanoic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, acid citric, ascorbic acid, amino acids, such as -glutamic acid or aspartic acid, benzoic acid, cinnamic acid, salicylic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid or other acidic organic compounds. Certain compounds of the present invention may, on the other hand, contain one or more acid functional groups and, thus, be capable of forming the pharmaceutically acceptable base addition salts. These salts can be prepared by the addition of an appropriate amount, usually in a stoichiometric ratio, of an alkaline reagent, such as hydroxide, carbonate or alkoxide, containing the appropriate cation, to the free acid in a suitable solvent. Preferred inorganic salts include, but are not limited to, ammonium, sodium, potassium, calcium or magnesium salts, also zinc salts and the like. Preferred salts derived from the organic bases include, but are not limited to, salts of primary, secondary and tertiary amines, substituted amines, cyclic amines, and basic ion exchange resins, such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, ethanolamine, lysine, arginine, N-ethylpiperidine, piperidine, polyamine resins and the like. The compounds of the present invention which contain acidic and basic groups can also form internal salts (sutures or amphoterics). For purposes of isolation or purification, it is also possible to use the pharmaceutically unacceptable salts, for example perchlorates, picolinates, picrates or the like. For therapeutic use, only pharmaceutically acceptable salts or free compounds are used, where it is applicable in the form of pharmaceutical preparations, and these are therefore preferred. Certain compounds of the formulas I, IC1, IC2, IP, IIP, IIIp or IVp including their salts, can exist in the solvated as well as unsolvated form, such as, for example, the hydrated forms, or their crystals can, for example , include the solvent used for crystallization. Different crystalline forms may be present. The present invention encompasses such solvated and unsolvated forms. The present invention also relates to the prodrug derivatives of the progenitor compounds of the formulas I, IC ?, Ic2, Ip, Hp, IIIp or IVP. The term "prodrug" refers to pharmacologically inactive precursors of a drug that can be converted to its therapeutically active form under physiological conditions in vivo, for example, when they undergo solvolysis or enzymatic degradation in the blood, or in cells (Bundgard H., "Design of Prodrugs," pp. 7-9, 21-24, -Elsevier, Amsterdam (1985), Silverman RB, "The Organic Chemistry of Drug Design and Drug Action," pp. 352-401, Academic Press , San Diego, California (1992), Higuchi T. et al., "Pro-drug as Novel Delivery Systems", ACS Symposium Series, Vol. 14). The term "prodrug" also includes any covalently linked carriers, which release the active parent compound in vivo when administered to a mammal. Prodrug modifications of a compound often offer advantages of solubility, bioavailability, absorption, tissue compatibility, tissue distribution, or delayed release in the mammalian organism. Prodrugs are variations or derivatives of the compounds of formula I, which have cleavable groups under metabolic conditions, for example, pharmaceutically acceptable esters or amides. Such groups can be cleaved enzymatically or non-enzymatically, or hydrolytically to the hydroxyl, carboxyl or free amino group of the active parent compound. In yet another embodiment, the prodrug is a reduced form, which is oxidized in vivo to the therapeutic compound, for example, a thiol, which is oxidized to a sulfonate or sulfate, an alcohol to a carboxylic acid. Further within the scope of the present invention are included the pharmaceutically acceptable esters of the compounds of the formulas I, IC1, IC2, Ip, IIp, IIIP or IVP. The term "pharmaceutically acceptable esters" refers to the relatively non-toxic, esterified products of the parent compound.These esters can be prepared in situ during the final isolation and purification of the compounds, or by reacting the purified compounds separately in Its free acid or hydroxyl form, with a suitable esterification agent, The carboxylic acids can be converted to esters via treatment with an alcohol in the presence of a catalyst.The hydroxyl-containing derivatives can be converted to esters via treatment -with an agent of esterification such as alkanoyl halides The term also includes lower hydrocarbon groups capable of being solvated under physiological conditions, for example, alkyl esters, with methyl, ethyl and propyl ester, methoxymethyl ester, methylthiomethyl, pivaloyloxymethyl ester and the like (see, by example, Berge et al., J. Pharm. Sci. (1977), 66, 1-19). The compounds of the present invention have, in particular, pharmacologically useful properties. These are capable of specifically antagonizing the effect of endogenous PGD on the CRTH2 receptor. A compound or a pharmaceutical composition of the invention can be used as a drug (medicine) or therapeutic agent for the prevention and / or treatment of chronic and acute allergic / immune disorders such as allergic asthma, rhinitis, chronic obstructive pulmonary disease (COPD) , dermatitis, inflammatory bowel disease, rheumatoid arthritis, allergic nephritis, conjunctivitis, atopic dermatitis, bronchial asthma, food allergy, systemic disorders of mast cells, anaphylactic shock, urticaria, eczema, itching, inflammation, ischemia-reperfusion injury, disorders vascular brain, pleuritis, ulcerative colitis, diseases related to. eosinophils, such as Churg-Strauss syndrome and sinusitis, diseases related to basophils, such as basophilic leukemia and basophilic leukocytosis. In yet another aspect, the compounds of the formulas I, IC ?, Ic2 or Ip can be used as standard or reference compounds in tests or assays' involving the inhibition of the CRTH2 receptor. Such compounds could be made commercially available for use as a reference, quality standard or control, for example, in pharmaceutical research when developed in new assays or protocols related to activity in CRTH2. As mentioned at the beginning, the compounds of the formulas I, IC ?, Ic2 or IP, or the salts or prodrugs thereof, antagonize the activation of PGD2 of the CRTH2 receptor. The biological effect of such compounds can be tested in a variety of in vitro, ex vivo and in vivo assays. The ability of the compounds of the formulas I, IC ?, Ic2 or IP to bind to the CRTH2 receptor can be measured by methods similar to those described in Sawyer N. et al., Br. J. Pharmacol. (2002), 137, 1163-1172 and by the method described later in Example B-1. With this type of assay, the IC50 values (for example the concentrations where the maximum mean inhibition of the interaction is found) in the range of 0.001 to 10 μM, preferably values below 1 μM, in particular values below 0.05 μM, are found with the test compounds of formula I, IC ?, Ic2 or IP, (see the paragraph entitled "Biological results"). A functional assay with cells expressing the human CRTH2 receptor can be used to detect changes in the levels of intracellular calcium concentration after treatment with the compound. After the addition of the compound the cells are challenged with PGD2.

In a Plate Reader Fluorescent Image Formation (FLIPRMR, Molecular Devices, Sunnyvale, California) Fluorescence emission is recorded during both additions, peak emission values above the base level after the addition of PGD2 were exported, normalized to low (not PGD2) and high controls levels (without the active compound). The relative values of the remaining activity were used to determine the IC 50 values by adjusting the data curve to a simple site for a sigmoidal dose-response curve, logistic of four parameters of the equation (A + ((BA) / (1- ((C / x)? D)))). The ability of the compounds to antagonize the PGD2-induced challenge of intracellular calcium levels via activation of CRTH2 can be measured by methods known to a person skilled in the art, or by the method described later in Example B- 2. With this assay, the IC50 values (for example the concentration of a compound in which the activity. remnant is 50%) in the range of 0.001 and 10 μM, preferably below 0.5 μM, are obtained with the test compounds of formulas I, IC1, IC2 or IP, (see the paragraph entitled "Biological results") . The results of these tests clearly demonstrate that the present invention provides functional antagonists of the PGD2 receptor. Based on the biological studies discussed above in the present, a compound of Formula I according to the invention can show therapeutic efficacy against allergic asthma, rhinitis, chronic obstructive pulmonary disease (COPD), dermatitis, inflammatory bowel disease-, rheumatoid arthritis, allergic nephritis, conjunctivitis, atopic dermatitis, bronchial asthma, food allergy, systemic mast cell disorders, anaphylactic shock, urticaria, eczema, itching, inflammation, ischemia-reperfusion injury, cerebrovascular disorders, pleuritis, ulcerative colitis, diseases related to eosinophils, such as Churg-Strauss syndrome and sinusitis, diseases related to basophils, such as basophilic leukemia and basophilic leukocytosis. A compound of the formulas I, IC ?, Ic2 or IP, a pharmaceutically acceptable salt or a prodrug thereof, can be administered alone in pure form or in combination with one or more other therapeutic agents, the possible combination therapy taking the form of fixed combinations or administration of a compound of the invention and one or more other therapeutic agents that are staggered or independently of one another, or the combined administration of the fixed combinations and one or more other therapeutic agents. A compound of Formula I can, in addition or in addition, be administered especially for the prevention and / or treatment of chronic or acute allergic or immune disorders in combination with other inflammatory diseases. Long-term therapy is equally possible as is adjuvant therapy in the context of other treatment strategies, as described above. Other possible treatments are preventive therapies, for example in patients at risk. The invention is refers to pharmaceutical compositions comprising the compounds of formula I, Ic2 or Ip, for use in therapeutics, in a broader aspect of the invention also to prophylactic treatment or a method of. treatment of the diseases mentioned above, to the compounds for said use and to the preparation of the pharmaceutical formulations (medicines). The pharmaceutically acceptable compounds of the present invention can be used, for example, for the preparation of pharmaceutical compositions comprising an effective amount of the active ingredient together or in admixture with a significant amount of one or more inorganic, organic, solid or liquid carriers, 5 pharmaceutically acceptable. The invention also relates to a pharmaceutical composition that is suitable for administration to a warm-blooded animal, especially a human (or to - r cells or cell lines derived from a blood animal Hot, especially a human, for the treatment or, in a broader aspect of the invention, the prevention of (eg prophylaxis against) a disease that responds to blockade of the interaction of the CRTH2 receptor with PGD2, which comprises The amount of a compound of the formula I, IC1, IC2, or IP, or a pharmaceutically acceptable salt or a prodrug thereof, which is effective for said inhibition, together with at least one pharmaceutically acceptable carrier. The pharmaceutical compositions according to the invention are those for enteral administration, such as nasal, buccal, rectal, dermal or especially oral administration, and for parenteral administration, such as intramuscular, intravenous or subcutaneous injection or infusion. , intrasternal, intravitreal, warm-blooded animals, especially 5 humans. Such compositions comprise an effective dose of pharmaceutically active ingredient, alone or together with a significant amount of a pharmaceutically acceptable carrier. The dose of the active ingredient depends on the species of the warm-blooded animal, the body weight, the age and the individual conditions, the individual pharmacokinetic data, the disease to be treated and the mode of administration. The invention also relates to a process or method for the treatment of a pathological condition mentioned hereinabove, especially a disease, which corresponds to blocking the interaction of the receptor of -CRTH2 with PGD2, especially "allergic / immune" disorders. such as allergic asthma, rhinitis, chronic obstructive pulmonary disease (COPD), dermatitis, inflammatory bowel disease, rheumatoid arthritis, allergic nephritis, conjunctivitis, atopic dermatitis, bronchial asthma, food allergy, systemic disorders of mast cells, anaphylactic shock, urticaria , eczema, itching, inflammation, ischemia-reperfusion injury, cerebrovascular disorders, pleuritis, ulcerative colitis, eosinophil-related diseases, such as Churg-Strauss syndrome and sinusitis, basophil-related diseases, such as basophilic leukemia and leukocytosis basophilic compounds, the compounds of formula I, , Ic2 / Ip- or the salts or prodrugs thereof may be administered as such or especially in the form of pharmaceutical compositions. The dose to be administered to warm-blooded animals, for example humans of approximately 70 kg body weight, is preferably from about 3 mg to about 30 g, more preferably from about 10 mg to about 1000 mg per person per day , preferably divided into 1 to 3 single doses, which can be, for example, the same size. The amount of the compound actually administered will typically be determined by a physician, in light of the relevant circumstances, including the condition to be treated, the chosen route of administration, the effective compound administered, the age, weight and response of the patient. individual patient, the severity of the patient's symptoms, and the like, for example, children usually receive half the dose of adults. The pharmaceutical compositions comprise from about 1% to about 95%, preferably from about 20% to about 90% of the active ingredient. The pharmaceutical compositions according to the invention may be, for example, in unit dosage forms-such as coated and uncoated tablets, pills, ampoules, flasks, suppositories, dragees or capsules. The additional dosage forms are, for example, ointments, creams, pastes, emulsions, foams, chewing gums, tinctures, lipsticks, drops, sprays or aerosols, syrups or elixirs, dispersions, transdermal patches or pads, or via a device intravitreal that releases the compound in a sustained capacity, and the like. Examples are capsules containing from about 0.05 g to about 1.0 g of the active ingredient. The pharmaceutical compositions of the present invention are prepared in a manner known per se, for example by means of conventional mixing, granulating, coating, dissolving, lyophilizing or making processes. The solutions of the active ingredient, and also suspensions, and especially isotonic aqueous solutions or suspensions, are preferably used, - being possible, for example in the case of lyophilized pharmaceutical compositions, comprising the active ingredient alone or together with a carrier, for example mannitol, so that such solutions or suspensions are produced before use. The pharmaceutical compositions can be sterilized and / or can comprise excipients, for example preservatives, stabilizers, wetting agents and / or emulsifiers, solubilizers, salts for regulating the osmotic pressure and / or buffers, and are prepared in a manner known per se, by example by means of conventional processes of dissolution or lyophilization. The solutions or suspensions may comprise viscosity-increasing substances, such as sodium carboxymethyl cellulose, carboxymethyl cellulose, dextran, polyvinyl pyrrolidone or gelatin. The suspensions in oil comprise as the oily component the vegetable, synthetic or semi-synthetic oils customary for injection purposes. Mention may especially be made, such as liquid fatty acid esters containing, as the acid component, a long-chain fatty acid having from 8 to 22, in particular from 12 to 22 carbon atoms, for example lauric acid, tridecyl acid, myristic acid, penadecyl acid, palmitic acid, margaric acid, stearic acid, arachidic acid, behenic acid or corresponding unsaturated acids, for example oleic acid, elaidic acid, erucic acid, brasidic acid or linoleic acid, if desired with the addition of antioxidants , for example vitamin E, β-carotene or 3,5-di-tert-butyl-4-hydroxytoluene. The alcohol component of these fatty acid esters have a maximum of 6 carbon atoms and is the mono- or polyhydroxy alcohol, for example a mono-, di- or trihydroxy alcohol, "for example methanol, ethanol, propanol, butanol or pentanol or the isomers thereof, but especially glycol and glycerol The following examples of fatty acid esters must therefore be mentioned: ethyl oleate, isopropyl myristate, isopropyl palmitate, "Labrafil M2375" (trioleate polyoxyethylene glycol, Gattefossé, Paris), "Migiyol 812" (triglyceride of saturated fatty acids with chain length of 8 to 12 carbon atoms, Hüls AG, Germany), but especially vegetable oils, such as cottonseed oil, almond oil, olvia oil, castor oil, oil of sesame, soybean oil and more especially peanut oil. - The compositions for injection or infusion are prepared in the customary manner under sterile conditions; the same applies also for the introduction of the compositions into ampoules or flasks and the sealing of the containers. Pharmaceutical compositions for oral administration can be obtained by combining the active ingredient with solid carriers, if desired by granulating a resulting mixture, and processing the mixture, if desired or if necessary, after the addition of the appropriate excipients. , in tablets, dragee cores or capsules. It is also possible that these are incorporated into plastic carriers that allow the active ingredients to diffuse or be released in measured amounts. Suitable carriers are especially fillers, such as sugars, for example lactose, sucrose, mannitol or sorbitol, cellulose and / or calcium phosphate preparations, for example tricalcium phosphate or calcium acid phosphate, and binders, such as starch pastes using for example corn, wheat, rice or potato starch, gelatin, tragacanth, methylcellulose, hydroxypropylmethylcellulose, sodium carboxymethylcellulose and / or polyvinylpyrrolidone, and / or] if desired, disintegrators, such as the above-mentioned starches, and / or carboxymethyl starch, cross-linked polyvinylpyrrolidone, agar, alginic acid or a salt thereof, such as sodium alginate. The excipients are especially flow conditioners and lubricants, for example silicic acid, talc, stearic acid or salts thereof, such as magnesium or calcium stearate, and / or polyethylene glycol. The dragee cores are provided with suitable, optionally enteric coatings, being used, among other things, the concentrated sugar solutions which may comprise Arabica gum, talc, polyvinylpyrrolidone, polyethylene glycol, and / or titanium dioxide, or solvent coating solutions. suitable organic compounds or, for the preparation of the enteric coatings, solutions of suitable cellulose preparations, such as ethylcellulose phthalate or hydroxypropylmethylcellulose phthalate. Capsules are dry filled capsules made of gelatin and soft sealed capsules made of gelatin and a plasticizer, such as glycerol and sorbitol. The dry-filled capsules can comprise the active ingredient in the form of granules, for example with fillers, such as lactose, binders, such as starches, and / or glidants, such as talc or magnesium stearate, and if desired with stabilizers. In soft capsules the active ingredient is preferably dissolved or suspended in suitable oily excipients, such as fatty oils, paraffin oil or liquid polyethylene glycols, it also being possible for the stabilizers and / or antibacterial agents to be added. The dyes or pigments can be added to the tablets or dragee coatings or to the capsules, for example for identification purposes or to indicate different doses of the active ingredient. For parenteral administration, aqueous solutions of an active ingredient in water-soluble form, for example of a water-soluble salt, or aqueous injection suspensions containing viscosity-increasing substances and stabilizers, are especially suitable. The active ingredient, optionally together with excipients, can also be in the form of a lyophilizate and be made into a solution before parenteral administration by the addition of solvents. A further object of the invention is a process for preparing pyridoindole derivatives according to formulas I, IC ?, Ic2 or IP. The compounds according to formula I of the present invention are prepared according to the general sequence of the reactions detailed in the following schemes, wherein R1. R2, R3, R4, R5 and R6 are as defined in formula I, IC1, IC or IP. The obtained compounds can also be converted to a pharmaceutically acceptable salt thereof, in a manner known per se. . "The compounds of the invention can be manufactured by the application or adaptation of known methods, by which is meant the methods used up to now or described in the literature, for example those described by Larock RC in" Comprehensive organic transformations: In the reactions described hereinafter, it may be necessary to protect the reactive functional groups, for example the hydroxyl, amino, imino, thio or carboxyl, where these are desired in the present invention. the final product, to avoid its unwanted participation in the reactions.The conventional protective groups can be used in accordance with standard practice, for example see Greene TW and Wuts PGM in "Protective groups in organic synthesis" Wiley-Interscience, 1999. In general, the synthesis of the indoleacetic acid derivatives of the formula I begins as described in the Reaction Schemes. 1 and 2 with the indole of the formula I, which by means of phosphorus oxychloride in dimethylformamide is converted into a Vilsmeyer reaction to the formyl derivative of the formula 2 (R. Gastpar et al. Med. Chem. (1998), 41, 4965-4972). Subsequent condensation with a secondary amine, such as pyrrolidino or the like, in a suitable solvent to azeotropically remove the water formed in a reaction, such as toluene, benzene or the like, leads to the Schiff base of formula 3, which then reacts with a compound of the formula L-CH2C02R, in which R represents an alkyl group, preferably ethyl or tertbutyl, and L is a leaving group, the presence of a base, such as cesium carbonate, sodium hydride or the like, in a suitable solvent, such as alcohol, preferably ethanol, or acetone, tetrahydrofuran, dioxane, to produce the indole salt of Formula 4. The group L Suitable is a leaving group such as halo, in particular bromine or chlorine Preferably, the compound of the formula L-CH 2 CO 2 R is ethyl bromoacetate The indole salt of the formula 4 is condensed with the cyanoacetic acid ester of the formula NC -CH2-COOR ', -where R 'represents an alkyl group, preferably ethyl or tert-butyl, in the presence of a base, such as sodium ethoxide, to form the cyanoacrylic ester of the formula 5 (T. Moriya et al., Chem. Pharm. Bull. 1980, 28, 1711-1721). Cleavage of the ester group, either under acidic or alkaline conditions, such as TFA in dichloromethane or sodium hydroxide in THF, respectively, gave the carboxylic acid of formula 6, which was then converted to the corresponding acyl halide of the formula 7, by means of a halogenation reagent - under conditions known to a person skilled in the art. Preferably, the carboxylic acid is converted to the chloride, of acid using oxalyl chloride in the presence of a catalytic amount. of dimethylformamide in a suitable solvent, such as dichloromethane or toluene or the like.

Reaction Scheme 1 Precursor A-G Deprotection Intermediary A-G Reaction Scheme 2 Intermediary A-G Treatment of an acyl halide of the formula 7 with a primary amine of the formula R 6 -NH 2 in a suitable solvent, such as dichloromethane, tetrahydrofuran, or N, N-dimethylformamide, gives an α-substituted amide of the formula , where R? is a hydrogen atom, while a secondary amine of the formula? HR5Re gives a?,? - disubstituted amide of the formula 8. Preferably, a base such as triethylamine -, - N,? -diisopropylethylamine,? -ethyl-morpholine, ? -methylpiperidine or pyridine is added to combine with the hydrochloric acid released. "The hydrolysis of ester group R in formula 8 can be carried out using routine procedures, as described in Reaction Scheme 2, Step b), eg by stirring with aqueous sodium hydroxide, or trifluoroacetic acid for Alternatively, the indoleacetic acid derivatives of Formula I can be synthesized in two consecutive steps as described in Reaction Scheme 3, starting from the Schiff base above. mentioned of formula 4 (Step c), which is first reacted with the 2-cyanoacetamide of the formula? C-CH2-CO? R? R6 to form an amide of Formula 8. The final deprotection under standard conditions , as described in Reaction Scheme 3, Step b), gives a final compound of the formula (I, 4).

The 2-cyanoacetamide reagent of the formula NC-CH2-CONR5R6 is prepared from the cyanoacetic acid and a primary or secondary amine, under conditions known to a skilled person.

Reaction Scheme 3 Pasoc) A-G DETAILED DESCRIPTION OF THE INVENTION The particular embodiments of the invention are described in the following Examples, which serve to illustrate the invention in more detail, without limiting its scope in any way.

Examples The temperatures are indicated in degrees Celsius (° C). Unless indicated otherwise, the reactions take place at room temperature (ta). In mixtures, the ratios of the parts of the solvent or the eluent or the mixtures of reagents in liquid form are given as volumetric (v / v) ratios, unless indicated otherwise.

Abbreviations and acronyms used: AcOH: acetic acid; NHOH: ammonium hydroxide; BSA: bovine serum albumin; caled: calculated; CH2C12: dichloromethane; DIEA: N, N-diisopropylethylamine; DMF:?,? - dimethylformamide; DMSO: dimethyl sulfoxide; EDTA Ethylenediaminetetraacetic acid; Et3 ?: triethylamine; EtOAc: ethyl acetate; EtOH: ethanol; g: gram; h: hour; H20: water; HCl: hydrochloric acid; HEPES: 4- (2-hydroxyethyl) -piperazin-1-ethanesulfonic acid buffer; HPLC: high performance liquid chromatography; k: kilo; K2C03: potassium carbonate; KHS0: potassium acid sulfate; 1 liter; MgCl2: magnesium chloride; MgSO: magnesium sulfate; μ: micro; m: military; mol: mol; M: molar; MeOH: methanol; Me: methyl; min: minute; ESI-MS: ionization mass spectrometry of 'electrorocium; ?: normality of the solution; ? a? 3: sodium azide; NaCl: sodium chloride; ? aHC03: sodium acid carbonate • sodium; ? a2C03: sodium carbonate; αOH: sodium hydroxide; ? a2S04: sodium sulfate; PBS: saline buffered with phosphate; PGD2: prostaglandin D2; PMSF: phenyl ethanesulfonyl fluoride; P0C13: phosphorus oxychloride; THF Tetrahydrofuran; tR: retention time; Tris: tris- (hydroxymethyl) aminomethane buffer.

Terms; Analytical HPLC used in the following Examples: LC-1: Analytical HPLC on an XterraMR MS column C18 (50 x 2.1 mm, 5 μm, .waters): linear water gradient / 0.06% formic acid (A) and acetonitrile / O .06% formic acid (B) from 5% to 95% B in 6 minutes; flow rate 0.25 ml / min, detection at 215 nm. LC-2: Analytical HPLC on a GromSil MS column CIB (50x2.1 mm, 5 μm, Waters): linear water gradient / 0.06% formic acid (A) and acetonitrile / O .06% formic acid (B) from 5% up to 95% B in 6 minutes; flow rate 0.25 ml / min, detection at 215 nm. LC-3: Analytical HPLC on a Waters column Xterra "11 C18 (4.6 x 50 mm, 5 mm): linear water gradient / 0.06% formic acid (A) and acetonitrile / O .06% formic acid (B) from 5% to 95% B in 1 minute, flow rate 3 ml / min LC-4: Analytical HPLC on a Zorbax SB-AQ column (4.6 x 50 mm, 5 mm): linear water gradient / 0.06% formic acid (a) and acetonitrile / O .06% formic acid (B) from 5% up to 95% B in 1 minute; flow rate 3 ml / min LC-5: Analytical HPLC on a Zorbax SB-AQ column (50 x 4.6 mm, 5 mm, Agilent 1100 equipped with a Dionex P580 binary pump, a Dionex PDA-100 Photodiode Array Detector and a Finnigan mass spectrometer AQA);.} linear water gradient / 0.04% TFA (A) and acetonitrile (B) from 5% up to 95% B in 1 minute; flow rate 4.5 ml / min, detection at 210, 220, 230, 254 and 280 nm.

Synthesis of the AG precursors of the Formula 4 Precursor A: l-ethoxycarbonylmethyl-3-pyrrolidin-1-ylmethylene-3H-indolium bromide Aa) 3-pyrrolidin-1-yl-methylene-3H-indole: In a bottom flask round equipped with a Dean Stark condenser, 1H-indole-3-carbaldehyde (40 g, 0.275 mmol) and pyrrolidine (27 ml, 0.330 mmol) were suspended in 480 ml of toluene and kept warm at reflux overnight. After cooling to room temperature, the solid was filtered, washed with toluene and recrystallized from 100 ml of THF, providing the subtitle compound (47.7 g) as a reddish solid in 87% yield. tR (LC-2): 0.47 min; ESI-MS (-f): m / z 199.46 [M + H] + (calculated 198.26 for C? 3H14N2).

Ab) l-Ethoxycarbonylmethyl-3-pyrrolidin-1-ylmethylene-3H-indolium bromide: Ethyl bromoacetate (6.1 ml, 55.4 mmol) was added dropwise to a stirred solution of 3-pyrrolidin-1-yl-methylene 3H-indole (10 g, 50.4 mmol) in 40 ml of EtOH and the reaction mixture was allowed to stir at room temperature overnight. The solid was filtered, washed with small portions of ethanol and then dried in vacuo to give 17 g of the title compound as a beige solid in 93% yield. tR (LC-1): 1.45 min; ESI-MS (+): "m / z 285.31 [M] + (calculated 285.36 for C17H21BrN202 +).

Precursor - B: 5-bromo-l-ethoxycarbonylmethyl-3-pyrrolidin-1-ylmethylene-3H-indolium bromide The title compound is prepared using a procedure analogous to Precursor A, substituting 5-bromo-lH-indole-3 -carbaldehyde by the H-indol-3 -carbaldehyde. tR (LC-2): 1.52 min; ESI-MS -. (+): M / z 365.10 [M + H] + (calculated 364. 26 for Ca7H2oBrN2? 2+).

Preparation of 5-bromo-1H-indole-3-carbaldehyde: 7.5 ml of anhydrous dimethylformamide are cooled to 0 ° C, and treated dropwise with P0C13 (3.66 ml, 40 mmol).

After stirring at this temperature for 15 minutes, a solution of 5-bromo-1H-indole (784 mg, 4 mmol) in 2 ml of anhydrous dimethylformamide is added and the reaction mixture is allowed to warm to room temperature within 1 hour. hour. The stirring is continued at 40 ° C for an additional hour, then the reaction mixture is cooled to room temperature and emptied onto ice. An aqueous solution of sodium hydroxide was added to neutralize the acid solution, adjusting to pH6. After stirring overnight at room temperature, the precipitate was collected by filtration, washed with water and dried under a high vacuum to give 932 mg of the pure subtitled compound, as a beige solid with a quantitative yield. (LC-2): 1.85 min; ESI-MS (+): m / z 226.10 [M + 2] + (calculated 224.05 for C9H6BrN0).

Precursor C: l-ethoxycarbonylmethyl-7-methyl-3-pyrrolidin-1-ylmethylene-3H-indolium bromide The title compound is prepared using a procedure analogous to the process of preparation of Precursor B, substituting 7-methyl-1H- indole-3-carbaldehyde by 5-bromo-1H-indole-3-carbaldehyde. The preparation of 7-methyl-1H-indole-3-carbaldehyde is carried out analogously to 5-bromo-1H-indole-3-carbaldehyde. tR (LC-1) 1.56 min; ESI-MS (+): m / z 299.47 [M] + (calculated 299.39 for C? 8H23? 202+).

Precursor D: l-ethoxycarbonylmethyl-5-fluoro-3-pyrrolidin-1-ylmethylene-3H-indolium bromide The title compound was prepared using a procedure analogous to the preparation procedure for Precursor B, substituting 5-fluoro-lH -indol-3-carbaldehyde by 5-bromo-IH-indole-3 -carbaldehyde. The preparation of 5-fluoro-1H-indole-3-carbaldehyde is carried out analogously to 5-bromo-1H-indole-3-carbaldehyde. tR (LC-2) 1.45 min; ESI-MS (+): m / z 303-26 [M] + (calculated 303.35 for C17H20FN2O2 +).

Precursor E: l-ethoxycarbonylmethyl-5-methyl-3-pyrrolidin-1-ylmethylene-3H-indolium bromide The title compound is prepared using a procedure analogous to the preparation procedure for Precursor A, substituting 5-methyl-1H -indol-3-carbaldehyde by 1H-indole-3-carbaldehyde. The preparation of 5-methyl-lH-indole-3-carbaldehyde is carried out analogously to 5-bromo-lH-indole-3-carbaldehyde. tR (LC-2) 1.46 min; ESI-MS (+): m / z 299.25 [M] + (calculated 299.39 for C18H23N202 +).

Precursor F: l-ethoxycarbonylmethyl-6-fluoro-3-pyrrolidin-1-ylmethylene-3H-indolium bromide The title compound is prepared using a procedure analogous to the preparation procedure for Precursor A, substituting 6-fluoro-1H -indol-3-carbaldehyde by the H-indol-3 -carbaldehyde. The preparation of 6-fluoro-IH-indole-3-carbaldehyde is carried out analogously to 5-bromo-lH-indole-3-carbaldehyde. tR (LC-2) 1.45 min; ESI-MS (+): m / z 303.26 [M] + (calculated 303.35 for C17H20FN2O2 +).

Precursor G: l-ethoxycarbonylmethyl-6-nitro-3-pyrrolidin-1-ylmethylene-3H-indolium bromide The title compound is prepared using a procedure analogous to the preparation procedure for Precursor A, substituting 6-nitro-1H -indol-3 -carbaldehyde by lH-indol-3-carbaldehyde. The preparation of 6-nitro-1H-indole-3-carbaldehyde is carried out analogously to 5-bromo-1H-indole-3-carbaldehyde. tR (LC-2) 1.37 min; ESI-MS (+): - m / z 330.26 [M] + (calculated 330.36 for C17H20N3O4 +).

Preparation of Intermediates AG of Formula 7: Intermediate A: [3- (2-chlorocarbonyl-2-cyano-vinyl) -indol-1-yl] -acetic acid ethyl ester To a stirred suspension of 2-cyano-3- ( 1-ethoxycarbonylmethyl-1H-indol-3-yl) -acrylic acid (3.0 g, 10 mmol in 120 ml of anhydrous dichloromethane, in the presence of a few drops of anhydrous DMF, oxalyl chloride (1.7 ml, 20 mmol) was added. After stirring at room temperature overnight, the volatile materials were removed under reduced pressure, the residue was azeotropically distilled twice with anhydrous toluene and dried in vacuo to give 3.18 g of the crude title compound in a quantitative yield. it was stored under an argon atmosphere and used without further purification.

Ac) 2-cyano-3- (1-ethoxycarbonylmethyl-1H-indol-3-yl) -acrylic acid To a stirred solution of Precursor A (1-ethoxycarbonylmethyl-3-pyrrolidin-1-yl-methylene-3H- bromide) indole, 4.0 g, 10.8 mmol) and tert-butyl cyanoacetate (15.0 g, 10.8 mmol) in 100 ml of chloroform was added dropwise a solution of sodium ethylate (0.74 g, 10.8 mmol) in 40 ml of anhydrous ethanol . The reaction mixture was allowed to stir at room temperature overnight, then diluted with 60 ml of ethyl acetate and 30 ml of water, acidified to pH 3 by the addition of IN aqueous HCl. After phase separation, the aqueous phase was extracted twice with ethyl acetate. The combined organic layers were washed with water and brine, dried over sodium sulfate and the solvent was removed under reduced pressure. The residue was dissolved in 20 ml of dichloromethane and treated with trifluoroacetic acid (8.3 ml, 108 mmol) at room temperature for 4 hours. The volatile materials were removed under reduced pressure and the residue was azeotropically distilled three times with toluene, then recrystallized from ethyl acetate to give 3.15 of the subtitle compound as a yellow solid in 97% yield: tR (LC-2 ) 1.98 min; ESI-MS (+): m / z 324.35 [M-Na] + (calculated 298.29 for C16H? 4N204).

Intermediate B: [3- (2-chlorocarbonyl-2-cyano-vinyl) -5-bromo-indol-1-yl] -acetic acid ethyl ester The title compound was prepared using a procedure analogous to Intermediate A, substituting Precursor B (5-bromo-l-ethoxycarbonylmethyl-3-pyrrolidin-1-ylmethylene-3H-indolium) by Precursor A.

Intermediate C: [3- (2-chlorocarbonyl-2-cyano-vinyl) -7-methyl-indol-1-yl] -acetic acid ethyl ester The title compound was prepared using a procedure analogous to Intermediate A, substituting Precursor C by the Precursor A.

Intermediate D: [3- (2-chlorocarbonyl-2-cyano-vinyl) -5-fluoro-indol-1-yl] -acetic acid ethyl ester The title compound was prepared using a procedure analogous to Intermediate A, substituting Precursor D by the Precursor A.

Intermediate E: [3- (2-chlorocarbonyl-2-cyano-vinyl) -5-methyl-indol-1-yl] -acetic acid ethyl ester The title compound was prepared using a procedure analogous to Intermediate A, substituting the Precursor E by the Precursor A.

Intermediate F: [3- (2-chlorocarbonyl-2-cyano-vinyl) -6-fluoro-indol-1-yl] -acetic acid ethyl ester The title compound was prepared using a procedure analogous to Intermediate A, substituting Precursor F by the Precursor A.

Intermediate G: [3- (2-chlorocarbonyl-2-cyano-vinyl) -6-nitro-indol-1-yl] -acetic acid ethyl ester The title compound was prepared using a procedure analogous to Intermediate A, substituting the Precursor G by Precursor A.

Example 1: [3- ((E) -2-cyano-2-phenylcarbamoyl-vinyl) -indol-1-yl] -acetic acid Step A: [3- (2-cyano-2-phenylcarbamoyl-vinyl) -indole] -1-yl] -ethyl acetate Aniline (8 μL, 0.09 mmol) is added to a stirred solution of Intermediate A (25 mg, 0.08 mmol) and DIEA (41 μL, 0.24 mmol) in 1 mL of anhydrous dichloromethane. The reaction mixture was stirred at room temperature overnight, then washed with IN aqueous HCl, with water and with saturated aqueous sodium hydrogen carbonate solution. The solvent of the organic phase is eliminated by producing the crude compound of the subtitle: tR (LC-2) 2.18 min (single peak); ESI-MS (+): m / z 374. 45 [M + H] + (calculated 373.40 for C22H19N303).

Step B: A stirred solution of [3- (2-cyano-2-phenylcarbamoyl-vinyl) -indol-1-yl] -acetic acid ethyl acetate (0.079 mmol) in 0.8 mL of THF is treated with 0.2N aqueous NaOH (0.4 ml, 0.08 mmol) at room temperature for 10 min. The yellow reaction mixture is diluted with 2 ml of water and washed two with 2 ml of diethyl ether. The aqueous phase is acidified to pH 1 by the addition of concentrated HCl and extracted with dichloromethane. The solvent is evaporated and the residue is recrystallized from acetonitrile to yield the pure title compound. tR (LC-2) 1.91 min (single peak); ESI-MS (+): m / z 346.16 [M + H] + (calc. 345.35 for C20H15N3O3). Alternatively upon recrystallization, the final purification of the title compound is carried out by column chromatography on silica gel (hexane / ethyl acetate 3: 1, containing 2% AcOH), and by preparative reverse phase HPLC. Alternatively, the indoleacetic acid vatives of the general formula I are prepared as described below for Example 107, starting with the respective Precursor B and the 2-cyanoacetamide reagent of the formula NC-CH2-C0? R5Rs. Example 107: [5-bromo-3 - ((E) -2-cyano-2-phenylcarbamoyl-vinyl) -indol-1-yl] -acetic acid Step a) [5-bromo-3- ((E) -2-cyano-2-phenylcarbamoyl-vinyl) -indol-1-yl] -ethyl acetate: A mixture of 2-cyano-β-phenyl-acetamide ( 122 mg, 0. 14 mmol) and sodium ethylate (9.3 mg, 0.14 mmol) in 1 ml of anhydrous ethanol is ultrasonicated for 2 minutes and then added to a solution of Precursor B (50 mg, 0.14 mmol) in 1 ml of anhydrous ethanol. The reaction mixture is stirred at room temperature for 15 minutes, the precipitate is filtered and washed twice with a small amount of ethanol. The pure compound of the subtitle is obtained as a brown solid (24 mg) with a yield of 39%. tR (LC-2) 2.51 min; ESI-MS (+): m / z 454.09 [M + 2] + (calculated 452.30 for C22H18BrN303).

Step b): The title compound is obtained using the conditions for the hydrolysis of the above ester, analogously to Example 1. tR (LC-2) 2.25 min; ESI-MS (+): m / z 424.08 [M + H] + (calculated 423.03 for C20H? 4NrN303).

Preparation of the 2-cyanoacetamide reagents of the formula NC-CH2-CONR5R6. 2-cyano-N-phenyl-acetamide Cyanoacetic acid (1.0 g, 11.7 mmol) is added to a stirred solution of PC15 (2.4 g, 11.7 mmol) in 200 ml of anhydrous dichloromethane. The reaction mixture was heated to reflux and kept "stirring for 30 minutes." After cooling to room temperature, aniline was added. (1.07 ml, 11.7 mmol) dropwise and the reaction is stirred at reflux for an additional 2 hours, then cooled to 0 ° C and neutralized by the addition of a saturated aqueous solution of sodium carbonate. The precipitate is filtered, washed with water and dried under a high vacuum to give 1.54 g of the title compound as a white solid in 82% yield: tR (LC-2) 1.50 min; ESI-MS (+): m / z 183.33 [M + Na] + (calculated 160.17 for C9H8N20).

Other Useful 2-Cyano-Acetamide Reagents The following 2-cyanoacetamide reagents were prepared using a procedure analogous to the preparation of 2-cyano-β-phenyl-acetamide, substituting the appropriate amine for the aniline: Fenethylphenylamine (HNR11412 for Example 84) Sodium triacetoxyborohydride (5.46 g, 26 mmol) is added in small portions to a stirred solution of aniline (2.0 g, 21.5 mmol) and phenylacetaldehyde (2.83 g, 24 mmol) in DMF anhydrous / MeOH / AcOH (87: 10.3, 120 ml). After stirring at room temperature for 90 minutes, the volatile materials are removed under reduced pressure. The residue is dissolved in 200 ml of dichloromethane and extracted twice with IN HCl. The combined aqueous layers are washed with - ethyl acetate, then add ammonium hydroxide solution to pH 9, and extract the mixture with dichloromethane. The solvent is evaporated, and the crude product is purified by chromatography on silica gel (hexane / ethyl acetate, 5: 1) to give the pure title compound as a yellow oil. tR (LC-2) 2.16 min; ESI-MS (positive ion) m / z 198.22 [M + H] + (calculated 197.28 for C 14 H 5 N). , 6, 1-1, 12-tetrahydro-dibenzo [b, f] azocine (HNR11R12 for Example 85) to a suspension of 11,12-dihydro-SH-dibenzo [b, f] azocin-6-one (2.0 g, 8.96 mmo-1) in 20 ml of anhydrous THF is added dropwise a solution of LiAlH4 (1.0 N in. THF, 8.96 ml) in a period of 10 minutes. After cessation of gas evolution, the reaction mixture is kept under stirring at reflux overnight, then quenched by the addition of 0.48 ml of water. The precipitate is filtered and the filtrate is extracted twice with ethyl acetate. The combined organic layers are dried over sodium sulfate, the solvent is evaporated and the residue is recrystallized from boiling hexane to give off-white crystals of the title compound (1.35 g) in 72% yield: tR (LC-2 ) 1.65 min; ESI-MS (+): m / z 210.70 [M + H] + (calculated 209.29 for C? 5 HlsN). 6, 11-dihydro-5H-dibenzo [b, e] azepine (H? R11R12 for Example 89) Step i) 5, 11-dihydro-dibenzo [b, e] azepin-6-one: A suspension of Anhydrous aluminum (319 mg, 2.39 mmol) in o-xylene is heated to 110 ° C. Then, a solution of 2-benzylphenylisocyanate (500 mg, 2.39 mmol) is added dropwise and the brown reaction mixture is kept stirring at 150 ° C for 1 hour. After cooling to room temperature, the solvent is evaporated, the residue is dissolved in dichloromethane / methanol (19: 1) and filtered through a small plug of silica gel. The solvent is evaporated and the crude product is recrystallized from acetonitrile to give the pure subtitle compound as a beige solid (170 mg) in a yield of 34% (arawa et al., ". Med. Chem. 2001, 44 , 372-389): tR (LC-2) 1.87 min; ESI-MS (+): m / z 210-13 [M + H] + (calculated 209.24 for Hn O).

Step i) To a stirred solution of 55, 11-dihydro-dibenzo [b, e] azepin-6-one (170 mg, 0.81 mmol) in 20 ml of anhydrous THF is added dropwise a solution of LiAlH4 (1.0 N in THF, 0.81 mmol) over a period of 10 minutes. After cessation of gas evolution, the reaction mixture is kept stirring at reflux overnight, cooled to room temperature and poured into 100 ml of water. The mixture is extracted with diethyl ether, the combined organic layers are dried over sodium sulfate, and the solvent is removed under reduced pressure. The residue is recrystallized from boiling hexane to give the title compound as an off-white solid (130 mg) in 82% yield: tR (LC-2) 2.09 min; ESI-MS (+): m / z 197.33 [M + H] + (calculated 195.26 for C? 4H13N).

Diffenethylamine (HNR11R12 for Example 90) Sodium triacetoxyborohydride (8.87 g, 41. 3 mmol) in small portions at 0 ° C to a stirred solution of phenethylamine (5.0 g, 41.3 mmol) and phenylacetaldehyde (4.96 g, 41.3 mmol) in 50 mL of methanol. The reaction mixture is stirred at room temperature overnight, is poured into a saturated aqueous solution of H2P0 and extracted twice with ethyl acetate. The solvent is evaporated, the residue is taken up in HCl 1? and washed twice with dichloromethane. The aqueous layer is adjusted to pH 9 by the addition of sodium hydroxide solution and extracted with dichloromethane. Drying the combined organic layers over sodium sulfate and evaporating the solvents gives the crude title compound as a pale yellow oil. tR (LC-2) 1.40 min; ESI-MS (+): m / z 226.23 [M + H] + (calculated 225.33 for C1SH19N). Examples 2-106 and 108-156 of the following Tables 1 to 8 are prepared using a procedure analogous to that described for Example 1, substituting the appropriate amine for the aniline and the appropriate Intermediary by Intermediary A respectively; or analogously to that described for Example 107, substituting the appropriate 2-cyanoacetamide for the 2-cyano-N-phenyl-acetamide and the appropriate Precursor for Precursor B.

Table 1: Examples 1-106 with the general structure of Formula, where R1 = R3 = R4 = H.

Data Ex. Name R5 R6 Formula [mio] of MS Molecular Weight (Met) ni / z [M + H Acid p - ((E) -2- cyano-2-phenylcar C20H15N3O3 1.91 ba oil-vinyl) -indol H phenyl 345.357 (LC-2) 346.16-1-yl] -acetic Acid [3- ((E) -2- cyano-2 ~ m-tolylcar bamoyl-vinyl) -indol H 3 -methyl-eneyl C 21 H 17 N 3 O 3 2.22 359,384 (LC-1) 260.20 -1-ill -acetic Acid { 3- [< E.}. -2- cyano-2- (4-mβfcoxy- N 304 2.10 phenylcarbamoyl) - H 4-methoxy-C 21 H 17 .25 phenyl 375,383 (LC-1) 376 vinyl] -indol-1-yl} -acetic Data Man Rs Rd Formula Imín] of MS Molecular Weight (Met.) M / z [+ H Acid { 3- [(E) -2-. { 3-bramo-phenylalany C20H14N3O3Br 2.34 moil) -2-cyano-vxnilJ H 3-bro o- £ enyl 426.00 -indol-1-yl-acetic 424.253 (LC-1) Acid { 3 ~ [(E) -2-ciaaa -2- (cyclohexylmethylohexyl-C21H23N303 2.08 -carbamoyl] -vinyl] -H 366.24 ethyl 365.432;, (LC ~ 2) indole-1-yl.} - acetic Acid [3-. { (E) -2-cyano ~ 2- eeti-cyicarbamoyl-C22H19N303 1.94 vinyl) -in-ol-i-yl] - H-enefeyl 374.20 373.411 (LC-2) acetic Acid [3-. { (E.} -2-cyano-2-isopropylsaxba trc> il-C17H17N303 1.73 vinyl) -indol-l-yl] - H isopropyl 312.23 311.34 (LC-2) acetic Acid [3-. { < E) -2-eiano-2-propyXcarbamoyl-C17H17N303 1.73"19, vinyl) -indol-l-yl] - H propyl 311.34 (LC-2) D i" -3 acetic Acid [3- ((E) -2-cyano-2-cyc ?? exylcarbap? Oá.1 C20H21N3O3 1.96 -vinyl) -indol-l-il] H -hexyohexyl 52.26 351.405 (LC-2) ° -acetic Acid { 3 ~ £ ÍE} ~ 2 ~ cyano -2-. { 3-methyl-bufcylcar C19H21N303 1.96 bamoyl) -vinyl] -indole H 3-methyl-bufcyl 40.20 339394 (LC-2) -1-il} -acetic Data R * 6 Formula (rni l de MS E, Name Molecular Weight (Met.) M / z [M + Hf Beneyl carbamoyl-2-cyano acid C21H17H303 1.91 11 -vinyl) -indole H bencxlo 360.21 359384 (LC-2) -1-il3 -acetic Acid { 3- [ . { E) -2- (benzyl-phenyl-carbazole) -2-cyano-phenyl-benayl C27H21N303 2.34 436.26 vinyl] -indol-l- 435.-4S2 (Ol) il} -acetic Acid { 3 ~ . { E > ~ 2 ~ -. n cyano-2- < 4-cyano- C21H1-4N403 2.15 i? 13 phenylcarbamoyl) H 4-axan-xenxyl 371.09 370367 (LC-1) -vinyl] -indol-1- il} ~ acetic Acid [3-. { (E) -2-cyano- 2-o-tol £ lcajrbamoil ~ C21H1JN303 2.14 360.26 14 vinyl) -indol-l-yl] - H o -folyl 359-384 (LC-1) acetic Acid. { 3- [(E) -2-eiano- C22H1 9N303 2.33 15 2-. { 4-ethyl-1-enylcarba JJ 4 -eti-phenyl 374.21 moil) -vinyl] -indol- 373.411 (LC-1) 1-yl) -acetic Acid { 3-[ . { E.}. -2-eiaao- C20H1-4N3O3F 2.16 ¿2-. { 4- £ luoro-benzylcarbamyl) -vinyl] -indole H 4-flnoro-eiixlo 363.347 (LC-1) 364.21 -1-il} -acetic acid. { 3-[. { E) ~ 2-cyano C26H19N304 2.42 Yj -2- (4-eneoxi-phenylcar H 4 -phen.oxx-fem.lo 43 * 7,454 438.30 bamoyl) -vinyl] -indol- (LC-1) l-il} -acetic Data eg, Name R3 R ° F ula of MS mili! Molecular Weight (Me-fc.) Ni / z fM + Hf Acid { 3-C (E) -2-cyanogen -2- Cnaphthaln-2-ylcar C24H17N303 2.33 H na £ taleii-2-xlo 596.32 bamoil) -via.il] -indol- 395.417 (LC-1) l- il) -acetic Acid { 3- [ÍE) -2 -ciano -2- (2-isopropyl-phenyl B3 O3 2.27 19 carbamoyl) -vinyl] - H 2 -isopropyl- C23H21? 388.23 387,438 (LC-1) indol-l-il} -acetic fenxlo Acid [3-. { (E) -2 - cyano 2Q -2-p-tolylcarbamoyl-C21H17N3.03 2.23 H p-tolyl 360.26 vinyl) -indol-l-il] 359.384- (LC-1) -acetic Acid { 3- < (E) -2-aiano 2-. { 4-isopropyl-f-enyl rr C23H21N303 2.40 21 388.29 carbamoyl) -vinyl] - 4"-isopropyl-387.43S (LC-1) indol-l-yl.}. -acetic phenyl Acid { 3- [(E) -2-cyano ^ 2 -2- (3-methoxy-phenyl C 21 H 17 N 3 O 4 2.16 3-oxo-376.12 ** carbamoyl) -vinyl-H 375,383 (LC-1) indole-1-yl} -acetic fen Acid { 3-((E) -2-cyano-23 2- (3-fluoro-phenyl) C20H14N3-O3P 2.21 H 3-fl? Toro-feni or 364.15 carbamoyl) -vinyl] - 363.347 (LC-1) indol-l- ilJ-acetic Acid { 3 ~ £ (£.}. -2-cyano -2- (9H- £ uorßn-2-yl C27H19? C303 2.47 24 carbaaoyl) -vinyl] - H 9H- £ li? Orer_ ~ 2- ~ ilo 434.22 433.46 S (LC-1) indol-l-il.}. -acetic Ex. Man R5? T Formula Molecular Weight Acid { 3- [(E) -2-cyano ^ 25 b: a2m-o (xl :) - v °? xni: xl: l] s ~ nxinidol-l? H 4 ~ propyl-phenyl C2 ^ 387, l4J3¡l8 ° 3 - (YL'rCY-1) 388-16 -il} -acetic Acid { 3- [(E) -2-. { bi? phenyl-4-ylcarbamoyl) C 26 H 19 N 303 2.44 H bifenxyl-4-yl 422.24 -2-cyanovinyl] -indole 421,455 (LC-1) -1-yl} -acetic Acid { 3- [(E) -2-ciapo -2-. { 3,2'-dimethy? Biphenyl 3,2'-dia »il-C28H23N303 2.53 27 -4-ylcarbamoyl) -vinyl] H 450.15 -indol-l-il} -acetic bxfenil-4-ilo 449.509 (LC-1) Acid { 3- E (E) -2- (4-tert-butyl phenyl baaoyl) - - r 4-tert-buty-C24H23N303 2.46 2S 2 -cyanovinyl 3 -indol-1 - "• fstii or 402.24 401.465 (LC-1) -il.}. -acetic Acid { 3- [(E) -2 ~ < 2- _ bbßßnnaaiill-ffaanniillccaairbamoyl C27I? 21N303 2 5 ¿9 - 22 - ciazinno-vviinniill]] -indole H 2 -benzyl-phenyl 436.13 435.4S2 (LC-1) -1-il} -acetic Acid { 3- [< E.}. -2-. { 4-3Q butyl--nilcarbamoyl) JJ 4 -buyl-phenyl C 24 H 23 N 3 Cl 3 2.52 402.37 -2-cyanovinyl] -indole 401.465 (LC-1) -1-il} -acetic Acid { 3- [< E.}. -2- acyl-ß-nilcarbamoyl) C22H17M3C4 2.24 31 -2-cyanovinyl] -indole H 2 ~ acetyl-e ~? -? Il 588.16 387.394 (LC-1) -1-il} -acetic Ej - Man Ra R6 Formula Molecular Weight. (Acid { 3-1 (E) -2-cyano -2- { Indan-5-ylcarba 9N303 2.36 32 moil) -vinyl] -indol-l H indan-5-yl C23H1-yl} -acetic 385.422 386.19 (LC-1) Acid { 3-[. { E.}. -2-. { 4- ?? sec-butylcarbonyl TT 4-sec-butyl C 24 H 23 M 303 2.51 oil) -2-cyanovinyl] -phenyl 402.24 401.465 (LC-1) -indol-1-yl} -acetic Acid { 3- [(E) -2-cyano-- "S? 2- {4-ethoxy-£ enylcarba C22H19N3Q4 2.20 -moyl) -vinyl] -indol-l- H 4 -etos: i ~ phenyl 390.20 389.41 (LC-1) * .. il] -acetic Acid { 3- l (E> -2-cyano 25 -2- < 3 ~ ßt? 3-i- £ enylcar C22H19N304 2.25 H 3 ~ et 2 L ~ £ enilo 390.14 bamoil) -vinyl] -indol- 389.41 - ( LC-1) l-il} -acetic Acid { 3- [(E) -2-cyano-2- (2-propyl-3-enylcar 3-A + 33 36 bamoyl) -vinyl] -indol-1 H 2 -propyl-phenyl C 23 H 21 N 30 388.23 -il} -acetic 387,438 (LC-1) Acid { 3- [(E) -2-cyano. "-2- (3- £ enoxy-enylcar C26H19N304 2.44 37 bamoyl.}. -vi? Iil3 -indol-l H 3-phenoxy-phenyl 438.18 -il} -acetic 437.454 (LC-1) Acid { 3- [ . { E) -2-ciaao -2? --22--. { . { 33 ~~ eettiill - f £ eernilcar C22H19N303 2.33 bbaammooiill} } - vviinniill]] -indol- H 3 -ethyl-feni or 374.21 373.411 (LC-1) 1-il} -acetic faith Facts Ex. Name 5 R6 Formula [min] of MS Molecular Weight (Met.) ^ M / z Acid { 3- [ . { E) -2-cyano -2-. { 2-ßtoXi-phenylcar J7 bamoil} -vinyl] -indole H 2 -ethoxy-pheni or C 22 H 19 N 304 2.39 -1-il} -acetic 389.41 (LC-1) 390.20 Acid { 3-[. { E.}. -2- (3-ene benzyloxy-3-benzaloyl-benzyloxy »C27H21N304 2.42 bamoyl.} -2-cyano-vinyl] H fetyyl 451.481 (LC-1) 452.19 -indol-l-yl.}. -acetic Acid { 3-í. { E) -2- (4-i n, 11 bromo-phenylcarbaoyl) C20H14H3O3Br Í.5Ó i U 41 -2-cyano-vinyl] -indole H 4-bromo-fesayl 424.253 (LC-1) 424.09 -1-il} -acetic Acid { 3 ™ [(E3 -2-cyano j /, - 22 - { { 44 - yyooddoo - f £ eernilcar JJ 4 ~ iodo- £ e_ilo C20H14N3O3I 2.37 ** bbaammosiill)) - vviinniill]] -indol- 471-249 (LC-1) 472.00 1-il} -ac ico Acid. { 3- [(E) - -ciano -2-. { 3-ioda- £ enylcar C20H14N3O3I 237 43 bamoyl) -vinyl] -indole H 3-iodo-enyl 472.00 471.249 (LC-1) -1-il} -acetic Acid (3 ~ { (E) -2-cyano 4 -2- E (4-fluoro-enyl) -methyl-4-γ-chloro-f-enyl C '21H16N303F 2.08 methyl-carbamoyl] -vinyl. 377374 (LC-1) 378.22 -indol-1-il) -acetic 0 Acid (3- { { E) -2-cyano 4-xaetoxi-C22H19N3C4 2.06 -2- [. { 4-methoxy-phenyl) -methyl-phenyl-methylcarbamoyl] -vinyl} 389.41 (LC-1) 390.20 -indsl-1-yl) -acetic Faith data Ex. Name B8 |? D Formula of MS jmin] Molecular Weight (Mef,) m / z Acid { 3- [ . { E.}. -2- cyano-2- (methyl-eneylmethyl phenyl 46 -carba odl) -vinyl] -C21H17N303 2.05 indole -l-i} -acetic 359.384 (LC-1) 360.20 Acid { 3-[. { E) -2-cyano -3- (3, -dihydro-2H-3, 4-dihydro-2H-47-quinolin-1-yl) -3-oxo-C23H19N303 2.16 quinolin-1-yl propenyl] -indol-l -il} 385.422 (LC-1) 386.25 -acetic Acid { 3 - [(E) -2 ~ cyano. -2- (methyl-p-tolyl-sar methyl p-olyl C22H19N303 2.14 48 bamoyl) -vinyl] -indol-l 374.21 -il} -acetic 373.411 (LC-1) Acid (3- { (E) -2-cyano -2- £ 2- (2,4-t-chloro-41-phenoxy) -phenylcarba 25 H 2, -dichloro-C 26 H 17 N 304 C 12 2. 374.15 moyl] -vinyl. -indol-f-enoxi) -f in 506344 (LC-1) l-il) -acetic Acid { 3- (E) -2-cyano -? -2-. { 2,5-dimethyl-eneryl TT, 5 ~ di? Aefcil C22H19N3G3 2.25 374.15 ** "carbaaoyl) -vinyl] -indsl-phenyl 373.411 (LC-1) -1 -il} -acetic Acid { 3-E (E) -2-cyano 51 -2-. { 9-ethyl-9H ~ caxbazole C28H22N403 2.48 -3-ylcarbamoyl} -vinyl3H9-etxl-9H-caxbazol-3-yl 463.21 462.508 (LC-1) -indol-l-il} -acetic Acid { 3- [. { E.}. -2- . { 3,5-bis-trifluoromethyl-3,5-bis- 13N303F6 2.56 52 phen lcarbamo l) -2- H trifluoromethyl-C 22 H cyanovinyl] -indole-1-phen 481,351 (LC-1) 482.07 -il} -acetic Data Ex. Name s R 6 Formula [m t &ili] Molecular Weight (Met.) Acid { 3- . { E.}. - -ciano -2-. { 5-methoxy-2-methyl-s-methoxy-2-C22H19N3C 2.16 ^ 3 phenylaxammoyl) -vinyl] "ethyl-phenyl 389.41 (LC-1) 90.14 -indol-l-il} -acetic Acid { 3-[. { E.}. -2- (3- benzoyl-phenylcarbamoyl) S4 -2-cyanovinyl] -indol- H - -, *. , C27H19 304"233 ..n nQ 3-benzoxl-renxlo. N? - {? C" W - + - > u, tJ "1-il.}. -acetic Acid i3 - [(E) -2- (4-benzyloxy-4-ylamino-5-bamoyl) -2-cyano-H 4-b-cxn-oxoxy- -C27H21N304 2.40 vinyl] -indol-1-yl} ? phenyl 451.481 (LC-1) -acetic Acid { 3-t (E) -2- _ cians ~ 2- (3-n ro- TT,. A ... C20H14N4O5 2.20"01? 0 3"phenylcarbamoyl) -vinyl] •" •, 3-nxtro-fenxlo ^^^^, 91.09 -in ol-l-il} -acetic Acid { 3- [(E) -2-cyano __ -2-. { 9-oxo-9H- £ luoren XO-9H-C27H17N304 236 448.05 £ > / -2-ylcarbamoyl) -vinyl] H 9-O fl oren-2-yl 447,449 '(LC-1) -nol-1-yl} -acetic Acid { 3- [(E) -2-cyano __, -2-. { 4-methox-biphenyl-p '4-methoxy-C27H21N304 2.56 ° 3-ilsarbamoyl) -vinyl] biphenyl-3-yl 451.481 (LC-1) 452.12 -indol- 1-il} -acetic Acid { 3- [(E) -2-cyano -2- (2-methoxy-dibenzo-2-methoxy- C27H19N305 2.63 59 £ wran-3-ylcarbamoyl) - H-dibenaofan-3-yl 4g5.4g (LC-1 466.14 vinyl] -indol-1-yl} - acétieo Fact data eg Name te R Formula [min] of MS Molecular Weight (Met.) m / z [M + Hf Acid { 3- [CE) -2-cyano -2-. { 9-oxo-SH- £ luoren-9-OXO-9H- «60 4-ylcarbamoyl) -vinyl] H C27H17N304 2.22 fluoren-4-yl © 448.11 -indol-l -il} -acetic 447,449 (LC-1) Acid { 3- [(E) -2-cyano-2- (9-oxo-9H-laoren-l-9-oxo-9H-C27H17N304 2.22 -ylcarbamoyl) -vinyl} - H fluoren-l-yl 448.11 indole-1-yl} -acety 447,449 (LC-1) Acid (3-((E.) -2- (2- j bbeennzzooiill-ffeenniillccarbamoyl) TT C27H19N304 2.43 ° "- ~ 22 - cciiaan« oo - vviinniill] -indo ~ 2-benzoyl-fenxlo 450.15 - 449.465 (LC-1) 1-il.}. -acetic Acid { 3- [(E) -2- (3-chloro-4-methoxy-fnyl C21H16M304CI 2.21 63 carba oi1.} -2-cyano-a methoxy-phenyl 409.828 (LC-1) ^ l v'uo vinyl] - indol-l-il.} - acetic Acid { 3-1 (B) -2- (5- chloro-2-methoxy-1-ene-5-chloro-2-C21H16N304CI 2.45 64 carbamoyl) -2-cyano-H-methoxy-phenyl 410.08 vinyl] -indol-l-i} - 409,828 (LC-1) acetic Methyl ester of 3- [(E) -3-) acid. { 1-sarboxymethyl-2-methyl-S-55 iH-indol-3-yl) -2-eyano- H etoxxcarbonyl- C23H19N305 2.15 418.10 acryloylamino] -4-phenyl-phenyl-417.42 (LC-1) benzoic Acid { 3- E (E.) -2- (4-chloro-2-methyl-f-nyl-4-chloro-2-C21H16N303C1 231-66-carba-a-oil.} -2-H-ethyl-phenyl 394.09 cyanovinyl] - indol-l- 393,829 • (LC-1) il.}. -acetic Data E j. Name R of MS H 5 Formula [m tRin] Molecular Weight (Met.) Mz [M + Hf Methyl ester of 2-t (E) -3- acid. { l ~ carboxymethyl-lH ™ 67 indole-3-yl} -2-sia- H 2-methoxy- C22H17N305 2.35 426.13 acryloyl ino] carbonyl-f-enyl 403,393 (LC-1) [? Vi + benzoic Naph Acid { 3- [(E) -2- cyano-2-. { 4-trifluoro-4-trifluoro-C 21 H 14 N 304 F 3 237 68 methoxy-phenylenedmomoyl) H-methoxy-f-enyl-vinyl] -indol-1-yl} - 429,353 (LC-1) 430.08 acetic Aoido-3-E (E) -2"-cyano-? 2- < 3,5-dimethy-phenyl JJ 3, 5-dxmethyl-C22H19N303 233 374.15 carbamoyl) -vinyl] -indol-phenyl 373.411 (LC-1 ) 1-il} -aaxco Acid { 3 - [(E.). -2- {3-bromo-4-methyl-e-enyl 3-bromo-4- C21Hl6Ñ303Br 2.41? Carbamoyl) -2-cyano H xaet l-fenxlo 438.28 (LC-1 ) 438.04 -vinyl] -indo-1-yl.} -acetic Acid { 3- £. { E.}. -2-. { 4- bromo-3-methyl-4-enyl 4-bromo-3-C21H165N303Br 2.42 71 carbamoyl) -2-cyano-H ethyl-f nyl 4 «38o.2 n8o (nLC-1) \ 4 U.U2 vinyl] - indol-l ~ il) -acé ico Methyl ester of the acid 4- E (E) -3-. { l- 2 sarboxi ethyl-lH-TT 4-ethoxycarbonyl-C23H19N305 2 7 ^. g, "indol-3 ~ il > -2-cyano-H phenyl 417.42 (LC-1) ida? aeriloi lamino] benzoi co Methyl ester of Acid 4-1. { E > -3- (1- 3-carboxymethyl-lH-H 3-methoxycarbonyl-C22H17M3O0 2.15 404 09 indole -3-yl-2-syn phenylene 403393 (LC-1) U -Uy -asyloylamino] -benzoic Facts Ex. Man Rs Formula [min] Molecular Weight (Me £.) Acid { 3- £. { E) -2-cyano -2-. { 4-trifluoromethyl-4-trifluoro-diethyl-C21H14N3Q3F3 236'4-phenylearbamoyl) -viayl] H-phenol-indol-1-yl} -acetic 413.354 (LC-1) 414.09 Acid { 3- £. { E.}. -2 ~ cia «or 75 -2-. { 3,5-dimethoxy-en-enyl JJ 3,5-d? Methoxy-C22H19N305 2.18 406.13 carbamoyl) -vinyl] -indole phenyl 405.409 (LC-1) -1-il} -acetic Acid { 3-1 CE) -2- (4-bromo-3-chloro-phenyl 4-bromo-3-C20H13N3O3BrCl 2.45 76 carbamoyl) -2-cyano-H chloro-phenyl 459.96 458.698 (LC-1) vinyl] -indol- l- il} -acetic Acid { 3- [ . { E) ~ 2-. { 4-bromo-2-yl-phenyl 4 ~ foromo ~ 2- C21H16N303Br 235 77 carbastoyl) -2-cyano- H 440.02 methyl phenyl 438.28 - (LC-1) vinyi] -indol-1-yl} -acetic Acid { 3-1 CE) -2-. { 4- acetyl-phenylcarbamoyl) C22H17N304 2.06"R. fi 78 -2-cyano-vinyl] -indole H 4-acetyl-phenyl R7 ^ Q4 (C-1") • 3dS-10-l-yl.} -acetic Acid { 3-C. { E.}. -2- (2-bromo-4-methyl-phenyl-2-bro or-4-C21H16N303Br 2.41 ... 7 carbamoyl) -2-cyanovinyl] -indol-l? met l-phen lo 438.28 (LC-1) '? -il} -acetic Acid { 3-[ . { E.}. -2- . { betts: or "" £ [1 x ,, 3 ¿] id aiiooxxool x --So - ixllccaarrbbaa TT benzo [1, 3] dioxol C21H15N305 2.10"? n ry °" m nooiill)) - 22 - cciiaannoo ~ ~ vviinnllll]] -5-xio 389.366 (LC-1) jy ?? " -indol-l-lil} -acetic faith Facts Ex. Man 3 R6 Formula [mifl] of ** S Molecular Weight (Met ..) ~ *, -Í ¿- - J [M + H] " Acid { 3- E. { E) ~ 2-aiano -2- (2,3-dibydro-benzo 2 r 3-dihydro-gj_ [1,4] dxoxin-6-ylcarba C22H17N3Q5 2.08 H benzo El,] dioa? N moil.}. -vinil ] -indol-l- -6- ilo 403393 (LC-1) 404.09 il.} -acetic Acid { 3- [ . { E.}. ~ 2-cyano -2-. { 2-methoxy-f enylcar 2-methoxy-C21H17N304 2.28 82 ba oil} -vinyl] -indole-H phenyl 37631 1- i 1} -acetic 375.383 (LC-1) Acid { 3- [(E) -2-cyano- 2-. { 2-phenoxy-2-enylcar-2-phenoxy-C26H1SN304 2.48 83 bamoyl} -vinil] -indol- H fen lo 438.24 1-il} -acetic 437.454 (LC-1) . { 3- E-CE) -2-cyano-2- C2SH22N303Na 237 «4 (e-phenylbenzyl phenyl phenethyl 450.15 bamoyl) -vxnil] -indole 471.491 (LC-1) -l-il} sodium acetate . { 3-[ . { E) -2-cyano-3-yl, 12-dihydro-6E-dibenzo-l, 2-dihydro-6H-C29H22N303Na 233 85 P > / f 3 azocin-5-yl) -3-oxo-dibenzo [b, f] azocin 4g3 Q2 (LC-1) 462.19-propynyl] -indol-l-yl} -5-yl sodium acetate [3- . { (E) -2-cyano-2-phenyl phenyl C26H18N303Na 2.20 86 di phenylcarbamoyl-vini 1.}. 422.12 -indol-l-yl] -acetate 443,437 (LC-1) sodium [3- . { < £} -2-cyano-3-dibenzs lb, f] azepin-dibenzo [, f 3 azepin C28H18N303Na 2.26 87 5-yl-3-oxo-propenyl) 5-ylo 446.14 467.459 (LC-1) -indol-l-il] Sodium acetate Ex. MS * of MS R formula [niin] Molecular Weight (Mef.) M / z [M + H . { 3-. { CE) -2-E. { 4-chloro-phenyl) -ethoxylcarba-4-chloro-methyl-88-moyl] -2-cya-o-v-yl} -phenyl C21H15 303CINa 2.14 416.06 -indol-l-il) -acetate 415,811 (LC-1) sodium Acid { 3-[. { E) -2-cyano -3-. { 6, 11-dihydro-di 6,11-dihydro-C28H21N303 2.31 89 benzob, e] azepin-5-yl) dbenz [b, e] aepin-448.24 -3-oxo-propenyl] -indole 5-xlo 447.493 (LC -1) -1-il} -acetic E3- acid. { (E) -2-cyano phenethyl phenethyl C30H27N3O3 2.40 90 2-dif enetylcarbamoyl-47831 vinyl) -indol-l-yl] - 477.562 (LC-1) acetic Acid { 3- [CE) -2-cyano-10, 11-dihydro-3-. { 10, 11-dihydro-di-91-benzo [b, 3azepin-S-il} dibenzo [, f] azepn C28H21N303 2.27 44830 -3-oxo-propenyl] -indol -5-yl 447; 493 (LC-1) -1-i} -acetic Acid { 3-. { CE) -2-cyano- 2- [methyl-. { (R) -l- £ enylmethyl < R) -1-phenyl C23H21N303 2.23 92 388.23 ethyl) -carbaaoyl] -vinyl} -ethyl 387,438 (LC-1) -indol-l-il) -acetic Acid { 3- £. { E) -2- < beacon i -methyl-aarbamoyl) -2- methyl benzyl C22H19N303 2.13 374.21 cyanovinyl] -indol-1-yl} 373,411 (LC-1) -acetic Acid C3-Í CE3 -2-E C4- acetyl-phenyl} methyl-methyl 4-aaethyl-C23H19N3C4 2.00 94 carbamoyl] -2-cyano-402.18 f enyl vinyl} -indol-l-il) 401.421 (LC-1) -acetic Data fe - Man R5 Ré Formula [min] of MS- Molecular Weight (Met). / z [M + H Acid (3- { CE) -2-E (4- acetyl-phenyl) -furan) 5 -2-ylmethyl-carbaaoyl] furan-2- 4-aaethyl- C27H21N305 2.15 -2- cyano-vinyl} -indol-ilme ilo f enyl 467.48 (LC-1) 468.07 l-il} -acetic Acid { 3- £. { E.}. -2- (bensylcarboxymethyl 1-96 carfoamoyl) -2-cyano benoyl carboxyC23H19N305 2.01 416.19 -vinyl] -indol-l-il} - methyl 417.42 (LC-1) IM-HG acetic Acid 3-. { bencil- £. { E) -3-. { 1-sarboxymethyl-JQ? LH-indol-3-yl) -2- benzyl sarboxiethyl C24H21N305 1.97 sianediarylaryl} 432.18 431.447 (LC-1) -amino) -propionic Acid { 3-E (E) -2 ~ cyano-3- (, 3-dihydro-indol-l-yl) -3-oxo-β-pentyl] -2,3-dihydro-iftdol-l-yl C22H17N303 2.2 372.19 371395 ( LC-1) indol-l-il} -acetic Acid. { 3- £ CE) -2-. { carboxy nn methyl £ enyl carbamoyl} -2- phenyl carboxy C22H17N305 1.86 402.11"" cyanovinyl] -indol-1-yl} - -methyl 403393 (LC-1) [-HG acetic Acid { 3- . { CS) -2-cyano-2-100 £ (2-cyano-ethyl) -phenyl-phenyl 2-cyano C23H18N403 2.01 399.18 carbamoyl] -vinyl} -indole-ethyl 398,421 (LC-1) -1-yl) -acetic acid 20 (3-i CE) -2- £. { 3-chloro-phenyl) -methyl-sarbamoyl] methyl 3-chloro-C21H16N303C1 2.14 101 -2-cyanovinyl} -indol-l- phenyl 394.15 393,829 (LC-1) il) -acetic Data 6 faith Ex. Man R5 R Formula [min] of MS Molecular Weight (Meí.) M / z 1M + Hf Acid { 3 ~ [(E. ~. ~ 2 ~ Calyl-phenyl-sar 102 bamoyl.} -2-phenylaryl-allyl C23H19N303 2.18 vinyl] -indol-l- 385.422 (LC-1) 386.19 il.}. -acetic Acid { 3- £. { E) -2- cyano-2-. { cyclohexyl-103-phenyl-carbamoyl) - phenyl cyclohexyl C26H25N303 2.43 vinyl] -indol-l -i} - 427.503 (LC-1) 428.23 acetic 104 Acid. { 3- (E.sub.2) -2- cyano-2- { Methyl-o .. -toli-sarbaaoyl) -vinyl] -indol-l methyl o-tolyl C22H19N303 2.09 il} -acetic 373.411 - (LC-1) 374.21 Acid { 3-[ . { E.}. -2- ^ ,,,, cyano-2-. { ethyl-phenyl phenyl-ethyl C22H19N303 2.13 1U3 -carbamoyl) -vinyl] - 374.21 373.411 (LC-1) indole-1-yl} -acetic Acid { 3- [CE) -2- phenyl butyl C24H23N303 2.34 1U0 (butyl-phenyl-carbamoyl.) 402.24 -2-cyano-vinyl] -indole 401.465 (LC-1) -1-yl.}. -acetic Table 2: Examples 107-109 with the general structure of Formula, where R1 = R3 = R4 = H.

MS data Ex. Name R2 R5 Rd Formula faith. [™ i? -l Molecular Weight (Mét ° d?) P I + H Acid [5-bromo-3-1 i 1 ((E> -2-cyano-2-, C20H 1"'phenylcarbazoyl-bromo TH * phex-i, or 42144N2533O3Br 2C.25?) 44 + 8m.04 + vinyl) -indol-l- il] -acetic Acid 13- CE) -2- -a 108 cyano-2-phenylcar J bamoyl-vinyl) -5- fluoro T H * f ^ x • i-, or C203H6134MN37O3F ^ 2C.13 ?} _ 36.4, .2_.1 fluoro-indole-1-yl] -acetic Acid E3-C (E) -2-IßQ aiano-2- £ enylate C21H17N303 2.18 methyl H phenyl 360.20 bamoyl-vinyl) -5- 359384 (LC-2) ethyl-indol-l-yl] -acetic Table.3: Examples 110-111 with the general structure of Formula, where? = 13? = £? = H. Data Ex. Man * 3 1 Rf > S3 Acid [3- c. { E.}. -2- .- r nw? W? N-n? or 110 cyano-2-phenylcarbamoxl fluoro H fe ilo ^ ^^^ T ^ ^ 364.14 -vinil) -6- luoro-indole 363.347 (LC-2) -1-il3 -acetic Acid £ 3-. { . { E.}. -2-cyano-2-phenylcarbamoyl-. C20H14N4O5 Y > W vinyl) - € -nitro-indole £ > & H phenyl ~ "^^" '391.22 -1-il] -acetic -5 0.O54 (LC-2) Wise 4: Example 112 with the general structure of Formula, where 8, = R, R - = H. Data r. , from MS S j, Compound R4 R3 R «Formula M«? Molecular WeightÍMet? < Í? 3. { M + Hf Acid-. £ 3- CÍE) -2- cyano'-2-phenylcar "? C21H17N3O3 2.16. ?? n 112 bamoyl-vinyl) -7- methyl-phenyl "? Qcso? FtVT \ J? -?" Methyl-inido-1-yl] -acetic Table 5: Examples 113-132 with the general structure of Formula, where R1 = R = R3 = * = H. MS data Bj. Man R *: R «Formula & i ml n? / z Molecular Weight I ^ Iet. ) p i + H Acid C3- [. { E) -3- • f-j? T. { 2-alsro-phenothiazine 2-aloro-phenothiazine C26H16N303C1S 1.17 508.04 -10-il) ~ 2-eiano-3 ~ -10-yl 485.95 (LC-4) [M + Na] 4 oxo-propeni 1] -indole -1-il} -acetic Acid f3 - [(E.) -2- cyano-2-. {Phenyl-114 phenyl thiophen- C25H19N303S 1,10 thiophen-3-methylmethyl-3-ylmethyl 442.81 441.51 (LC-4) carbamoyl) - vincil] -indol-l-il} -acetic Acid (3 ~ £ (E) -2- cyano-2- [< 2,2-eesyl { 2,2-diphenyl-C34H27N303 1.18 15-diphenyl-ethyl) -phenyl-ethyl 525,606 526.06 (LC- 4) -carbaraoil] - vinyl} -indol-l-il) -acetic Data Ex. Man R3 w Molecular MS Formula Molecular Formula (Met.}. Tn / z | M + H] * Acid { 3-. { . { E) -2- aiano-2- [γ-enyl-3-phenyl-phenyl C29H25N303 1.14 116. { 3-phenyl-? Ro? Il) -propyl 464.07 carbamoyl] -vinyl} 463.536 (LC-4) -indol-1-iX) - acetic Acid [3- ( { E.}. -2- cyano-2- { F-2- (4- 4- fl-uoro- feni 1 - 117 f luoro-f epil) -atyl] fepyl ethyl C28H22N303F 1.13 468.98 - £ enil-aarbamoil} 467,499 (LC-4) -vinyl} -indol-l-il] - acetic acid. { 3-[. { E.}. -2- siane-3- (HH-lO-oxa-5-aza-8 dibenzo [a,) HH ~? Oo a ~ 5-assa- C27H19N304 1.10 118 cyclohepten-5-yl) -3-dibenzo [a, d] ecyclohepten- 449 ^ 55 (LC-4) 450.98 oxo-propenyl] -indol-5-yl-l-yl} -acetic Acid { 3 ~ £. { E.}. -2- cyano-2- (isopropy-110 phenyl-carbamoyl) -isopropyl phenyl C23H21N303 1.10 38786 vinyl] -indol-1-yl} - 387,438 (LC-3) acetic C3-eCE acid) -2- cyano-2- [. { 3,4-dichloro 3,4-dxchloro-C21H15N303CI2 1.11 427.86 120-phenyl) -methylcarba methyl phenyl moyl] -vinyl} -indol- 428274 (LC-3). { M-Hf 1-i) -acetic Acid { 3-. { . { E.}. -2- cyano-2- [ethyl- (4- ethyl 4-trifluo or C23H18N304F3 1,16 121 458.94 trifluoroethoxy-methoxy-457.407 (LC-3) phenyl) -abamoyl] f enyl-vinyl} -indol-í-il) - acetic Acid { 3- £ CE} -2- C27H211NT303 1.16 Vj. { benzhydril-carba H benzhydril 435.96 moil} -2-cyanovinyl] 435,482 (LC-3) indole-1-il} -acetic Example ombre s R6 Formula Molecular Weight Acid. { 3-. { EC} -2- siane-2- [ethylmethyl 2 -s-- C22H16N304F3 123. { 2-trifluoromethaxy 1.10-phenyl) -carbamoyl] trxfluoromethoxy- A ^ ^ Q 443.85 -vinyl} -indsl-1-il) phenyl - ^ (LC-3 > -acetic Acid { 3-E E.}. -2- cyano-2- (2,4-difluoro-2, -dif luoro- C 20 H 13 N 3 O 3 F 2 1.07 124 -phenylcarbamoyl) -vinyl] H 382.94 -indol-l-il} -acetic phenyl 381337 (LC-3 ^ Acid { 3-. { ÍE) -2- cyano-2-Emethyl-. { 4- trifluoromethoxymethyl 4- C22H16N304F3 1.11 123 phenyl) -carbamoyl] tri f lucróm oxy 444.96 (LC-33-vinyl.). -indol-l-yl) -phenyl-acetic Acid C3- E CE) -2-cyano naphthalene -2- (ethyl-naph alen-1-yl ethyl C26H21N303 1.14 12o -oarbamoyl.}. -vinyl] -l-yl 423.84 423.471 (LC-3) -indol-l -il) -acetic Acid (3- £ (E) -2-Sial 2, 4 -2- [(2,4-difluoro-methyl difluoro- G21H15 303F2 1.05 127 phenyl) -methyl-carbamoyl] phenyl 396.92 395.364 (LC-3) -vinil} -indol-l-il} -acetic Acid { 3-ECE) -2-eiano 2,4,6-128 -2-. { 2,4,6-tri-oluoro-H C20H12N3O3F3 1.03 fcrifluoro-400.9 ^ phenylcarbamoyl) -vinyl] 399327 (LC-3) phenyl-indol-1-yl} -acetic Acid { 3- £. { E) -2-cyano 2, 3,4- C20H12N3O3F3 IO 129 -2-. { 2,3-trifluoro-H trifluoro-399.76 phenylcarbaoyl) -vinyl] phen lo 399327 (LC-3) -indol-l-il} -acetic Data. [mine] S. ombre R3 Rd MS Formula Molecular Weight. { Met. ) m / z [M + Hf Acid { 3- £ CE) -2- cyano-3-. { 3, -dihydro 3, -dihydro-l- - C23H19N303- 1.07 130 '-lH-isoq? Ainoli? T-2-yl) isoquinolin-2-yl 386.96 -3-oxo-propenyl] -indole 385.422 (T C -3) • -l-il} -acetic Acid { 3- [CE) -2-eiano -3-0x0-3-. { 7-trifluoride 7-trifluorooxy-CZ4H18N303F3 1.13 131 methyl 1-3, 4-dihydro-2H-454.92 3,4-dxhydro-2H-quinolin ~ 453,419 (JLC-3) quinolin-1-xl) -propenyl] -indo -l-il} l-ilo-acetic Acid { 3-. { (E.} -2-cyano 132 ~ 2 ~ I (3-noro-phenyl) -3-fl-o-C21H16N303F 1.03 methyl 377.89 methyl-carbamoyl] -vinyl) phenyl 377374 CLC-3) -indole-1-il -acetic Table 6: Examples 133-147 with the general structure of Formula, where R sr = K "= H. Data iR [m J of MS E «Compound R ~ * R6 Formula (Method) n / z Molecular Weight 1M + H14 Acid E3-. { EC} -2- cyano-3-dibenzo [b, f] aze? In-5-yl dibenzo [b, e] C28H18N303F LOO 133 -3 ~ oxo-propenyl) -fluoro azepxa- 464.29 5-fluoro-indol-l-5 -yl 463,467 (LC-5) il] -acetic Acid { 3- [(E.} -2- siane-3-C6, ll-dihydro-dibenzo 6, 11-dihydro-C28H20N3O3F 1.02 134 tb, e] azepin-S-il.}. Fluoro dxbenzo [b, e] 466.3 azepin-5-yl 465,483 (LC-5) -3 -oxo-propenyl] -5-f luoro-indole-1-yl.} -acetic Acid { 3- £ (E.}. -2- { Benzyl-enyl-C27H20N3O3F 1.00 135 carbamoyl) -2-cyano-fluoro-benzyl-phenyl454.28 453.472 (LC-5) -vinyl] -S- £ luoro- indole- 1-il} -acetic Data Ex. Compound R¿ R3 6 Formula Molecular Weight Acid. { 3- [ . { E) -2- siano-2-. { síalotexil? ^ -phenylcarbamoyl} - ^ Í "?« - Cishexyl phenyl C26H24N303F 1.03 136 vinyl] -5-f luoro- ñmX0 445.493 (LC-5) 44631 indol-1-í1} -acetic Acid { 3-E CE} -2- . { butyl-phenyl-carba moil} -2-cyano-vinyl] 137 -5-fl? Oro-indol-l-fluoofO butyl phenyl C24H22N303F 1.01 420.29l) -acetic 419.455 (LC-5) Acid { 3 ~ £ CE) -2 ~ cyano-2- t. { -fluoro 138 7f nyl- "? ethyl-car flioro methyl 4-fluoro C21H15N303F2 1.04 396.02 bamoil] -vinyl} -5- phenyl 395.364 (LC-3) fluoro-indol-1-yl) -acetic Acid { 3-. { . { E.}. -2- cyano-2- E. { 3- luoro- or C21H15N3Q3F2 1.04 139 -phenyl} methyl-trifluoromethyl 3-fluoro-phenyl 396.02 sarbamoyl] -vinyl} 395364 (LC-3) ~ 5-f luoro-indol-1-yl) -acetic Acid (3- { (E.}. -2 C21H14 303C1 1.15 áfy siano-2 ~ [3,4- fioro methyl 3,4- 447.86 dichloro-phenyl) dichloro- 2F 446,264 (LC-3) -methyl- carbamoyl] phenyl -vini1.}. -5-fluoro-indol-1-11) -acetic acid. { 3-. { EC} -2- cyano-2-Cmethyl-. { 2 C22H15 303F4 0.97 141 -trifluoromethyl-fluoro methyl trifluoro 446.2 phenyl) -carbamoyl J me il- 445.371 (LC-5) -vinyl} -5-fluoro-phenyl indol-1-yl) -acetic Data S. Compound R Rs R6 Formula? T finln] of Ms Molecular Weight (Method) ni / z [M + Bf C3- acid. { (E.} -2- aiano-2- £ { 2,4- 2,4-1 2 difluoro-phenyl) fluoro methyl d fluoro- C21H14N303F3 0.95 -methyl-carbamoyl] phenyl 413354 - (LC-5) 414.2 -vinyl} -5 ~ f luoro -indol-l-il) -acetic Acid { 3- [ . { E) -2- sians-2- Cphenylthiophene-143 thiophen-3-ylmethyl phenylthio 3- C25H18N303FS 1.15 460.05 -carbamoyl) -vinyl] ilmethyl 459.5 (LC-3) -5-f luoro-indole-1-yl } -acetic Acid { 3- £ CE) -2- cyano-3-oxo-S-. { 7 - 7 - trifluoroate-1-trifluoromethyl-3-trifluoromethyl-3-trifluoromethyl-2H-C24H17M303F4 1.15 phylin-1-yl) -quinolin-1-yl 471.409 (LC-3) 472.99 propenyl] -5-f luoro -indol-1-il} -acetic ACTION. { 3-. { . { E.}. -2- cyano-2-ethyl- (4-trifluoromethoxy-fnyl) -IS -carbamoyl] -vinyl} trifluoro C23E17N3Q4F4 1.20! - '* - > 5-Fluoro-indole-1-phthaoryl ethyl at Aeettoc, xxx-475.97 475397 (LC-3) il) -acetic acid Acid { 3- (E) -2- cyano-3- (3,4- dihydro-lH-isoquinolin-2-yl.) -3- 3,4-dibid o-lH-C23H18N303F 1.09 146 oxo- prope «il] -5 fluoro 403.98 isoqai? olin-2-yl 403,412 (LC-3) -fluoro-indole-1-yl.} -acetic Acid £ 3- £ CS) -2- cyano-2-phenethyl C28H22N303F 1.22 47 -phenyl-earba oil) phenyl phenyl-phenethyl 468.08 -vinyl] -S-fluoro-467.499 (LC-3) indole-1-yl} -acetic Table 7: Examples 148-154 with the general structure of Formula, where R = R = R * = H, 10 Data Ex. Compound R R3 * Formula * R ^ mhx of MS Molecular Weight < M < = all) m / z pM + Hf [3-cyano] -2- cyano-3-dibenzo [,] azepin-5-yl dibenzo [b, e] azepine C29H21N303 1.01 148 -3-oxo-propenyl) methyl-5-yl-6-methyl-indole -l "459.504 (LC-5) 460.31 -il] acetic 15 Acid £ 3- £. {E) -2- cy no-3- 6, 11- 149 dihydro-dibensso 6,11-dihydrs- C29H23N303 1.03 £ b, e] azepin-5-yl) methyl dibenzs [b, e] azepin- 461.52 (LC-5) 46232 -3-o? O-propenyl] • S -yl-6-methyl-indol-1-y1} -acetic Acid { 3- [(E) -2- cyano-3-. { 10, 11 - 0.11-dihydro- 0 1S0 dihydro-dibenzo methyl C29H23N303 1.02 dibenzo [b, f] azepin-? £ b, f] azepin-5-yl) 5-yl 461.52 (LC-5) 462.32 -3-oxo-propenyl] -6-methyl-indol-1-yl} -acetic Data Ex. Compound R3 W Rd Formula & JE? H?] Of MS Molecular Weight ^ o or > m / z JM + HT Acid { 3- £ < E.}. -2- . { benzyl-phenyl-151 carbaaoyl) -2- cyanovinyl] -d-methyl phenyl benzyl C28H23N303 1.02 meti-indol-1- 449.509 (LC-5) 45031 il} -acetic Acid (3 ~ £ { E.}. -2 ~ cyano-2- { Cyclohexyl 152 -f '? R? I3.- <: ar3: &g., Oil.}. Methyl phenyl cyclohexyl C27H27N303 1.05 -vinyl] -6-methyl-441,529 (LC-5) 44232 indole-1-yl.}. -acetic Acid (3- {, { E.}. -2- cyano-2- (4-fluoro-153-phenyl) -methyl-msfc-1-methyl-4-fluoro-C22H18N303F 0.95 392.26 sarbamoyl] -vinyl. phenyl 391,401 (LC-5) -d-methyl-indol-1-yl) -acetic Acid { 3- [CE) -2- Cbutxl-phenyl-C 25 H 25 N 303 1.02 154 carbamoyl) -2- methyl butyl phenyl cyanovinyl] -6- 415,492 (LC-5) methyl-indol-1-yl} -acétxao Table 8: Examples 155-156 with the general estrustura of Formula, where R = R2 = HT H, Data s "-, faith ft ?? ln1 of MS E j. Compound R4 R3 R6 Formula R l J. Molecular Weight i ^ to o)? N / JM + H] * Acid { 3- E CE) -2- cyano-2- < ciciohexii C27H27N303 1.04 Aár. v -fss -fenxl-carbamoxl} - methyl phenyl cyclohexyl, ,, mn? -?.? - iSD vinyl] -7-methyl- 441,529 (LC-5) indole-1-yl} -acetic C3-CE acid) -2- 4-f luoro C22H18N303F 0.98 A 156 cyano-2- E C4- "wtüß methyl- £ &391401 (LC-5)" ^ £ luoro-phenyl) -methylcarbamoyl .}. -vinyl.} - 7-methyl-indol-1-yl) -acetic Biological assays: Example B-1: Preparation of the CRTH2 membranes and radioligand binding assay: The preparation of the membranes and the radioligand binding assays are carried out according to known procedures, for example, Sawyer N. et al. (Br. J. Pharmacol, 2002, 137, 1163-1172). A HEK 293 clonal cell line, which expresses a high level of the recombinant hCRTH2 receptor, is selected for the preparation of membranes.

The cells are detached from the culture plates in 5 ml of buffer A per plate (5 mM Tris, 1 mM MgCl 2 x 6 H20, 0.1 mM PMSF, 0.1 mM phenanthroline) using a gendarme rubber and transferred to the tubes centrifugation and frozen at -80 ° C. After thawing, the cells are centrifuged at 500 g for 5 minutes, and then resuspended in buffer A. The cells are then fragmented by homogenization with a homogenizer Politrón for ... 30_ seconds. The membrane fragments are centrifuged at 3000 g for 40 minutes and resuspended in: the membranes in buffer B (50 mM Tris, 25 mM MgCl2, 250 mM sucrose, pH 7.4) and the aliquots are stored frozen. The binding assay is performed in a total volume of 250 μl In each well, 75 μl of C buffer is mixed (50 M Tris, 100 mM NaCl, 1 mM EDTA, 0.1% BSA (protease-free), NaN3 of 0.01%, pH 7.4) with 50 μl of. {3 H.} -PGD2 (at 2.5 nM (220,000 dpm per well) of Amersham, TRK734), 100 μl of CRTH2 membrane to give 80 μg per well and 25 μl of the test well in buffer C containing 1% DSMO For the non-specific binding, PGD2 is added to the reaction mixture to a final concentration of 1 μM.

This binding assay mixture is incubated at room temperature for 90 minutes and then filtered through a GF / C filter plate. The filter is washed three times with ice-cooled binding buffer. Then, 40 μl is added per well of Microscint-40 (Packard) and the bound radioactivity is quantified by means of Topsount (Packard).

Example B-2: Intracellular Calcium Mobilization Assay (FLIPR) Cells (HEK-293) stably expressing the hCRTH receptor under the control of the cytomegalovirus promoter from a single insertion of the expression vector pcDNA5 (Invitrogen) are developed to confluence in DMEM (low glucose, Gibco) supplemented with 10% fetal calf serum (both from Bioconcept, Switzerland) under standard mammalian cell culture conditions (37 ° C in a humidified atmosphere with 5% C02). The cells are detached from the culture boxes using a dissociation buffer (0.02% EDTA in PBS, Gibco) for 1 minute, and harvested by centrifugation at 200g at room temperature for 5 minutes in assay buffer (equal parts of BSS Hank (HBSS, Bioconcept) and DMEM (low glucose, no phenol red, Gibco) After incubation for 45 minutes (37 ° C and 5% C02) in the presence of 1 μM of Fluo- 4 and 0.04% Pluronic F-127 (both from Molecular Probes), 20 mM HEPES (Gibco) in assay buffer, the cells are washed with and resuspended in assay buffer, then plated on FLIPR assay plates of 384 wells (Greiner) at 50,000 cells in 66 μl per well), and sedimented by centrifugation. The reserve solutions of the test compounds are constituted up to a concentration of 10 mM in ".DMSO, and diluted1 in series in assay buffer to the concentrations required for inhibition dose-response curves.Prostaglandin D2 (Biomol, Plymouth Meeting, PA) is used as an agonist.A FLIPR384 instrument (Molecular Devices) open according to the manufacturer's standard instructions, adding 4 μl of the dissolved test compound to 10 mM in DMSO, and dilute it before the experiment in the test buffer to obtain the desired final concentration.Add 10 μl of prostaglandin D2 80 nM (Biomol, Plyraouth Meeting, PA) in assay buffer, supplemented with 0.8% bovine serum albumin (fatty acid content <0.02%, Sigma), is then added to obtain a final concentration of 10 nM and 0.1 %, respectively, changes in fluorescence are monitored before and after the addition of the test compounds? ex = 488 nm and? em - 540 nm. Peak emission values above the base level l After the addition of prostaglandin D2, they are reported after the baseline subtraction. The values are normalized to a high level control (the non-added test compound) after the subtraction of the baseline value (without prostaglandin D2 added). Prostaglandin XLlfit 3.0 (IDBS) is used to fit the data to a single-site dose-response curve of the equation (A + ((BA) / (1+ ((C / x)? D)))) and to calculate the IC50 values.

Biological results: The following results have been obtained using the procedures given above (biological tests Bl and B2) for the exemplary compounds mentioned above: It is noted that in relation to this date, the best method known to the applicant to carry out the aforementioned invention is that which is clear from the present description of the invention.

Claims (16)

CLAIMS Having described the invention as above, the content of the following claims is claimed as property:

1. As a medicament, a compound selected from the group consisting of a compound of the general formula

I - ' characterized in that A represents hydrogen; I rent; halogen or cyano; B represents hydrogen, alkyl or halogen; R1, R2, R3 and R4 independently represent hydrogen, alkyl; halogen; nitro; cyano or formyl; R5 and R6 independently represent hydrogen; I rent; cycloalkyl; cycloalkyl-alkyl; heteroaryl; heteroaryl-alkyl; alkenyl; carboxyalkyl; cyanoalkyl; diphenylalkyl; arylaryl-alkoxy-aryl, aryl-alkyl, arylaryl-aryl, arylcarbonyl-aryl or aryloxy-aryl, or R5 and Rd, together with the nitrogen atom to which they are attached, form a heterocyclic ring system; and an optically pure enantiomer, a mixture of enantiomers, a racemate, an optically pure diastereomer and a mixture of diastereoisomers, a diastereomeric racemate, a mixture of diastereomeric racemates, a meso form, a geometric isomer, a prodrug form, a solvate or a morphological form, or a pharmaceutically acceptable salt or a compound of the general formula I. 2. As a medicament, a compound according to claim 1, characterized in that A is cyano; OR B is hydrogen or methyl; < C > R1, R2, R3 and R4 are all hydrogen atoms, or one of R1, R2, R3 and R4 is halogen, while the others are all hydrogen; at least one of R5 and R5 is selected from the group consisting of heteroaryl, heteroaryl-alkyl, diphenylalkyl, aryl, arylalkoxy-aryl, arylalkyl, aryl-alkyl-aryl, arylcarbonyl-aryl and aryloxy-aryl; or R5 and R6, together with the nitrogen atom to which they are linked, form a heterocyclic ring system.

3. As a medicament, a compound according to claim 1, characterized in that it is selected from the following compounds: [3- ((E) -2-cyano-2-phenylcarbamoyl-vinyl) -indol-1-yl] -acetic acid; [3- ((E) -2-cyano-2-m-tolylcarbamoyl-vinyl) -indol-1-yl] -acetic acid; Acid { 3- [(E) -2-cyano-2- (4-methoxy-phenylcarbamoyl) -vinyl] -indol-l-yl} -acetic; Acid { 3- [(E) -2- (3-bromo-phenylcarbamoyl) -2-cyanovinyl] -indol-1-yl ".} -acetic acid: {.3- [(E) -2-cyano] -2- (cyclohexylmethyl-carbamoyl) -vinyl] -indol-1-yl} -acetic acid [3- ((E) -2-cyano-2-phenethylcarbamoyl-vinyl) -indol-l-yl] - acetic acid [3- ((E) -2-cyano-2-isopropylcarbamoyl-vinyl) -indol-l-yl] -acetic acid [3- ((E) -2-cyano-2-propylcarbamoyl-vinyl]] -indol-l-yl] -acetic acid [3- ((E) -2-cyano-2-cyclohexylcarbamoyl-vinyl) -indol-l-yl] -acetic acid; {.3- [(E) - 2-cyano-2- (3-methyl-butylcarbamoyl) -vinyl] -indol-1-yl.} -acetic acid [3- ((E) -2-benzylcarbamoyl-2-cyanovinyl) -indol- l-il] -acetic; Acid { 3- [(E) -2- (benzyl-phenyl-carbamoyl) -2-cyanovinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (4-aiane-phenylcarbamoyl) -vinyl] -indol-1-yl} -acetic; [3- ((E) -2-cyano-2-o-tolylcarbamoyl-vinyl) -indol-1-yl] -acetic acid; Acid { 3- [(E) -2-cyano-2- (4-ethyl-phenylcarbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (4-fluoro-phenylcarbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (4-phenoxy-phenylcarbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (naphthalen-2-carbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (2-isopropyl-phenylcarbamoyl) -vinyl] -indol-1-yl} -acetic; [3- ((E) -2-cyano-2-p-tolylcarbamoyl-vinyl) -indol-1-yl] -acetic acid; Acid { 3- [(E) -2-cyano-2- (4-isopropyl-phenylcarbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (3-methoxy-phenylcarbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (3-fluoro-phenylcarbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (9H-fluoren-2-ylcarbamoyl) -vinyl] -indol-l-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (4-propyl-phenylcarbamoyl) -vinyl] -indol-l-yl} -acetic; Acid { 3- [(E) -2- (biphenyl-4-ylcarbamoyl) -2-cyano-vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (3,2'-dimethyl-biphenyl-4-ylcarbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2- (4-tert-Butyl-phenylcarbamoyl) -2-cyanovinyl] -indol-1-yl} -acetic; Acid (3- [(E) -2- (2-benzyl-phenylcarbamoyl) -2-cyano-vinyl] -indol-1-yl.} -acetic acid; Acid {3- [(E) -2- (4-Butyl-phenylcarbamoyl) -2-cyanovinyl] -indol-1-yl.} -acetic acid; {.3 - "[(E) -2- (2-acetyl-phenylcarbamoyl) -2- cyanovinyl] -indol-l-yl} -acetic acid: {.3- [(E) -2-cyano-2- (indan-5-ylcarbamoyl) -vinyl] -indol-l-yl} -acetic; Acid { 3- [(E) -2- (4-sec-butyl-phenylcarbamoyl) -2-cyano-vinyl] -indol-l-yl}. -acetic; (3- [ (E) -2-cyano-2- (4-ethoxy-phenylcarbamoyl) -vinyl] -indol-1-yl} -acetic acid: {.3- [(E) -2-cyano-2- ( 3-ethoxy-phenylcarbamoyl) -vinyl] -indol-1-yl.} -acetic acid; {.3.3- (E) -2-cyano-2- (2-propyl-phenylcarbamoyl) -vinyl] -indole -l-il.}. -acetic; Acid { 3- [(E) -2-cyano-2- (3-phenoxy-phenylcarbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (3-ethyl-phenylcarbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (2-ethoxy-phenylcarbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2- (3-benzyloxy-phenylcarbamoyl) -2-cyanovinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2- (4-bromo-phenylcarbamoyl) -2-cyanovinyl] -indol-l-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (4-iodo-phenylcarbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (3-iodo-phenylcarbamoyl) -vinyl] -indol "-l-yl.} -acetic; (3 { (E) -2-cyano- 2- [(4-fluoro-phenyl) -methyl-carbamoyl] -vinyl.}. -indol-1-yl) -acetic acid: (3- ({(E) -2-cyano-2- [(4)} -methoxy-phenyl) -methyl-carbamoyl] -vinyl.}. -indol-1-yl) -acetic acid; {.3- [(E) -2-cyano-2- (methyl-phenyl-carbamoyl) - vinyl] -indol-l-yl.} -acetic acid; {.3- [(E) -2-cyano-3- (3,4-dihydro-2H-quinolin-l-yl) -3-oxo -propenyl] -indol-l-yl.} -acetic acid: {. 3- [(E) -2-cyano-2- (methyl-p-tolyl-carbamoyl) -vinyl] -indol-l-il <RTI ID = 0.0>. </ RTI> acetic; (3- {(E) -2-cyano-2- [2- (2,4-dichloro-phenoxy) -phenylcarbamoyl] -vinyl} -indol-l-yl) - acetic acid, {.3- [(E) -2-cyano-2- (2,5-dimethyl-phenylcarbamoyl) -vinyl] -indol-1-yl} -acetic acid; (E) -2-cyano-2- (9-ethyl-9H-carbazol-3-ylcarbamoyl) -vinyl] -indol-1-yl} -acetic acid; - (3,5-bis-trifluoromethyl-phenylcarbamoyl) -2- cyanovinyl] -indol-li l.}. -acetic, - Acid. { 3- [(E) -2-cyano-2- (5-methoxy-2-methyl-phenylcarbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2- (4-tert-butyl-phenylcarbamoyl) -2-cyano-vinyl] -indol-1-yl} -acetic; - Acid { 3- [(E) -2- (2-benzyl-phenylcarbamoyl) -2-cyanovinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2- (4-Butyl-phenylcarbamoyl) -2-cyanovinyl] -indol-1-yl} -acetic; Acid { 3- t (E) -2- (2-acetyl-phenylcarbamoyl) -2-cyanovinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (indan-5-ylcarbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2- (4-sec-butyl-phenylcarbamoyl) -2-cyanovinyl] -indol-1-yl} -acetic; Acid (3- [(E) -2-cyano-2- (4-ethoxy-phenylcarbamoyl) -vinyl] -indol-1-yl.} -acetic acid; {.3- [(E) -2- cyano-2- (3-ethoxy-phenylcarbamoyl) -vinyl] -indol-1-yl} -acetic acid; Acid { 3- [(E) -2-cyano-2- (2-propyl-phenylcarbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (3-phenoxy-phenylcarbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (3-ethyl-phenylcarbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (2-ethoxy-phenylcarbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2- (3-benzyloxy-phenylcarbamoyl) -2-cyanovinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2- (4-bromo-phenylcarbamoyl) -2-cyanovinyl] -indpl-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (4-iodo-phenylcarbamoyl) -vinyl] -indol-l-il} -acetic; Acid { 3- [(E) -2-cyano-2- (3-iodo-phenylcarbamoyl) -vinyl] -indol-1-yl} -acetic; (3- {(E) -2-cyano-2- [(4-fluoro-phenyl) -methyl-carbamoyl] -vinyl} -indol-1-yl) -acetic acid; (3- ({(E) -2-cyano-2- [(4-methoxy-phenyl) -methyl-carbamoyl] -vinyl} -indol-1-yl) -acetic acid; - Acid { 3- [(E) -2-cyano-2- (methyl-phenyl-carbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-3- (3,4-dihydro-2H-quinolin-1-yl) -3-oxo-propenyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (methyl-p-tolyl-carbamoyl) -vinyl] -indol-1-yl} -acetic; (3- ({(E) -2-cyano-2- [2- (2,4-dichloro-phenoxy) -phenylcarbamoyl] -vinyl} -indol-1-yl) -acetic acid; Acid { 3- [(E) -2-cyano-2- (2,5-dimethyl-phenylcarbamoyl) -vinyl] indole-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (9-ethyl- "9H-carbazol-3-ylcarbamoyl) -vinyl] -indol-1-yl} -acetic acid; -3- [(E) -2- (3, 5-bis-trifluoromethyl-phenylcarbamoyl) -2- cyanovinyl] -indol-1-yl} -acetic acid; Acid. {3- [(E)] -2-cyano-2- (5-methoxy-2-methyl-phenylcarbamoyl) -vinyl] -indol-1-yl} -acetic acid (3- [(E) -2- (3-benzoyl-phenylcarbamoyl) ) -2-cyano-vinyl] -indol-1-yl.} -acetic acid ("3- [(E) -2- (4-benzyloxy-phenylcarbamoyl) -2-cyanovinyl] indole-1- il.) -acetic, - Acid { 3- [(E) -2-cyano-2- (3-nitro-phenylcarbamoyl) -vinyl] -indol-l-yl}. -acetic; Acid { 3- [(E) -2-cyano-2- (9-oxo-9H-fluoren-2-ylcarbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (4-methoxy-biphenyl-3-ylcarbamoyl) -vinyl] -indol-l-yl} -acetic; Acid { 3 - [(E) -2-cyano-2- (2-methoxy-dibenzofuran-3-ylcarbamoyl) -vinyl] -indol-l-yl} -acetic; Acid (3- [(E) -2-cyano-2- (9-oxo-9H-fluoren-4-ylcarbamoyl) -vinyl] -indol-1-yl} -acetic acid; Acid { 3- [(E) -2-cyano-2- (9-oxo-9H-fluoren-1-ylcarbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2- (2-benzoyl-phenylcarbamoyl) -2-cyanovinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2- (3-chloro-4-methoxy-phenylcarbamoyl) -2-cyanovinyl] -indol-1-yl} -acetic; Acid { 3 - [(E) -2- (5-chloro-2-methoxy-phenylcarbamoyl) -2-cyanovinyl] -indol-1-yl} -acetic; 3- [(E) -3- (1-Carboxymethyl-IR-indol-3-yl) -2-cyano-acryloylamino] -4-methyl-benzoic acid methyl ester; Acid (3- [(E) -2- (4-chloro-2-methyl-phenylcarbamoyl) -2-cyanovinyl] -indol-1-yl}. -acetic acid 2- ([E] methyl ester ) -3- (l-carboxymethyl-lH-indol-3-yl) -2-cyano-acryloylamino] -benzoic acid; {.3- [(E) -2-cyano-2- (4-trifluoromethoxy-phenylcarbamoyl) ) -vinyl] -indol-l-yl.} -acetic acid: {.3- [(E) -2-cyano-2- (3, 5-dimethyl-phenylcarbamoyl) -vinyl] -indol-l- Figure imgf000014_0001 - acetic acid: {.3- [(E) -2- (3-bromo-4-methyl-phenylcarbamoyl) -2-cyanovinyl] -indol-1-yl} -acetic acid; Acid {3- [(E) -2- (4-bromo-3-methyl-phenylcarbamoyl) -2-cyano-vinyl] -indol-1-yl} -acetic acid ethyl ester of 4- [ (E) -3- (l-carboxymethyl-lH-indol-3-yl) -2-cyano-acryloylamino] -benzoic acid; 3- [(E) -3- (l-carboxymethyl-7H-indole) methyl ester -3-yl) -2-cyano-acryloylamino] -benzoic acid; {.3- [(E) -2-cyano-2- (4-trifluoromethyl-phenylcarbamoyl) -vinyl] -indol-1-yl}. . -acetic; Acid { 3- [(E) -2-cyano-2- (3,5-dimethoxy-phenylcarbam. il) -vinyl] indol-l-il} -acetic; Acid { 3- [(E) -2- (4-bromo-3-chloro-phenylcarbamoyl) -2-cyanovinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2- (4-bromo-2-methyl-phenylcarbamoyl) -2-cyanovinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2- (4-acetyl-phenylcarbamoyl) -2-cyanovinyl] -. Indol-1-yl} -acetic; Acid { 3- [(E) -2- (2-bromo-4-methyl-phenylcarbamoyl) -2-cyanovinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2- (benzo [1,3] dioxol-5-ylcarbamoyl) -2-cyanovinyl] -indol-l-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (2,3-dihydro-benzo [1,4] dioxin-6-ylcarbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (2-methoxy-phenylcarbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (2-phenoxy-phenylcarbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (phenethyl-phenyl-carbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-3- (ll, '12 -dihydro-6H-dibenzo [b, f] azocin-5-yl) -3-oxo-propenyl] -indol-l-yl} -acetic; [3- ((E) -2-cyano-2-diphenylcarbamoyl-vinyl) -indol-1-yl] -acetic acid; [3- ((E) -2-cyano-3-dibenzo [b, f] azepin-5-yl-3-oxo-propenyl) -indol-l-yl] -acetic acid sodium; (3- ({(E) -2- [(4-chloro-phenyl) -methyl-carbamoyl] -2-cyanovinyl} -indol-1-yl) -acetic acid, - Acid. { 3- [(E) -2-cyano-3- (6,11-dihydro-dibenzo [b, e] azepin-5-yl) -3 -oxo-propenyl] -indol-1-yl} -acetic; [3- ((E) -2-cyano-2-diphenethylcarbamoyl-vinyl) -indol-1-yl] -acetic acid; Acid { 3- [(E) -2-cyano-3- (10, '11 -dihydro-dibenzo [b, f] azepin-5-yl) -3 -oxo-propenyl] -indol-1-yl} -acetic; (3- ({(E) -2-cyano-2- [methyl- ((R) -1-phenyl-ethyl) -carbamoyl] vinyl} -indol-1-yl) -acetic acid; Acid { 3- [(E) -2- (benzyl-methyl-carbamoyl) -2-cyanovinyl] -indol-1-yl} -acetic; (3- ({(E) -2- [(4-acetyl-phenyl) -methyl-carbamoyl] -2-cyano-vinyl} -indol-1-yl) -acetic acid; (3- ({(E) -2- [(4-acetyl-phenyl) -furan-2-ylmethyl-carbamoyl] -2-cyano-vinyl} -indol-1-yl) -acetic acid; Acid { 3- [(E) -2- (benzyl-carboxymethyl-carbamoyl) -2-cyanovinyl] -indol-1-yl} -acetic; Acid 3-. { benzyl- [(E) -3- (l-carboxymethyl-lH-indol-3-yl) -2-cyano-acryloyl] -amino} -propionic; Acid { 3- [(E) -2-cyano-3- (2,3-dihydro-indol-1-yl) -3-oxo-propenyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2- (carboxymethyl-phenyl-carbamoyl) -2-cyanovinyl] -indol-1-yl} -acetic; (3- {(E) -2-cyano-2- [(2-cyano-ethyl) -phenyl-carbamoyl] -vinyl} -indol-1-yl) -acetic acid; (3- ({(E) -2- [(3-chloro-phenyl) -methyl-carbamoyl] -2-cyano-vinyl} -indol-1-yl) -acetic acid; Acid { 3- [(E) -2- (allyl-phenyl-carbamoyl) -2-cyano-vinyl] -indol-l-yl} -acetic; Acid { 3- [(E) -2-cyano-2 ~ (cyclohexyl-phenyl-carbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (methyl-o-tolyl-carbamoyl) -vinyl] -indol-1-yl} -acetic; Acid (3- [(E) -2-cyano-2- (ethyl-phenyl-carbamoyl) -vinyl] -indol-1-yl.} -acetic acid: {.3- [(E) -2- (butyl-phenyl-carbamoyl) -2-cyano-vinyl] -indol-1-yl} -acetic acid [5-bromo-3- ((E) -2-cyano-2-phenylcarbamoyl-vinyl) - indole-1-yl] -acetic acid [3- ((E) -2-cyano-2-phenylcarbamoyl-vinyl) -7-methyl-indol-1-yl] -acetic acid [3- ((E)] -2-cyano-2-phenylcarbamoyl-vinyl) -5-fluoro-indol-1-yl] -acetic acid [3- ((E) -2-cyano-2-phenylcarbamoyl-vinyl) -6-fluoro-indole] -1-yl] -acetic; [3- ((E) -2-cyano-2-phenylcarbamoyl-vinyl) -6-nitro-indol-1-yl] -acetic acid; [3- ((E) -2-cyano-2-phenylcarbamoyl-vinyl) -5-methyl-indol-1-yl] -acetic acid; Acid { 3- [(E) -3- (2-chloro-phenothiazin-10-yl) -2-cyano-3-oxo-propenyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (phenyl-thiophen-3-ylmethyl-carbamoyl) -vinyl] -indol-l-yl} -acetic; "Acid (3- {(E) -2-cyano-2- [(2, 2-diphenyl-ethyl) -phenyl-carbamoyl] -vinyl} -indol-l-yl) -acetic acid; (3- ({(E) -2-cyano-2- [phenyl- (3-phenyl-propyl) -carbamoyl] -vinyl} -indol-1-yl) -acetic acid; ((E) -2-cyano-2- { [2- (4-fluoro-phenyl) -ethyl] -phenylcarbamoyl.] -vinyl) -indol-1-yl] -acetic acid; - [(E) ~ 2-cyano-3- (HH-10-oxa-5-aza-dibenzo [a, d] cyclohepten-5-yl) -3 -oxo-propenyl] -indol-1-yl.} -acetic acid: {.3- [(E) -2-cyano-2- (isopropyl-phenyl-carbamoyl) -vinyl] -indol-1-yl} -acetic acid (3- { (E) -2-cyano-2- [(3,4-dichloro-phenyl) -methyl-carbamoyl] -vinyl] -indol-1-yl) -acetic acid (3- ({(E)} -2-cyano-2- [ethyl- (4-trifluoromethoxy-phenyl) -carbamoyl] -vinyl} -indol-1-yl) -acetic acid: {.3- [(E) -2- (benzhydryl -carbamoyl) -2-cyanovinyl] -indol-l-yl.} -acetic; (3- ({(E) -2-cyano-2- [methyl- (2-trifluoromethoxy-phenyl) -carbamoyl] -vinyl} -indol-1-yl) -acetic acid; Acid { 3- [(E) -2-cyano-2- (2,4-difluoro-phenylcarbamoyl) -vinyl] indole-1-yl} -acetic; (3- ({(E) -2-cyano-2- [methyl- (4-trifluoromethoxy-phenyl) -carbamoyl] -vinyl} -indol-1-yl) -acetic acid; Acid { 3- [(E) -2-cyano-2- (ethyl-naphthalen-1-yl-carbamoyl) -vinyl] -indol-l-yl} -acetic; (3- {(E) -2-cyano-2- [(2,4-difluoro-phenyl) -methylcarbamoyl] -vinyl} -indol-1-yl) -acetic acid; Acid { 3- [(E) -2-cyano-2- (2,4,6-trifluoro-phenylcarbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (2,3,4-trifluoro-phenylcarbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-3- (3, 4-dihydro-lH-isoquinolin-2-yl) -3-oxo-propenyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-3-oxo-3- (7-trifluoromethyl-3,4-dihydro-2H-quinolin-1-yl) -propenyl] -indol-1-yl} -acetic; (3- {(E) -2-cyano-2- [(3-fluoro-phenyl) -methyl-carbamoyl] -vinyl} -indol-1-yl) -acetic acid; [3- ((E) -2-cyano-3-dibenzo [b, f] azepin-5-yl-3-oxo-propenyl) -5-fluoro-indol-1-yl] -acetic acid; Acid { 3- [(E) -2-cyano-3- (6,11-dihydro-dibenzo [b, e] azepin-S-yl) -3-oxo-propenyl] -5-fluoro-indol-1-yl} -acetic; Acid { 3- [(E) -2- (benzyl-phenyl-carbamoyl) -2-cyanovinyl] -5-fluoro-indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (cyclohexyl-phenyl-carbamoyl) -vinyl] 5-fluoro-indol-1-yl} -acetic; Acid { 3- [(E) -2- (Butyl-phenyl-carbamoyl) -2-cyano-vinyl] -5-fluoro-indol-1-yl} -acetic; (3- {(E) -2-cyano-2- [(4-fluoro-phenyl) -methyl-carbamoyl] -vinyl} -5-fluoro-indol-1-yl) -acetic acid; (3- ({(E) -2-cyano-2- [(3-fluoro-phenyl) -methyl-carbamoyl] -vinyl} -5-fluoro-indol-1-yl) -acetic acid; Acid (3- {(E) -2-cyano-2- [(3,4-dichloro-phenyl) -methylcarbamoyl] -vinyl} -5-fluoro-indol-1-yl) -acetic acid; (3- ({(E) -2-cyano-2- [methyl- (2-trifluoromethyl-phenyl) -carbamoyl] -vinyl} -5-fluoro-indol-1-yl) -acetic acid; (3- {(E) -2-cyano-2- [(2, -difluoro-phenyl) -methyl-carbamoyl] -vinyl} -5-fluoro-indol-1-yl) -acetic acid, - Acid { 3- [(E) -2-cyano-2- (phenyl-thiophen-3-ylmethyl-carbamoyl) -vinyl] -5-fluoro-indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-3-oxo-3- (7-trifluoromethyl-3,4-dihydro-2H-quinolin-1-yl) -propenyl] -5-fluoro-indol-1-yl} -acetic; (3- ({(E) -2-cyano-2- [ethyl- (4-trifluoromethoxy-phenyl) -carbamoyl] -vinyl} -5-fluoro-indol-1-yl) -acetic acid; Acid { 3- [(E) -2-cyano-3- (3,4-dihydro-lH-isoquinolin-2-yl) -3-oxo-propenyl] -5-fluoro-indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (phenethyl-phenyl-carbamoyl) -vinyl] -5-fluoro-indol-1-yl} -acetic; [3- ((E) -2-cyano-3-dibenzo [b, f] azepin-5-yl-3-oxo-propenyl) -6-methyl-indol-1-yl] -acetic acid; Acid { 3- [(E) -2 ~ cyano-3- (6,11-dihydro-dibenzo [b, e] azepin-S-yl) -3-oxo-propenyl] -6-methyl-indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-3- (10,11-dihydro-dibenzo [b, f] azepin-5-yl) -3 -oxo-propenyl] -6-methyl-indole-1-yl} -acetic; Acid { 3- [(E) -2- (benzyl-phenyl-carbamoyl) -2-cyano-vinyl] -6-methyl-indole-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (cyclohexyl-phenyl-carbamoyl) -vinyl] -6-methyl-indol-1-yl} -acetic; (3- {(E) -2-cyano-2- [(4-fluoro-phenyl) -methyl-carbamoyl] -vinyl} - 6-methyl-indol-1-yl) -acetic acid; Acid { 3- [(E) -2- (Butyl-phenyl-carbamoyl) -2-cyano-vinyl] -6-methyl-indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (cyclohexyl-phenyl-carbamoyl) -vinyl] -7-methyl-indole-1-yl} -acetic; (3- {(E) -2-cyano-2- [(4-fluoro-phenyl) -methyl-carbamoyl] -vinyl} - 7-methyl-indol-1-yl) -acetic acid.

4. A compound selected from a group consisting of a compound of the general formula IC? * C1 characterized in that A represents hydrogen; I rent; halogen or cyano; B represents hydrogen; alkyl or halogen; R1, R2, R3 and R4 independently represent hydrogen; I rent; halogen; nitro; cyano or formyl (and preferably independently represent hydrogen, alkyl, halogen or nitro); R5 and R6 independently represent hydrogen; I rent; cycloalkyl; cycloalkyl-algayl; heteroaryl; heteroarylalkyl; alkenyl; carboxyalkyl; cyanoalkyl; diphenylalkyl; aryl, aryl-alkoxy-aryl, aryl-alkyl, aryl-alkyl-aryl, arylcarbonyl-aryl or aryloxyaryl, or R5 and R6, together with the nitrogen atom, to which they are bonded, form a heterocyclic ring system; and an optically pure enantiomer, a mixture of enantiomers, a racemate, an optically pure diastereomer and a mixture of diastereoisomers, a diastereomeric racemate, a mixture of diastereomeric racemates, a meso form, a geometric isomer, a prodrug form, a solvate or a morphological form, or a pharmaceutically acceptable salt or a compound of the general formula IC ?; with the exception, however, of the following compounds: Acid. { 3- [(E) -2-cyano-2- (4-fluoro-phenylcarbamoyl) -vinyl] -indol-1-yl} -acetic; [3- ((E) -2-cyano-2-m-tolylcarbamoyl-vinyl) -indol-1-yl] -acetic acid; Acid { 3- ~ [(E) -2- (3-bromo-phenylcarbamoyl) -2-cyano-vinyl] -indol-1-yl} -acetic; [3- ((E) -2-cyano-2-phenylcarbamoyl-vinyl) -indol-1-yl] -acetic acid; [3- ((E) -2-Benzylcarbamoyl-2-cyanovinyl) -indol-1-yl] -acetic acid; [3- ((E) -2-cyano-2-o-tolylcarbamoyl-vinyl) -indol-1-yl] -acetic acid; [3- ((E) -2-cyano-2-p-tolylcarbamoyl-vinyl) -indol-1-yl] -acetic acid; Acid { 3- [(E) -2- (4-bromo-phenylcarbamoyl) -2-cyanovinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (4-ethyl-phenylcarbamoyl) -vinyl] -indol-1-yl} -acetic, - Acid. { 3- [(E) -2-cyano-2- (4-methoxy-phenylcarbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (4-ethoxy-phenylcarbamoyl) -vinyl] -indol-1-yl} -acetic; [3- ((E) -2-cyano-2-isopropylcarbamoyl-vinyl) -indol-1-yl] -acetic acid; Acid { 3- [(E) -2-cyano-2- (3-ethoxy-phenylcarbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-3- [[2- (1H-indol-3-yl) ethyl] amino] -3-oxo-1-propenyl] -indol-1-yl} -acetic; Acid (3- [(E) -2-cyano-2- (4-chloro-phenylcarbamoyl) -vinyl] -indol-1-yl.} -acetic acid: {.3- [(E) -2- cyano-3- (4-methyl-piperidin-1-yl) -3-oxo-propenyl] -indol-1-yl.} -acetic acid: {.3- [(E) -2- (3- chloro-4-methyl-phenylcarbamoyl) -2-cyano-vinyl] -indol-1-yl} -acetic acid; {.3- [(E) -2-cyano-2- (3-phenyl-propylcarbamoyl) ) -vinyl] -indol-l-il.} -acetic; acid { 3- [(E) -2-cyano-2- (2,3-dichloro-phenylcarbamoyl) -vinyl] -indol-l- Figure imgf000014_0001 acetic acid, {.3- [(E) -2- (5-chloro-2-methyl-phenylcarbamoyl) -2-cyanovinyl] -indol-1-yl} -acetic acid; Acid {3- [(E) -2-cyano-2- (4-methoxy-benzylcarbamoyl) -vinyl] -indol-1-yl} -acetic acid; Acid {3- [(E) - 2-cyano-2- (2-fluoro-phenylcarbamoyl) -vinyl] -indol-1-yl} -acetic acid; and Acid. {3- [3 (E) -2-cyano-3-oxo-3) (4-phenyl-piperazin-1-yl) -propenyl] -indol-1-yl.} -acetic acid.

5. A compound according to claim 4, characterized in that OA is cyano; OR B is hydrogen; Or R1, R2, R3 and R4 are all hydrogen atoms, or one of R1, R2, R3 and R4 is halogen while the others are all hydrogen; and R5 is selected from the group consisting of heteroarylalkyl, diphenylalkyl, aryl, aryl-alkoxy-aryl, arylalkyl, aryl-alkyl-aryl, arylcarbonyl-aryl and aryloxyaryl wherein aryl, aryl-alkoxy-aryl, aryl-alkyl, aryl- alkyl-aryl, arylcarbonyl-aryl and aryloxy-aryl, are such that their aryl groups are unsubstituted or substituted once or twice with substituents independently selected from the group consisting of halogen, alkoxy, haloalkoxy and alkylcarbonyl; and R6 is selected from the group consisting of alkyl, alkenyl, cycloalkyl, aryl, arylalkyl and cyanoalkyl wherein aryl and aryl-alkyl is preferably such that their aryl groups are unsubstituted or substituted one or two times with substituents independently selected from the group que- consists of halogen, alkoxy, haloalkoxy and alkylcarbonyl); or R5 and R6, together with the nitrogen atom to which they are bound, form a dihydrophenanthyridine, dihydroacridine, dihydrodibenzoazocin, dihydrodibenzoazepine, dihydroindol, dihydroquinoline, dibenzoazepine, phenothiazine, oxa-aza-dibenzocycloheptene, dihydroisoquinoline, which may be substituted or unsubstituted with a substituent selected from halogen, methyl, methoxy and trifluoromethyl.

6. A compound according to claim 4, characterized in that the groups R5 and R6 do not form a -heterocyclic ring system together with the nitrogen atom to which they are linked.

7. A compound according to claim 6, characterized in that R5 is aryl and R6 is selected from the group consisting of alkyl, cycloalkyl, alkenyl, cyanoalkyl, diphenylalkyl, heteroarylalkyl, aryl-alkyl and aryl.

8. A compound according to claim 6, characterized in that R5 is aryl-alkyl and R6 is selected from a group consisting of alkyl, aryl and aryl-alkyl.

9. A compound according to claim 4, characterized in that the groups R5 and R6 form a heterocyclic ring system together with the nitrogen atom to which they are linked.

10. A compound according to claim 4, characterized in that it is selected from the group consisting of: Acid. { 3- [(E) -2-cyano-2- (cyclohexylmethyl-carbamoyl) -vinyl] -indol-1-yl} -acetic; [3- ((E) -2-cyano-2-phenethylcarbamoyl-vinyl) -indol-1-yl] -acetic acid; [3- ((E) -2-cyano-2-isopropylcarbamoyl-vinyl) -indol-1-yl] -acetic acid; [3- ((E) -2-cyano-2-propylcarbamoyl-vinyl) -indol-1-yl] -acetic acid; [3- ((E) -2-cyano-2-cyclohexylcarbamoyl-vinyl) -indol-1-yl] -acetic acid; -Acid. { 3- [(E) -2-cyano-2- (3-methyl-butylcarbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2- (benzyl-phenyl-carbamoyl) -2-cyano-vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (4-cyano-phenylcarbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (4-fluoro-phehylcarbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (4-phenoxy-phenylcarbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (naphthalen-2-ylcarbamoyl) -vinyl] -indol-l-il} -acetic; Acid { 3 - [(E) -2-cyano-2 - (2-isopropyl-phenylcarbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (4-isopropyl-phenylcarbamoyl) -vinylj-indole-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (3-methoxy-phenylcarbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (3-fluoro-phenylcarbamoyl) -vinyl] -indol-1-yl} -acetic; Acid (3- [(E) -2-cyano-2- (9H-fluoren-2-ylcarbamoyl) -vinyl] -indol-1-yl.} -acetic acid; {.3- [(E) - 2-cyano-2- (4-propyl-phenylcarbamoyl) -vinyl] -indol-1-yl.} -acetic acid: {.3- [(E) -2- (biphenyl-4-ylcarbamoyl) - 2-cyano-vinyl] -indol-1-yl.} -acetic acid; {.3- [(E) -2-cyano-2- (3,2'-dimethyl-biphenyl-4-ylcarbamoyl) - vinyl] -indol-l-yl.} -acetic acid: {.3- [(E) -2- (4-tert-butyl-phenylcarbamoyl) -2-cyanovinyl] -indol-l-yl} -acetic; Acid { 3- [(E) -2- (2-benzyl-phenylcarbamoyl) -2-cyano-vinyl] -indol-l-yl}. -acetic acid; [(E) -2- (4-Butyl-phenylcarbamoyl) -2-cyano-vinyl] -indol-1-yl} -acetic acid: {.3- [(E) -2- (2-acetyl) phenylcarbamoyl) -2-cyanovinyl] -indol-1-yl.} -acetic acid; {.3- [(E) -2-cyano-2- (indan-5-ylcarbamoyl) -vinyl] - indole-1-acetic acid; (3- [(E) -2- (4-sec-butyl-phenylcarbamoyl) -2-cyano-vinyl] -indol-1-yl} -acetic acid; Acid { 3- [(E) -2-cyano-2- (2-propyl-phenylcarbamoyl) -vinyl] -indol-l-il} -acetic; Acid { 3- [(E) -2-cyano-2- (3-phenoxy-phenylcarbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (3-ethyl-phenylcarbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (2-ethoxy-phenylcarbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2- (3-benzyloxy-phenylcarbamoyl) -2-cyanovinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (4-iodo-phenylcarbamoyl) -vinyl] -indol-l-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (3-iodo-phenylcarbamoyl) -vinyl] -indol-1-yl} -acetic; (3- ({(E) -2-cyano-2- [(4-fluoro-phenyl) -methylcarbamoyl] -vinyl} -indol-1-yl) -acetic acid; (3- ({(E) -2-cyano-2- [(4-methoxy-phenyl) -methyl-carbamoyl] -vinyl} -indol-1-yl) -acetic acid; Acid { 3- [(E) -2-cyano-2- (methyl-phenyl-carbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-3- (3,4-dihydro-2H-quinolin-1-yl) -3-oxo-propenyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (methyl-p-tolyl-carbamoyl) -vinyl] -indol-1-yl} -acetic; (3 ~. {(E) -2-cyano-2- [2- (2,4-dichloro-phenoxy) -phenylcarbamoyl] -vinyl} -indol-1-yl) -acetic; Acid { 3- [(E) -2-cyano-2- (2,5-dimethyl-phenylcarbamoyl) -vinyl] • indole-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (9-ethyl-9H-carbazol-3-ylcarbamoyl) -vinyl] -indol-l-yl} -acetic; Acid { 3- [(E) -2- (3, 5-bis-trifluoromethyl-phenylcarbamoyl) -2- cyanovinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (5-methoxy-2-methyl-phenylcarbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2- (3-benzoyl-phenylcarbamoyl) -2-cyanovinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2- (4-benzyloxy-phenylcarbamoyl) -2-cyanovinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (3-nitro-phenylcarbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (9-oxo-9H-fluoren-2-ylcarbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano ~ 2- (4-methoxy-biphenyl-3-ylcarbamoyl) -vinyl] -indol-l-yl} -acetic; . Acid { 3- [(E) -2-cyano-2- (2-methoxy-dibenzofuran-3-ylcarbamoyl) -vinyl] -indol-l-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (9-oxo-9H-fluoren-4-ylcarbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (9-oxo-9H-fluoren-1-ylcarbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2- (2-benzoyl-phenylcarbamoyl) -2-cyanovinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2- (3-chloro-4-methoxy-phenylcarbamoyl) -2-cyanovinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2- (5-chloro-2-methoxy-phenylcarbamoyl) -2-cyanovinyl] -indol-1-yl} -acetic; 3- [(E) -3- (l-Carboxymethyl-lH-indol-3-yl) -2-cyano-acryloylamino] -4-methyl-benzoic acid methyl ester; 2- [(E) -3- (1-carboxymethyl-1H-indol-3-yl) -2-cyano-acryloylamino] -benzoic acid methyl ester; Acid { 3- [(E) -2-cyano-2- (4-trifluoromethoxy-phenylcarbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (3, 5-dimethyl-phenylcarbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2- (3-bromo-4-methyl-phenylcarbamoyl) -2-cyanovinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2- (4-bromo-3-methyl-phenylcarbamoyl) -2-cyanovinyl] -indol-1-yl} -acetic; Methyl ester of 4- [(E) -3- (1-carboxymethyl-IH-indol-3-yl) -2-cyano-acryloylamino] -benzoic acid methyl ester; 3- [(E) -3- (l-carboxymethyl-lH-indol-3-yl) -2-cyano-acryloylamino] -benzoic acid; Acid { 3- [(E) -2-cyano-2- (4-trifluoromethyl-phenylcarbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (3, 5-dimethoxy-phenylcarbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2- (4-bromo-3-chloro-phenylcarbamoyl) -2-cyanovinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2- (4-bromo-2-methyl-phenylcarbamoyl) -2-cyanovinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2- (4-acetyl-phenylcarbamoyl) -2-cyanovinyl] -indol-1-yl} -acetic; Acid { 3 - [(E) -2- (2-bromo-4-methyl-phenylcarbamoyl) -2-cyanovinyl] -indole-1-yl} -acetic; Acid { 3- [(E) -2- (benzo [1,3] dioxol-5-ylcarbamoyl) -2-cyanovinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (phenethyl-f-enyl-carbamoyl) -vinyl] -indol-l-yl} -acetic; Acid { 3- [(E) -2-cyano-3- (11,12-dihydro-6 H -dibenzo [b, f] azocin-5-yl) -3 -oxo-propenyl] -indol-l-yl} -acetic; [3- ((E) -2-cyano-2-diphenylcarbamoyl-vinyl) -indol-1-yl] -acetic acid; [3- ((E) -2-cyano-3-dibenzo [b, f] azepin-5-yl-3-oxo-propenyl) -indol-1-yl] -acetic acid; (3- { (E) -2- [(4-chloro-phenyl) -methyl-carbamoyl] -2-cyano-vinyl} -indol-1-yl) -acetic; Acid { 3- [(E) -2-cyano-3- (6,11-dihydro-dibenzo [b, e] azepin-S-yl) -3 -oxo-propenyl] -indol-1-yl} -acetic; [3- ((E) -2-cyano-2-diphenethylcarbamoyl-vinyl) -indol-1-yl] -acetic acid; Acid { 3- [(E) -2- (5-chloro-2-methoxy-phenylcarbamoyl) -2-cyanovinyl] -indol-1-yl} -acetic; 3- [(E) -3- (l-Carboxymethyl-lH-indol-3-yl) -2-cyano-acryloylamino] -4-methyl-benzoic acid methyl ester; 2- [(E) -3- (1-carboxymethyl-1H-indol-3-yl) -2-cyano-acryloylamino] -benzoic acid methyl ester; Acid { 3- [(E) -2-cyano-2- (4-trifluoromethoxy-phenylcarbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (3, 5-dimethyl-phenylcarbamoyl) -vinyl] -indol-1-yl} -acetic; -0-- Acid. { 3- [(E) -2- (3-bromo-4-methyl-phenylcarbamoyl) -2-cyano-ynyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2- (4-bromo-3-methyl-phenylcarbamoyl) -2-cyanovinyl] -indol-1-yl} -acetic; -. Methyl ester of 4- [(E) -3- (1-carboxymethyl-lH-indol-3-5-yl) -2-cyano-acryloylamino] -benzoic acid methyl ester; 3- [(E) -3- (1-carboxymethyl-1H-indol-3-yl) -2-cyano-acryloylamino] -benzoic acid methyl ester; Acid { 3- [(E) -2-cyano-2- (4-trifluoromethyl-phenylcarbamoyl) -vinyl] -indol-1-yl} -acetic; 0 Acid. { 3- [(E) -2-cyano-2- (3, 5-dimethoxy-phenylcarbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2- (4-bromo-3-chloro-phenylcarbamoyl) -2-cyanovinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2- (4-bromo-2-methyl-phenylcarbamoyl) -2-cyanovinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2- (4-acetyl-phenylcarbamoyl) -2-cyanovinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2- (2-bromo-4-methyl-phenylcarbamoyl) -2-cyanovinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2- (benzo [1,3] dioxol-5-ylcarbamoyl) -2-cyanovinyl] -indol-l-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (phenethyl-phenyl-carbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-3- (11,12-dihydro-6 H -dibenzo [b, f] azocin-5-yl) -3-oxo-propenyl] -indol-1-yl} -acetic; [3- ((E) -2-cyano-2-diphenylcarbamoyl-vinyl) -indol-1-yl] -acetic acid; [3- ((E) -2-cyano-3-dibenzo [b, f] azepin-5-yl-3-oxo-propenyl) -indol-1-yl] -acetic acid; (3- { (E) -2- [(4-chloro-phenyl) -methyl-carbamoyl] -2-cyano-vinyl] -indol-1-yl) -acetic; Acid { 3- [(E) -2-cyano-3- (6,11-dihydro-dibenzo [b, e] azepin-S-yl) -3 -oxo-propenyl] -indol-1-yl} -acetic; [3- ((E) -2-cyano-2-diphenethylcarbamoyl-vinyl) -indol-1-yl] -acetic acid; Acid { 3- [(E) -2-cyano-3- (10,11-dihydro-dibenzo [b, f] azepin-S-yl) -3-oxo-propenyl] -indol-1-yl} -acetic; (3- ({(E) -2-cyano-2- [methyl- ((R) -1-phenyl-ethyl) -carbamoyl] -vinyl} -indol-1-yl) -acetic acid; Acid { 3- [(E) -2- (benzyl-methyl-carbamoyl) -2-cyano-vinyl] -indol-1-yl} -acetic; (3- ({(E) -2- [(4-acetyl-phenyl) -methyl-carbamoyl] -2-cyanovinyl} -indol-1-yl) -acetic acid; (3- ({(E) -2- [(4-acetyl-phenyl) -furan-2-ylmethyl-carbamoyl] -2-cyano-vinyl} -indol-1-yl) -acetic acid; Acid { 3- [(E) -2- (benzyl-carboxymethyl-carbamoyl) -2-cyanovinyl-] -indol-1-yl} -acetic; Acid 3-. { benzyl- [(E) -3- (l-carboxymethyl-lH-indol-3-yl) -2- cyano-acryloyl] -amino} -propionic; Acid { 3- [(E) -2-cyano-3- (2,3-dihydro-indol-1-yl) -3-oxo-propenyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2- (carboxymethyl-phenyl-carbamoyl) -2-cyano-vinyl] -indol-1-yl} -acetic; (3- {(E) -2-cyano-2- [(2-cyano-ethyl) -phenyl-carbamoyl] -vinyl} -indol-1-yl) -acetic acid; (3- ({(E) -2- [(3-chloro-phenyl) -methyl-carbamoyl] -2-cyano-vinyl} -indol-1-yl) -acetic acid; Acid { 3- [(E) -2- (allyl-phenyl-carbaoyl) -2-cyanovinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (cyclohexyl-phenyl-carbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (methyl-o-tolyl-carbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (ethyl-phenyl-carbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2- (butyl-phenyl-carbamoyl) -2-cyanovinyl] -indol-1-yl} -acetic; [5-Bromo-3- ((E) -2-cyano-2-phenylcarbamoyl-vinyl) -indol-1-yl] -acetic acid; [3- ((E) -2-cyano-2-phenylcarbamoyl-vinyl) -5-fluoro-indol-1-yl] -acetic acid; [3- ((E) -2-cyano-2-phenylcarbamoyl-vinyl) -5-methyl-indol-1-yl] -acetic acid; [3- ((E) -2-cyano-2-phenylcarbamoyl-vinyl) -6-fluoro-indol-1-yl] -acetic acid; [3- ((E) -2-cyano-2-phenylcarbamoyl-vinyl) -6-nitro-indol-1-yl] -acetic acid; [3- ((E) -2-cyano-2-phenylcarbamoyl-vinyl) -7-methyl-indol-1-yl] -acetic acid; Acid { 3- [(E) -3- (2-chloro-phenothiazin-10-yl) -2-cyano-3-oxo-propenyl] -indol-l-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (phenyl-thiophen-3-ylmethyl-carbamoyl) -vinyl] -indol-l-yl} -acetic; (3- ({(E) -2-cyano-2- [(2, 2-diphenyl-ethyl) -phenyl-carbamoyl] -vinyl} -indol-1-yl) -acetic acid; (3- ({(E) -2-cyano-2- [phenyl- (3-phenyl-propyl) -carbamoyl] -vinyl} -indol-1-yl) -acetic acid; [3- ((E) -2-cyano-2- {[[2- (4-fluoro-phenyl) -ethyl] -phenylcarbamoyl} -vinyl) -indol-1-yl] -acetic acid; Acid { 3- [(E) -2-cyano-3- (HH-10-oxa-5-aza-dibenzo [a, d] cyclohepten-5-yl) -3 -oxo-propenyl] -indol-l-yl} - acetic; Acid { 3- [(E) -2-cyano-2- (isopropyl-phenyl-carbamoyl) -vinyl] -indol-1-yl} -acetic; (3- {(E) -2-cyano-2- [(3,4-dichloro-phenyl) -methylcarbamoyl] -vinyl} -indol-1-yl) -acetic acid; (3- ({(E) -2-cyano-2- [ethyl- (4-trifluoromethoxy-phenyl) -carbamoyl] -vinyl} -indol-1-yl) -acetic acid; Acid { 3- [(E) -2- (benzhydryl-carbamoyl) -2-cyanovinyl] -indol-1-yl} -acetic; Acid "(3- {() -2-cyano-2- [methyl- (2-trifluoromethoxy-phenyl) -carbamoyl] -vinyl} -indol-1-yl) -acetic acid; 3- [(E) -2-cyano-2- (2,4-difluoro-phenylcarbamoyl) -vinyl] indole-1-yl} -acetic acid: (3 { (E) -2-cyano) -2 ~ [methyl- (4-trifluoromethoxy-phenyl) -carbamoyl] -vinyl] -indol-1-yl) -acetic acid: {.3- [(E) -2-cyano-2- (ethyl) -naphthalen-1-yl-carbamoyl) -vinyl] -indol-l-yl.} -acetic acid (3- {(E) -2-cyano-2- [(2,4-difluoro-phenyl)} ) -methyl-carbamoyl] -vinyl.}. -indol-1-yl) -acetic acid; {.3- [(E) -2-cyano-2- (2,, 6-trifluoro-phenylcarbamoyl) -vinyl) ] -indol-l-il.} -acetic; Acid { 3- [(E) -2-cyano-2- (2,3,4-trifluoro-phenylcarbamoyl) -vinyl] -indol-l-il .}. -acetic; Acid { 3- [(E) -2-cyano-3- (3,4-dihydro-lH-isoquinolin-2-yl) -3-oxo-propenyl] -indol-l- il.) -Acetic; Acid {3- [(E) -2-cyano-3-oxo-3- (7-trifluoromethyl-3,4-dihydro-2H-quinolin-1-yl) -propenyl] -indol-l-il.}. -acétic or; Acid (3- { (E) -2-cyano-2- [(3-fluoro-phenyl) -methyl-carbamoyl] -vinyl} -indol-l-il) -acetic; [3- ((E) -2-cyano-3-dibenzo [b, f] azepin-5-yl-3-oxo-propenyl) -5-fluoro-indol-1-yl] -acetic acid; Acid { 3- [(E.) -2-cyano-3- (6,11-dihydro-dibenzo [b, e] azepin-S-yl) -3 -oxo-propenyl] -5-fluoro-indol-1-yl } -acetic; Acid { 3 - "[(E) -2- (benzyl-phenyl-carbamoyl) -2-cyano-vinyl] -5-fluoro-indol-1-yl.} -acetic acid: {.3- [(E)} -2-cyano-2- (cyclohexyl-phenyl-carbamoyl) -vinyl] -5-fluoro-indol-1-yl} -acetic acid; {.3- [(E) -2- (butyl-phenyl) -carbamoyl) -2-cyano-vinyl] -5-fluoro-indole-1-yl} -acetic acid (3 { (E) -2-cyano-2- [(4-fluoro-phenyl) ) -methyl-carbamoyl] -vinyl.}. -5-fluoro-indol-1-yl) -acetic acid (3- {(E) -2-cyano-2- [(3-fluoro-phenyl)} -methyl-carbamoyl] -vinyl.}. -5-f-uoro-indol-1-yl) -acetic acid: (3- {(E) -2-cyano-2- [(3,4-dichloro- phenyl) -methyl-carbamoyl] -vinyl.}. -5-fluoro-indol-1-yl) -acetic acid (3- ({(E) -2-cyano-2- [methyl- (2-trifluoromethyl)} phenyl) -carbamoyl] -vinyl.} - 5-fluoro-indol-1-yl) -acetic acid (3- ({(E) -2-cyano-2- [(2,4-difluoro-) phenyl) -methyl-carbamoyl] -vinyl.} - 5-fluoro-indol-1-yl) -acetic; Acid { 3- [(E) -2-cyano-2- (phenyl-thiophen-3-ylmethyl-carbamoyl) -vinyl] -5-fluoro-indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-3-oxo-3- (7-trifluoromethyl-3,4-dihydro-2H-quinolin-1-yl) -propenyl] -5-fluoro-indol-1-yl} -acetic; (3- ({(E) -2-cyano-2- [ethyl- (4-trifluoromethoxy-phenyl) -carbamoyl] -vinyl} -5-fluoro-indol-1-yl) -acetic acid; Acid { 3- [(E) -2-cyano-3- (3,4-dihydro-lH-isoquinolin-2-yl) -3-oxo-propenyl] -5-fluoro-indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (phenethyl-phenyl-carbamoyl) -vinyl] -5-fluoro-indol-1-yl} -acetic; [3- ((E) -2-cyano-3-dibenzo [b, f] azepin-5-yl "-3-oxo-propylene) -6-methyl-indol-1-yl] -acetic acid; {.3- [(E) -2-cyano-3- (6,11-dihydro-dibenzo [b, e] azepin-S-yl) -3-oxo-propenyl] -6-methyl-indole-l- il.) -Acetic; Acid { 3- [(E) -2-cyano-3- (10,11-dihydro-dibenzo [b, f] azepin-5-yl) -3-oxo-propenyl] -6-methyl-indole-1-yl.} -acetic acid: {.3- [(E) -2- (benzyl-phenyl-carbamoyl) -2-cyanovinyl] -6-methyl-indole- 1-yl.) -acetic acid: {.3- [(E) -2-cyano-2- (cyclohexyl-phenyl-carbamoyl) -vinyl] -6-methyl-indol-1-yl}. acetic acid (3 ~. {(E) -2-cyano-2- [(4-fluoro-phenyl) -methyl-carbamoyl] -vinyl} -6-methyl-indol-1-yl) -acetic acid; Acid { 3- [(E) -2- (butyl-phenyl-carbamoyl) -2-cyano-vinyl] -6-methyl-indol-1-yl.} -acetic acid; [(E) -2-cyano-2- (cyclohexyl-phenyl-carbamoyl) -vinyl] -7-methyl-indol-1-yl} -acetic acid and (3. -cyano-2- [(4-fluoro-phenyl) -methyl-carbamoyl] -vinyl.} - 7-methyl-indole -l-il) -acetic

11. A compound according to claim 4, wherein the compound of the formula IC? is a compound of the formula Ic2, C2 characterized in that A represents hydrogen; I rent; halogen or cyano; B represents hydrogen; alkyl or halogen; R1, R2, R3 and R4 independently represent hydrogen; I rent; halogen; nitro; cyano or formyl; R5 and R6 independently represent hydrogen; I rent; cycloalkyl; cycloalkyl-alkyl; heteroaryl; heteroarylalkyl; alkenyl; carboxyalkyl; cyanoalkyl; diphenylalkyl; aryl, aryl-alkoxy-aryl, aryl-alkyl, aryl-alkyl-aryl, arylcarbonyl-aryl or aryloxyaryl, or R5 and R6, together with the nitrogen atom, to which they are bonded, form a heterocyclic ring system; it being understood however that at least one of the following conditions must be met: Or one of R1, R2, R3 and R4 is different from a hydrogen atom; Or O when R? and R6 are such that they do not form a heterocyclic ring system with the nitrogen atom to which they are linked, then R5 and R6 are different from hydrogen and one of R5 and R6 is different from alkyl; or when R5 and R6 are such that they form a heterocyclic ring system, together with the nitrogen atom to which they are linked, then said heterocyclic ring system is neither an unsubstituted or substituted pyridine nor an unsubstituted or substituted piperazine .

12. A pharmaceutical composition, characterized in that it contains, as an active ingredient, at least one compound according to claim 1, and a pharmaceutically acceptable carrier. The use of a compound according to claim 1 for the preparation of a medicament for the prevention and treatment of chronic and acute allergic immune disorders comprising allergic asthma, rhinitis, chronic obstructive pulmonary disease (COPD), dermatitis, inflammatory bowel disease, rheumatoid arthritis, allergic nephritis, conjunctivitis, atopic dermatitis, bronchial asthma, food allergy, systemic mast cell disorders, anaphylactic shock, urticaria, eczema, itching, inflammation, ischemia-reperfusion injury, cerebrovascular disorders, pleuritis, ulcerative colitis, diseases related to eosinophils, such as Churg-Strauss syndrome and sinusitis, diseases related to basophils, such as basophilic leukemia and basophilic leukocytosis. 14. The use of a compound according to claim 13, wherein the compound used is such that: O A is cyano; OR B is hydrogen or methyl; Or R1, R2, R3 and R4 are all hydrogen atoms, or one of R1, R2, R3 and R4 is halogen, while the others are all hydrogen; Or at least one of R5 and R6 is selected from the group consisting of heteroaryl, heteroaryl-alkyl, diphenylalkyl, aryl, arylalkoxy-aryl, arylalkyl, arylalkyl-aryl, arylcarbonyl-aryl and aryloxy-aryl; or R5 and R6, together with the nitrogen atom to which they are linked, form a heterocyclic ring system. 15. The use of a compound according to claim 13, wherein the compound used is selected from the group consisting of: Acid. { 3- [(E) -2-cyano-2- (cyclohexylmethyl-carbamoyl) -vinyl] -indol-1-yl} -acetic; [3- ((E) -2-cyano-2-phenethylcarbamoyl-vinyl) -indol-1-yl] -acetic acid; [3- ((E) -2-cyano-2-isopropylcarbamoyl-vinyl) -indol-1-yl] -acetic acid; [3- ((E) -2-cyano-2-propylcarbamoyl-vinyl) -indol-1-yl] -acetic acid; [3- ((E) -2-cyano-2-cyclohexylcarbamoyl-vinyl) -indol-1-yl] -acetic acid; Acid { 3- [(E) -2-cyano-2- (3-methyl-butylcarbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2- (benzyl-phenyl-carbamoyl) -2-cyanovinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (4-cyano-phenylcarbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (4-fluoro-phenylcarbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (4-phenoxy-phenylcarbamoyl) -vinyl] -indol-1-yl} -acetic, - Acid. { 3- [(E) -2-cyano-2- (naphthalen-2-ylcarbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (2-isopropyl-phenylcarbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (4-isopropyl-phenylcarbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (3-methoxy-phenylcarbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (3-fluoro-phenylcarbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (9 H -fluoren-2-ylcarbamoyl) -vinyl] -indol-l-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (4-propyl-phenylcarbamoyl) -vinyl] -indol-l-yl} -acetic; Acid { 3- [(E) -2- (biphenyl-4-ylcarbamoyl) -2-cyanovinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (3,2'-dimethyl-biphenyl-4-ylcarbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2- (4-tert-butyl-phenylcarbamoyl) -2-cyanovinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2- (2-benzyl-phenylcarbamoyl) -2-cyanovinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2- (4-Butyl-phenylcarbamoyl) -2-cyanovinyl] -indol-1-yl} -acetic, • Acid. { 3- [(E) -2- (2-acetyl-phenylcarbamoyl) -2-cyanovinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (indan-5-ylcarbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2- (4-sec-butyl-phenylcarbamoyl) -2-cyano-vinyl] -indol-l-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (2-propyl-phenylcarbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (3-phenoxy-phenylcarbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (3-ethyl-phenylcarbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (2-ethoxy-phenylcarbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2- (3-benzyloxy-phenylcarbamoyl) -2-cyanovinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (4-iodo-phenylcarbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (3-iodo-phenylcarbamoyl) -vinyl] -indol-1-yl} -acetic; (3- ({(E) -2-cyano-2- [(4-fluoro-phenyl) -methylcarbamoyl] -vinyl} -indol-1-yl) -acetic acid; (3- ({(E) -2-cyano-2- [(4-methoxy-phenyl) -methyl-carbamoyl] -vinyl} -indol-1-yl) -acetic acid; Acid { 3- [(E) -2-cyano-2- (methyl-phenyl-carbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-3- (3,4-dihydro-2H-quinolin-1-yl) -3-oxo-propenyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (methyl-p-tolyl-carbamoyl) -vinyl] -indol-1-yl} -acetic; (3- {(E) -2-cyano-2- [2- (2,4-dichloro-phenoxy) -phenylcarbamoyl] -vinyl} -indol-1-yl) -acetic acid; Acid { 3- [(E) -2-cyano-2- (2,5-dimethyl-phenylcarbamoyl) -vinyl] indole-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (9-ethyl-9H-carbazol-3-ylcarbamoyl) -vinyl] -indol-l-yl} -acetic; Acid { 3- [(E) -2- (3,5-bis-trifluoromethyl-phenylcarbamoyl) -2- cyanovinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (5-methoxy-2-methyl-phenylcarbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2- (3-benzoyl-phenylcarbamoyl) -2-cyanovinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2- (4-benzyloxy-phenylcarbamoyl) -2-cyanovinyl] • indole-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (3-nitro-phenylcarbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (9-oxo-9H-fluoren-2-ylcarbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (4-methoxy-biphenyl-3-carbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (2-methoxy-dibenzofuran-3-ylcarbamoyl) -vinyl] -i? Dol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (9-oxo-9H-fluoren-4-ylcarbamoyl) -vinyl] -indol-1-yl} -acetic; 'Acid. { 3- [(E) -2-cyano-2- (9-oxo-9H-fluoren-1-ylcarbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2- (2-benzoyl-phenylcarbamoyl) -2-cyanovinyl] -indol-l-yl} -acetic; Acid { 3- [(E) -2- (3-chloro-4-methoxy-phenylcarbamoyl) -2-cyano-5-vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2- (5-chloro-2-methoxy-phenylcarbamoyl) -2-cyanovinyl] -indol-1-yl} -acetic; 3- (E) -3- (1-carboxymethyl-1H-indol-3'-yl) -2-cyano-acryloylamino] -4-methyl-benzoic acid methyl ester; -10 2- [(E) -3- (1-carboxymethyl-lH-indol-3-yl) -2-cyano-acryloylamino] -benzoic acid methyl ester; Acid { 3- [(E) -2-cyano-2- (4-trifluoromethoxy-phenylcarbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (3, 5-dimethyl-phenylcarbamoyl) -vinyl] -15-indol-1-yl} -acetic; Acid { 3- [(E) -2- (3-bromo-4-methyl-phenylcarbamoyl) -2-cyanovinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2- (4-bromo-3-methyl-phenylcarbamoyl) -2-cyanovinyl] -indol-1-yl} -acetic; 20 Methyl 4- [(E) -3- (1-carboxymethyl-1 H-indol-3-yl) -2-cyano-acryloylamino] -benzoic acid methyl ester; 3- [(E) -3- (l-carboxymethyl-lH-indol-3-yl) -2-cyano-acryloylamino] -benzoic acid; Acid { 3- [(E) -2-cyano-2- (4-trifluoromethyl-phenylcarbamoyl) -25-vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (3, 5-dimethoxy-phenylcarbamoyl) -vinyl] indole-1-yl} -acetic; Acid { 3- [(E) -2- (4-bromo-3-chloro-phenylcarbamoyl) -2-cyanovinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2- (4-bromo-2-methyl-phenylcarbamoyl) -2-cyanovinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2- (4-acetyl-phenylcarbamoyl) -2-cyanovinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2- (2-bromo-4-methyl-phenylcarbamoyl) -2-cyanovinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2- (benzo [1,3] dioxol-5-ylcarbamoyl) -2-cyanovinyl] -indol-l-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (phenethyl-phenyl-carbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-3- (11,12-dihydro-6H-dibenzo [b, f] azocin-5-yl) -3-oxo-propenyl] -indol-1-yl} -acetic; [3- ((E) -2-cyano-2-diphenylcarbamoyl-vinyl) -indol-1-yl] -acetic acid; [3- ((E) -2-cyano-3-dibenzo [b, f] azepin-5-yl-3-oxo-propenyl) -indol-1-yl] -acetic acid; (3- { (E) -2- [(4-chloro-phenyl) -methyl-carbamoyl] -2-cyano-vinyl] -indol-1-yl) -acetic; Acid { 3- [(E) -2-cyano-3- (6,11-dihydro-dibenzo [b, e] azepin-S-yl) -3-oxo-propenyl] -indol-l-yl} -acetic; [3- ((E) -2-cyano-2-diphenethylcarbamoyl-vinyl) -indol-1-yl] -acetic acid; Acid { 3- [(E) -2- (5-chloro-2-methoxy-phenylcarbamoyl) -2-cyanovinyl] -indol-1-yl} -acetic; 3- [(E) -3- (l-Carboxymethyl-lH-indol-3-yl) -2-cyano-acryloylamino] -4-methyl-benzoic acid methyl ester; 2 - [(E) -3- (l-carboxymethyl-lH-indol-3-yl) -2-cyano-acryloyl] amino] -benzoic acid methyl ester; Acid { 3- [(E) -2-cyano-2- (4-trifluoromethoxy-phenylcarbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (3, 5-dimethyl-phenylcarbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2- (3-bromo-4-methyl-phenylcarbamoyl) -2-cyanovinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2- (4-bromo-3-methyl-phenylcarbamoyl) -2-cyanovinyl] -indol-1-yl} -acetic; Methyl ester of 4- [(E) -3- (l-carboxymethyl-lH-indol-3-yl) -2-cyano-acryloylamino] -benzoic acid methyl ester; 3- [(E) -3- (1-carboxymethyl-1H-indol-3-yl) -2-cyano-acryloylamino] -benzoic acid methyl ester; Acid { 3- [(E) -2-cyano-2- (4-trifluoromethyl-phenylcarbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (3, 5-dimethoxy-phenylcarbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2- (4-bromo-3-chloro-phenylcarbamoyl) -2-cyanovinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2- (4-bromo-2-methyl-phenylcarbamoyl) -2-cyanovinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2- (4-acetyl-phenylcarbamoyl) -2-cyanovinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2- (2-bromo-4-methyl-phenylcarbamoyl) -2-cyanovinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2- (benzo [1,3] dioxol-5-ylcarbamoyl) -2-cyanovinyl] -indol-l-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (phenethyl-phenyl-carbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-3- (11,12-dihydro-6H-dibenzo [b, f] azocin-5-yl) -3-oxo-propenyl] -indol-1-yl} -acetic; [3- ((E) -2-cyano-2-diphenylcarbamoyl-vinyl) -indol-1-yl] -acetic acid; [3- ((E) -2-cyano-3-dibenzo [b, f] azepin-5-yl-3-oxo-propenyl) -indol-1-yl] -acetic acid; (3- { (E) -2- [(4-chloro-phenyl) -methyl-carbamoyl] -2-cyano-vinyl] -indol-1-yl) -acetic; Acid { 3- [(E) -2-cyano-3- (6,11-dihydro-dibenzo [b, e] azepin-5-yl) -3-oxo-propenyl] -indol-1-yl} -acetic; [3- ((E) -2-cyano-2-diphenethylcarbamoyl-vinyl) -indol-1-yl] -acetic acid; Acid { 3- [(E) -2-cyano-3- (10,11-dihydro-dibenzo [b, f] azepin-5-yl) -3-oxo-propenyl] -indol-1-yl} -acetic; (3- ({(E) -2-cyano-2- [methyl- ((R) -1-phenyl-ethyl) -carbamoyl] -vinyl} -indol-1-yl) -acetic acid; Acid { 3- [(E) -2- (benzyl-methyl-carbamoyl) -2-cyanovinyl] -indol-1-yl} -acetic; (3- ({(E) -2- [(4-acetyl-phenyl) -methyl-carbamoyl] -2-cyanovinyl} -indol-1-yl) -acetic acid; Acid (3- { (E) -2- [(4-acetyl-phenyl) -furan-2-ylmethyl-carbamoyl] 2-cyanovinyl} -indol-l-il) -acetic; Acid { 3- [(E) -2- (benzyl-carboxymethyl-carbamoyl) -2-cyanovinyl] -indol-1-yl} -acetic; Acid 3-. { benzyl- [(E) -3- (l-carboxymethyl-lH-indol-3-yl) -2- cyano-acry] -amino} -propionic; Acid { 3- [(E) -2-cyano-3- (2,3-dihydro-indol-1-yl) -3-oxo-propenyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2- (carboxymethyl-phenyl-carbamoyl) -2-cyano-vinyl] -indol-1-yl} -acetic; (3- {(E) -2-cyano-2- [(2-cyano-ethyl) -phenyl-carbamoyl] -vinyl} -indol-1-yl) -acetic acid; (3- ({(E) -2- [(3-chloro-phenyl) -methyl-carbamoyl] -2-cyano-vinyl} -indol-1-yl) -acetic acid; -. Acid { 3- [(E) -2- (allyl-phenyl-carbamoyl) -2-cyanovinyl] -indol-1-yl} -acetic; Acid { 3 ~ [(E) -2-cyano-2- (cyclohexyl-phenyl-carbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (methyl-o-tolyl-carbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (ethyl-phenyl-carbamoyl) -vinyl] -indol-l-yl} -acetic; Acid { 3- [(E) -2- (butyl-phenyl-carbamoyl) -2-cyano-vinyl] -indol-l-yl} -acetic; [5-Bromo-3- ((E) -2-cyano-2-phenylcarbamoyl-vinyl) -indol-1-yl] -acetic acid; [3- ((E) -2-cyano-2-phenylcarbamoyl-vinyl) -5-fluoro-indol-1-yl] -acetic acid; [3- ((E) -2-cyano-2-phenylcarbamoyl-vinyl) -5-methyl-indol-1-yl] -acetic acid; - ' [3- ((E) -2-cyano-2-phenylcarbamoyl-vinyl) -6-fluoro-indol-1-yl] -acetic acid; [3- ((E) -2-cyano-2-phenylcarbamoyl-vinyl) -6-nitro-indol-1-yl] -acetic acid; [3- ((E) -2-cyano-2-phenylcarbamoyl-vinyl) -7-methyl-indol-1-yl] -acetic acid; Acid { 3- [(E) -3- (2-chloro-phenothiazin-10-yl) -2-cyano-3-oxo-propenyl] -indol-l-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (phenyl-thiophen-3-ylmethyl-carbamoyl) -vinyl] -indol-l-yl} -acetic; (3- ({(E) -2-cyano-2- [(2, 2-diphenyl-ethyl) -phenyl-carbamoyl] -vinyl} -indol-1-yl) -acetic acid; (3- {(E) -2-cyano-2- [phenyl- (3-phenyl-propyl) -carbamoyl] -vinyl} -indol-1-yl) -acetic acid; [3- ((E) -2-cyano-2-. {[2- (4-fluoro-phenyl) -ethyl] -phenyl-carbamoyl} -vinyl) -indol-1-yl] -acetic acid; Acid { 3- [(E) -2-cyano-3- (HH-10-oxa-5-aza-dibenzo [a, d] cyclohepten-5-yl) -3 -oxo-propenyl] -indol-l-yl} - acetic; Acid { 3- [(E) -2-cyano-2- (isopropyl-phenyl-carbamoyl) -vinyl] -indol-1-yl} -acetic; (3- {(E) -2-cyano-2- [(3,4-dichloro-phenyl) -methylcarbamoyl] -vinyl} -indol-1-yl) -acetic acid; (3- ({(E) -2-cyano-2- [ethyl- (4-trifluoromethoxy-phenyl) -carbamoyl] -vinyl} -indol-1-yl) -acetic acid; Acid { 3- [(E) -2- (benzhydrylcarbampyl) -2-cyanovinyl] -indol-l-il} -acetic; (3- ({(E) -2-cyano-2- [methyl- (2-trifluoromethoxy-phenyl) -carbamoyl] -vinyl} -indol-1-yl) -acetic acid; Acid { 3- [(E) -2-cyano-2- (2,4-difluoro-phenylcarbamoyl) -vinyl] indole-1-yl} -acetic; (3- ({(E) -2-cyano-2- [methyl- (4-trifluoromethoxy-phenyl) -carbamoyl] -vinyl} -indol-1-yl) -acetic acid; Acid { 3- [(E) -2-cyano-2- (ethi-1-naphthalen-1-yl-carbamoyl) -vinyl] -indol-1-yl} -acetic; (3- ({(E) -2-cyano-2- [(2,4-difluoro-phenyl) -methyl-carbamoyl] -vinyl} -indol-1-yl) -acetic acid; Acid { 3- [(E) -2-cyano-2- (2,4,6-trifluoro-phenylcarbamoyl) -vinyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (2, 3, 4-trifluoro-phenylcarbamoyl) - 22 vinyl] -indol-l-il } -acetic; Acid { 3- [(E) -2-cyano-3- (3,4-dihydro-IH-isoquinolin-2-yl) -3-oxo-propenyl] -indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-3-oxo-3- (7-trifluoromethyl-3,4-dihydro-2H-quinolin-1-yl) -propenyl] -indol-1-yl} -acetic; Acid (3- {(E) -2-cyano-2- [(3-fluoro-phenyl) -methyl-carbamoyl] -vinyl} -indol-1-yl) -acetic acid - [3] - ((E) -2-cyano-3-dibenzo [b, f] azepin-5-yl-3-oxo-propenyl) -5-fluoro-indol-1-yl] -acetic acid; 3- [(E) -2-cyano-3- (6,11-dihydro-dibenzo [b, e] azepin-5-yl) -3-oxo-propenyl] -5-fluoro-indol-1-yl} -acetic; Acid { 3- [(?) -2- (benzyl-phenyl-carbamoyl) -2-cyano-vinyl] -5-fluoro-indole-1-yl} -acetic acid; {.3- [(E) -2-cyano-2- (cyclohexyl-phenyl-carbamoyl) -vinyl] -5-fluoro-indol-1-yl} -acetic acid; ) -2- (Butyl-phenyl-carbamoyl) -2-cyano-vinyl] -5-fluoro-indole-1-yl.} -acetic acid (3- ({(E) -2-cyano-2) - [(4-fluoro-phenyl) -methyl-carbamoyl] -vinyl] -5-fluoro-indol-1-yl) -acetic acid (3- ({(E) -2-cyano-2-) [(3-fluoro-phenyl) -methyl-carbamoyl] -vinyl] -5-fluoro-indol-1-yl) -acetic acid (3- ({(E) -2-cyano-2- [ (3,4-dichloro-phenyl) -methyl-carbamoyl] -vinyl.}. -5-fluoro-in dol-1-yl) -acetic; (3- ({(E) -2-cyano-2- [methyl- (2-trifluoromethyl-phenyl) -carbamoyl] -vinyl} -5-fluoro-indol-1-yl) -acetic acid; Acid (3- {(E) -2-cyano-2- [(2,4-difluoro-phenyl) -methylcarbamoyl] -vinyl} -5-fluoro-indol-1-yl) -acetic acid; Acid { 3- [(E) -2-cyano-2- (phenyl-thiophen-3-ylmethyl-carbamoyl) -vinyl] -5-fluoro-indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-3-oxo-3- (7-trifluoromethyl-3,4-dihydro-2H-quinolin-1-yl) -propenyl] -5-fluoro-indol-1-yl} -acetic; Acid (3- {(E) -2-cyano-2- [ethyl- (4-trifluoromethoxy-phenyl) -carbamoyl] -vinyl} -5-fluoro-indol-1-yl) -acetic acid; Acid { 3- [(E) -2-cyano-3- (3,4-dihydro-lH-isoquinolin-2-yl) -3-oxo-propenyl] -5-fluoro-indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (phenethyl-phenyl-carbamoyl) -vinyl] -5-fluoro-indol-1-yl} -acetic; - [3- ((E) -2-cyano-3-dibenzo [b, f] azepin-5-yl-3-oxo-propenyl) -6-methyl-indol-1-yl] -acetic acid; Acid { 3- [(E) -2-cyano-3- (6,11-dihydro-dibenzo [b, e] azepin-5-yl) -3-oxo-propenyl] -6-methyl-indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-3- (10,11-dihydro-dibenzo [b, f] azepin-5-yl) -3 -oxo-propenyl] -6-methyl-indole-1-yl } -acetic; Acid { 3- [(E) -2- (benzyl-phenyl-carbamoyl) -2-cyano-vinyl] -6-methyl-indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (cyclohexyl-phenyl-carbamoyl) -vinyl] -6-methyl-indole-1-yl} -acetic; (3- ({(E) -2-cyano-2- [(4-fluoro-phenyl) -methyl-carbamoyl] -vinyl} -6-methyl-indol-1-yl) -acetic acid; Acid { 3- [(E) -2- (Butyl-phenyl-carbamoyl) -2-cyano-vinyl] -6-methyl-indol-1-yl} -acetic; Acid { 3- [(E) -2-cyano-2- (cyclohexyl-phenyl-carbamoyl) -vinyl] -7-methyl-indole-1-yl} -acetic; and (3- {(E) -2-cyano-2- [(4-fluoro-phenyl) -methyl-carbamoyl] -vinyl} -7-methyl-indol-1-yl) -acetic acid. 16. A pharmaceutical composition containing at least one compound of the general formula IP characterized in that wherein A represents hydrogen alkyl; halogen or cyano; B represents hydrogen; some or halogen; R1, R2, R3 and R4 independently represent hydrogen; I rent; halogen; nitro; cyano or formyl; R5 and R6 independently represent hydrogen; I rent; alkenyl; cycloalkyl; heteroaryl; or a member selected from the group consisting of aryl, alkoxy-aryl, alkoxycarbonyl-aryl, alkylcarbonyl-aryl, aryl-alkoxy aryl, aryl-alkyl, aryl-alkyl-aryl, arylcarbonyl-aryl and aryloxy-aryl, wherein the aryl group is unsubstituted or mono- or di-substituted by one or more independently selected substituents from the group consisting of alkyl, alkoxy, halogen, cyano, alkoxycarbonyl, alkylcarbonyl, phenyl, benzyl, benzoyl, benzyloxy, benzyloxycarbonyl, trifluoromethyl and trifluoromethoxy; or R5 and R6, together with the nitrogen atom to which they are linked, form a heterocyclic ring system; and optically pure enantiomers, mixtures of enantiomers, racemates, optically pure diastereoisomers, mixtures of diastereoisomers, diastereoisomeric racemates, mixtures of diastereoisomeric racemates, meso forms, geometric isomers, prodrugs of compounds in which a prodrug forming group is present and the solvates and morphological forms, the pharmaceutically acceptable salts thereof and the usual inert carriers or adjuvants; it being understood however that in the general formula IP: i) the term "alkyl" or "lower alkyl", used alone or in any combination, refers to a separate aliphatic group that includes a straight or branched hydrocarbon chain containing 1 to 8 carbon atoms (and preferably 1 to 4 carbon atoms), whose saturated aliphatic group can be optionally substituted with one or more substituents, each independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkylcarbonyl, alkylcarbonyloxy, alkylenedioxy, alkylsulfinyl, alkylsulfonyl, alkylthio, alkynyl, amino, aminocarbonyl, aryl, arylalkenyl, arylalkyloxy, aryloxy, aryloxycarbonyl, _ arylsulfinyl, ariisulfonilo, arylthio, carboxy, cyano, ~ - formyl, haloalkoxy, heterocyclyl, hydroxy, mercapto, nitro, and the like, linked to any carbon atom of the alkyl portion) the term "alkenyl" or "lower alkenyl", used alone or in any r combination, refers to a straight or branched hydrocarbon chain containing 2 to 8 carbon atoms, with at least one carbon-carbon double bond (RaRbC = CRcRd where Ra-Rd refers to substituents, each individual and independently selected from hydrogen and alkyl, alkoxy, alkoxyalkyl and the like); iii) the term "alkoxy" used alone or in any combination, refers to an alkyl group linked to the parent molecular moiety through an oxygen bridge; iv) the term "aryl" used alone or in any combination, refers to a carbocyclic group having at least one aromatic ring, for example, phenyl or biphenyl, or multiple fused ring systems, in which at least one ring is aromatic (eg, 1,2,3,4-tetrahydronaphthyl, naphthyl, anthryl, phenanthryl, fluorenyl, and the like), which aryl group may be optionally substituted with one or more functional groups individually and independently selected from alkenyl, alkoxy, alkoxyalkyl , alkoxycarbonyl, alkoxycarbonylalkyl, alkyl, alkylcarbonyl, alkylcarbonylalkyl, alkylcarbonyloxy, alkylenedioxy, alkylsulfinyl, alkylsulfinylalkyl, alkylsulfonyl, alkylsulfonylalkyl, alkylthio, alkylthioalkyl, alkynyl, amino, aminoalkyl, aminocarbonyl, aminocarbonylalkyl, aryl, arylalkenyl, arylalkyloxy, arylalkyl, aryloxy , aryloxycarbonyl, aryloxycarbonylalkyl, arylsulfinyl, arylsulfinylalkyl, arylsulfonyl, arylsulfonylalkyl, arylthio, arylthioalkyl, carboxyl, carboxyalkyl, cyano, cyanoalkyl, formyl, formylalkyl, halogen, haloalkoxy, haloalkyl, heteroaryl, heterocyclyl, hydroxyl, hydroxyalkyl, mercapto, nitro, and the like; v) the term "arylakoxy", used alone or in any combination, refers to an aryl group which may be unsubstituted or substituted as previously defined and which is linked to the parent molecular moiety through an alkoxy group; vi) the term "arylalkyl", used alone or in any combination, refers to an aryl group which may be unsubstituted or substituted as previously defined and which is linked to the parent molecular moiety through an alkyl group; vii) the term "aryloxy". used alone or in any combination, refers to an aryl group which may be unsubstituted or substituted as previously defined and which is linked to the parent molecular moiety through an oxygen bridge; viii) the term "arylcarbonyl" or "aroyl" used alone or in any combination, refers to an aryl group linked to the parent molecular moiety through a carbonyl group; ix) the term "cycloalkyl" used alone or in any combination, refers to a saturated cyclic hydrocarbon portion containing 3 to 15 carbon atoms, optionally substituted with one or more groups, each individually and independently selected from alkenyl, alkoxy , alkoxyalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, alkyl, alkylcarbonyl, alkylcarbonylalkyl, alkylcarbonyloxy, alkylendioxy, alkylsulfinyl, alkylsulfinylalkyl, alkylsulfonyl, alkylsulfonylalkyl, alkylthio, alkylthioalkyl, alkynyl, amino, aminoalkyl, aminocarbonyl, aminocarbonyl, aryl, arylalkenyl, arylalkyloxy, arylalkyl, aryloxy, aryloxycarbonyl , aryloxycarbonylalkyl, arylsulfinyl, arylsulfinylalkyl, arylsulfonyl, arylsulfonylalkyl, arylthio, arylthioalkyl, carboxyl, carboxyalkyl, cyano, cyanoalkyl, formyl, formylalkyl, halogen, haloalkoxy, haloalkyl, heteroaryl, heterocyclyl, hydroxyl, hydroxyalkyl, mercapto, nitro, and the like; it being understood that the polycyclic cycloalkyl groups of the distal rings may be aromatic (e.g., 1-indanyl, 2-indanyl, ^ tetrahydronaphthalene and the like (for example, 1-indanyl, 2-indanyl, tetrahydronaphthalene, and the like); x) - the term "heterocyclyl" alone or in any combination, refers to a monocyclic, bicyclic or polycyclic ring system containing up to 15 ring atoms, at least one of t is a heteroatom independently selected from nitrogen, oxygen or sulfur, which ring system may be saturated, partially unsaturated, unsaturated or aromatic, or may be optionally substituted with one or more groups, each individually and independently selected from alkenyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, alkyl, alkylcarbonyl, alkylcarbonylalkyl , alkylcarbonyloxy, alkylendioxy, alkylsulfinyl, alkylsulfinylalkyl, alkylsulfonyl, alkylsulfonylalkyl, alkylthio, alkylthioalkyl, alkynyl, amino, aminoalkyl, aminocarbonyl, aminocarbonyl, aryl, arylalkenyl, arylalkyloxy, arylalkyl, aryloxy, aryloxycarbonyl, aryloxycarbonylalkyl, arylsulfinyl, arylsulfinylalkyl, ariisulfonilo, ari l-sulfonylalkyl, arylthio, arylthioalkyl, carboxyl, carboxyalkyl, cyano, cyanoalkyl, formyl, formylalkyl, halogen, haloalkoxy, haloalkyl, heteroaryl, "heterocyclyl, hydroxyl, hydroxyalkyl, mercapto, nitro, and the like; xi) the term "heteroaryl" used alone or in any combination, is a special case of heterocyclyl and refers to a mono- or bicyclic or polycyclic ring system, in which at least one heterocyclic ring is aromatic.